



(86) Date de dépôt PCT/PCT Filing Date: 2010/02/17
(87) Date publication PCT/PCT Publication Date: 2010/08/26
(85) Entrée phase nationale/National Entry: 2011/07/22
(86) N° demande PCT/PCT Application No.: EP 2010/052005
(87) N° publication PCT/PCT Publication No.: 2010/094720
(30) Priorités/Priorities: 2009/02/19 (US61/153,746);
2009/09/10 (US61/241,198)

(51) Cl.Int./Int.Cl. *C07K 16/28* (2006.01),
A61K 39/395 (2006.01), *A61K 39/44* (2006.01),
A61K 47/48 (2006.01), *A61P 37/00* (2006.01)

(71) Demandeur/Applicant:
GLAXO GROUP LIMITED, GB

(72) Inventeurs/Inventors:
DUFFIELD, STEPHEN, GB;
ENEVER, CAROLYN, GB;
LIU, HAIQUN, GB;
SCHON, OLIVER, GB;
SEPP, ARMIN, GB;
STOOP, ADRIAAN ALLART, GB

(74) Agent: NORTON ROSE OR S.E.N.C.R.L., S.R.L./LLP

(54) Titre : POLYPEPTIDES, DOMAINES VARIABLES D'ANTICORPS, ET ANTAGONISTES AMELIORES, TOUS ETANT
DES ANTI-TNFR1

(54) Title: IMPROVED ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS

(57) **Abrégé/Abstract:**

The invention relates to anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 August 2010 (26.08.2010)

PCT

(10) International Publication Number
WO 2010/094720 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 39/44* (2006.01)
A61K 47/48 (2006.01) *A61P 37/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2010/052005

(22) International Filing Date:

17 February 2010 (17.02.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/153,746 19 February 2009 (19.02.2009) US
 61/241,198 10 September 2009 (10.09.2009) US

(71) **Applicant** (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **DUFFIELD, Stephen** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **ENEVER, Carolyn** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **LIU, Haiqun** [CN/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **SCHON, Oliver** [DE/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **SEPP, Armin** [EE/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB). **STOOP, Allart Adriaan** [NL/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge, Cambridgeshire CB4 0WG (GB).

(74) **Agents:** **CLUBE, Jasper Rupert** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**

13 January 2011

(54) **Title:** IMPROVED ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS

(57) **Abstract:** The invention relates to anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multi-specific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.



WO 2010/094720 A3

IMPROVED ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS

The present invention relates to anti-Tumor Necrosis Factor 1 (TNFR1, p55, CD120a, P60, TNF receptor superfamily member 1A, TNFRSF1A, TNF α receptor type I) polypeptides, immunoglobulin (antibody) single variable domains and antagonists
5 comprising these. The invention further relates to methods, uses, formulations, compositions and devices comprising or using such anti-TNFR1 ligands.

BACKGROUND OF THE INVENTION

TNFR1

10 TNFR1 is a transmembrane receptor containing an extracellular region that binds ligand and an intracellular domain that lacks intrinsic signal transduction activity but can associate with signal transduction molecules. The complex of TNFR1 with bound TNF contains three TNFR1 chains and three TNF chains. (Banner *et al.*, *Cell*, 73(3) 431-445 (1993).) The TNF ligand is present as a trimer, which is bound by three
15 TNFR1 chains. (Id.) The three TNFR1 chains are clustered closely together in the receptor-ligand complex, and this clustering is a prerequisite to TNFR1-mediated signal transduction. In fact, multivalent agents that bind TNFR1, such as anti-TNFR1 antibodies, can induce TNFR1 clustering and signal transduction in the absence of TNF and are commonly used as TNFR1 agonists. (See, *e.g.*, Belka *et al.*, *EMBO*,
20 14(6):1156-1165 (1995); Mandik-Nayak *et al.*, *J. Immunol.*, 167:1920-1928 (2001).) Accordingly, multivalent agents that bind TNFR1 are generally not effective antagonists of TNFR1 even if they block the binding of TNF α to TNFR1.

SEQ ID numbers in this paragraph refer to the numbering used in WO2006038027. The extracellular region of TNFR1 comprises a thirteen amino acid
25 amino-terminal segment (amino acids 1-13 of SEQ ID NO:603 (human); amino acids 1-13 of SEQ ID NO:604 (mouse)), Domain 1 (amino acids 14-53 of SEQ ID NO:603

- 2 -

(human); amino acids 14-53 of SEQ ID NO:604 (mouse)), Domain 2 (amino acids 54-97 of SEQ ID NO: 603 (human); amino acids 54-97 of SEQ ID NO:604 (mouse)), Domain 3 (amino acids 98-138 of SEQ ID NO: 603 (human); amino acid 98-138 of SEQ ID NO:604 (mouse)), and Domain 4 (amino acids 139-167 of SEQ ID NO:603 (human); amino acids 139-167 of SEQ ID NO:604 (mouse)) which is followed by a membrane-proximal region (amino acids 168-182 of SEQ ID NO:603_(human); amino acids 168-183 SEQ ID NO: 604 (mouse)). (See, Banner *et al.*, *Cell* 73(3) 431-445 (1993) and Loetscher *et al.*, *Cell* 61(2) 351-359 (1990).) Domains 2 and 3 make contact with bound ligand (TNF β , TNF α). (Banner *et al.*, *Cell*, 73(3) 431-445 (1993).) The extracellular region of TNFR1 also contains a region referred to as the pre-ligand binding assembly domain or PLAD domain (amino acids 1-53 of SEQ ID NO:603_(human); amino acids 1-53 of SEQ ID NO:604 (mouse)) (The Government of the USA, WO 01/58953; Deng *et al.*, *Nature Medicine*, doi: 10.1038/nm1304 (2005)). TNFR1 is shed from the surface of cells *in vivo* through a process that includes proteolysis of TNFR1 in Domain 4 or in the membrane-proximal region (amino acids 168-182 of SEQ ID NO:603; amino acids 168-183 of SEQ ID NO:604), to produce a soluble form of TNFR1. Soluble TNFR1 retains the capacity to bind TNF α , and thereby functions as an endogenous inhibitor of the activity of TNF α .

WO2006038027, WO2008149144 and WO2008149148 disclose anti-TNFR1 immunoglobulin single variable domains and antagonists comprising these. These documents also disclose the use of such domains and antagonists for the treatment and/or prevention of conditions mediated by TNF α . WO2006038027 discloses an immunoglobulin single variable domain (dAb), called TAR2h-205 (SEQ ID NO: 627 in WO2006038027), which has modest potency against human TNFR1. It would be desirable to provide improved anti-human TNFR1 immunoglobulin single variable domains, antagonists, ligands and products comprising these. The aim of these would be to provide improved diagnostic reagents for detecting human TNFR1 in samples, as well as or alternatively to provide improved therapeutics for the treatment and/or prophylaxis of TNFR1-mediated conditions and diseases in humans or other mammals. It would be particularly desirable to provide anti-TNFR1 immunoglobulin single

- 3 -

variable domains, antagonists, ligands and products comprising these that are potent neutralizers of TNFR1 (more so than TAR2h-205), especially of human TNFR1; are cross-reactive between human TNFR1 and TNFR1 from at least one other species (such as a species commonly used as a model for drug development and testing, eg, mouse, rat, dog, pig or non-human primate); are resistant to protease (eg, a protease likely to be encountered in a patient, such as trypsin, chymotrypsin, pepsin or leucozyme); have good pharmacokinetics (eg, favourable half-life); and/or display high affinity binding to TNFR1, for example, human TNFR1. TAR2h-205 is called DOM1h-574 (SEQ ID NO: 11) in the present text (see also figure 5).

10

The various aspects of the present invention meet these desirable characteristics.

SUMMARY OF THE INVENTION

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is a mutant of DOM1h-574-14 comprising one or more of the following mutations (numbering according to Kabat)

position 30 is L or F,
position 52 is A or T,
position 52a is D or E,
position 54 is A or R,
position 57 is R, K or A,
position 60 is D, S, T or K,

- 4 -

position 61 is E, H or G,
position 62 is A or T,
position 100 is R, G, N, K, Q, V, A, D, S or V, and
position 101 is A, Q, N, E, V, H or K.

5

Optionally, the single variable domain is a mutant of DOM1h-574-14
comprising one or more of the following mutations (numbering according to Kabat)

position 30 is L or F,
10 position 52 is A or T,
position 52a is D,
position 54 is A,
position 57 is R,
position 60 is D, S or T,
15 position 61 is H,
position 62 is A,
position 100 is V, A, R, G, N or K, and
position 101 is E, V, K, A Q or N.

20

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1;
p55) immunoglobulin heavy chain single variable domain comprising valine at position
101 (numbering according to Kabat).

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1;
25 p55) immunoglobulin single variable domain comprising one or more of 30G, 44D,
45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat, wherein the

- 5 -

amino acid sequence of the single variable domain is otherwise identical to the amino acid sequence of DOM1h-574. In one embodiment, the variable domain is provided for binding human, murine or *Cynomologus monkey* TNFR1.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of DOM1h-574-72, DOM1h-574-156, DOM1h-574-109, DOM1h-574-132, DOM1h-574-135, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180. This aspect provides variable domains that are potent neutralizers of TNFR1 (eg, at least human TNFR1) in cell assay.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 94% identical to the amino acid sequence of DOM1h-574-109, DOM1h-574-93, DOM1h-574-123, DOM1h-574-125, DOM1h-574-126, DOM1h-574-129, DOM1h-574-133, DOM1h-574-137, or DOM1h-574-160. This aspect provides variable domains that are proteolytically stable.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-125, DOM1h-574-126, DOM1h-574-133, DOM1h-574-135, DOM1h-574-138, DOM1h-574-139, DOM1h-574-155, DOM1h-574-156, DOM1h-574-162, or DOM1h-574-180. This aspect provides variable domains that bind human TNFR1 with high affinity and optionally also display desirable affinity for murine TNFR1.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain for binding human, murine or *Cynomologus monkey* TNFR1, wherein the single variable domain is encoded by a nucleotide sequence that is at least 80, 85, 90, 95, 96, 97, 98 or 99% identical to the nucleotide sequence of any one of the DOM1h sequences shown in Table 12 below, with the exception of DOM1h-574.

- 6 -

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain for binding human, murine or *Cynomolgus monkey* TNFR1, wherein the single variable domain is encoded by a nucleotide sequence that is at least 80, 85, 90, 95, 96, 97, 98 or 99% identical to the
5 nucleotide sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-
10 574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180 or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% identical to the CDR1 sequence of the selected amino acid sequence. In one embodiment, the immunoglobulin single variable domain comprises a CDR2 sequence that is at least
15 50% identical to the CDR2 sequence of the selected amino acid sequence. In one embodiment, the immunoglobulin single variable comprises a CDR3 sequence that is at least 50% identical to the CDR3 sequence of the selected amino acid sequence.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising an amino acid sequence that is
20 identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180 or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of the selected amino acid sequence. In one embodiment, the
25 immunoglobulin single variable domain comprises a CDR3 sequence that is at least 50% identical to the CDR3 sequence of the selected amino acid sequence. In one embodiment, the immunoglobulin single variable domain comprises a CDR1 sequence that is at least 50% identical to the CDR1 sequence of DOM1h-574-72.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1;
30 p55) immunoglobulin single variable domain which comprising an amino acid sequence

- 7 -

that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180 or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of the selected amino acid sequence.

In one aspect, the invention provides a protease resistant anti- TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is resistant to protease when incubated with

- (i) a concentration (c) of at least 10 micrograms/ml protease at 37°C for time (t) of at least one hour; or
- (ii) a concentration (c') of at least 40 micrograms/ml protease at 30°C for time (t) of at least one hour.

wherein the variable domain comprises an amino acid sequence that is at least 94% identical to the amino acid sequence of DOM1h-574-126 or DOM1h-574-133, and optionally comprises a valine at position 101 (Kabat numbering).

In one aspect, the invention relates to a polypeptide comprising an immunoglobulin single variable domain of the present invention and an antibody constant domain, optionally an antibody Fc region, optionally wherein the N-terminus of the Fc is linked (optionally directly linked) to the C-terminus of the variable domain.

In one aspect, the invention relates to a multispecific ligand comprising an immunoglobulin single variable domain of the present invention and optionally at least one immunoglobulin single variable domain that specifically binds serum albumin (SA). Surprisingly, the inventors found that fusion of an anti-TNFR1 single variable domain according to the invention to an anti-SA single variable domain provides the advantage of improved half-life (over an anti-TNFR1 dAb monomer alone), but also with the added benefit of an improvement in the affinity (KD) for TNFR1 binding. This observation has not been disclosed before in the state of the art. In one embodiment, the multispecific ligand is, or comprises, an amino acid sequence selected from the amino acid sequence of any construct labeled "DMS" disclosed herein, for example, any one of DMS0111, 0112, 0113, 0114, 0115, 0116, 0117, 0118, 0121, 0122, 0123, 0124,

- 8 -

0132, 0133, 0134, 0135, 0136, 0162, 0163, 0168, 0169, 0176, 0177, 0182, 0184, 0186, 0188, 0189, 0190, 0191, 0192, 5519, 5520, 5521, 5522, 5525 and 5527 (SEQ ID NOs: 45-92). In one embodiment, the multispecific ligand is, or comprises, an amino acid sequence encoded by the nucleotide sequence of any DMS disclosed herein, for
5 example, any one of the nucleotide sequences of DMS0111, 0112, 0113, 0114, 0115, 0116, 0117, 0118, 0121, 0122, 0123, 0124, 0132, 0133, 0134, 0135, 0136, 0162, 0163, 0168, 0169, 0176, 0177, 0182, 0184, 0186, 0188, 0189, 0190, 0191, 0192, 5519, 5520, 5521, 5522, 5525 and 5527. In one embodiment, the invention provides a nucleic acid encoding a multispecific ligand comprising an anti-TNFR1 immunoglobulin single
10 variable domain and an anti-SA single variable domain, wherein the nucleic acid comprises the nucleotide sequence of any DMS disclosed herein, for example, any one of the nucleotide sequences of DMS0111, 0112, 0113, 0114, 0115, 0116, 0117, 0118, 0121, 0122, 0123, 0124, 0132, 0133, 0134, 0135, 0136, 0162, 0163, 0168, 0169, 0176, 0177, 0182, 0184, 0186, 0188, 0189, 0190, 0191, 0192, 5519, 5520, 5521, 5522, 5525
15 and 5527. There is provided a vector comprising such a nucleic acid, as well as a host cell (eg, a non-human host cell) comprising such a vector.

In one aspect, the invention provides a multispecific ligand comprising (i) an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 93% identical (optionally at
20 least 94, 95, 96, 97, 98 or 99% identical or 100% identical) to the amino acid sequence of DOM1h-574-156, (ii) at least one anti-serum albumin (SA) immunoglobulin single variable domain that specifically binds SA, wherein the anti-SA single variable domain comprises an amino acid sequence that is at least 80% (optionally at least 85, 90, 95, 96, 97, 98 or 99% identical or 100%) identical to the sequence of DOM7h-11-3, and (iii)
25 optionally wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS. Alternatively, the linker is AS(G₄S)_n, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example AS(G₄S)₃.

- 9 -

In one aspect, the invention provides a multispecific ligand comprising (i) an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 93% identical (optionally at least 94, 95, 96, 97, 98 or 99% identical or 100% identical) to the amino acid sequence of DOM1h-574-156, (ii) at least one anti-serum albumin (SA) immunoglobulin single variable domain that specifically binds SA, wherein the anti-SA single variable domain comprises an amino acid sequence that is at least 80% (optionally at least 85, 90, 95, 96, 97, 98 or 99% identical or 100%) identical to the sequence of DOM7h-14-10, and (iii) optionally wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS. Alternatively, the linker is AS(G₄S)_n, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example AS(G₄S)₃.

In one aspect, the invention provides a TNFR1 antagonist comprising a single variable domain, polypeptide or multispecific ligand of any preceding aspect of the invention.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist of the invention, for oral delivery, delivery to the GI tract of a patient, pulmonary delivery, delivery to the lung of a patient or systemic delivery.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR1 sequence that is at least 50% identical to the CDR1 sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist

- 10 -

having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180.

5 In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist comprising an immunoglobulin single variable domain comprising the sequence of CDR1, CDR2, and/or CDR3 of a single variable domain selected from DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180.

10 In one aspect, the invention provides a TNFR1 antagonist of the invention for treating and/or prophylaxis of an inflammatory condition.

In one aspect, the invention provides the use of the TNFR1 antagonist of the invention in the manufacture of a medicament for treating and/or prophylaxis of an inflammatory condition.

15 In one aspect, an anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand of any one aspect of the invention is provided for targeting one or more epitopic sequence of TNFR1 selected from the group consisting of NSICCTKCHKGTYLY, NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF.

20 In one aspect, an anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand of any one aspect of the invention is provided for targeting one or more epitopic sequence of TNFR1 selected from the group consisting of NSICCTKCHKGTYLY, NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF, to treat and/or prevent any condition or disease specified
25 above.

In one aspect, the invention provides a method of treating and/or preventing any condition or disease specified above in a patient, the method comprising administering to the patient an anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand the invention for targeting one or more epitopic sequence of
30 TNFR1 selected from the group consisting of NSICCTKCHKGTYLY,

- 11 -

NSICCTKCHKGYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF in the patient.

An aspect of the invention provides a multispecific ligand comprising an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain and at least one immunoglobulin single variable domain that specifically binds serum albumin (SA), wherein

- (a) the anti-TNFR1 single variable domain comprises an amino acid that is at least 80% (optionally at least 85, 90, 95, 96, 97, 98 or 99% identical or 100%) identical to the amino acid sequence of DOM1h-574-156, DOM1m-15-12 or DOM1m-21-23; and
- 10 (b) the anti-SA single variable domain comprises an amino acid that is at least 80% (optionally at least 85, 90, 95, 96, 97, 98 or 99% identical or 100%) identical to the amino acid sequence of DOM7h-11-12 or DOM7h-11-12dh; and
- (c) the ligand comprises a linker between said variable domains, the linker comprising the amino acid sequence AS or AST. Another aspect of the invention provides
- 15 multispecific ligand comprising or consisting of DMS5537, DMS5538, DMS5539 or DMS5540. An aspect of the invention provides a nucleic acid encoding either multispecific ligand. Another aspect of the invention provides a nucleic acid comprising a nucleotide sequence that is at least 80% (optionally at least 85, 90, 95, 96, 97, 98 or 99% identical or 100%) identical to the nucleotide sequence of DMS5537,
- 20 DMS5538, DMS5539 or DMS5540. The invention further provides a vector comprising the nucleic acid, as well as a host, optionally a non-human embryonic cell, comprising the vector.

BRIEF DESCRIPTION OF THE FIGURES

- 25 **Figure 1.** BIAcore binding of dAbs from naïve selections to human TNFR1. Biotinylated human TNFR1 was coated on a SA BIAcore chip. Four purified dAbs (DOM1h-509, DOM1h-510, DOM1h-549 and DOM1h-574), from naïve selections, were injected over human TNFR1 and binding was determined. The curves corresponding to each dAb are indicated by arrows.

- 12 -

Figure 2. MRC5 cell assay for dAbs from naïve selections to human TNFR1. Four purified dAbs (DOM1h-509, DOM1h-510, DOM1h-549 and DOM1h-574) from the naïve selections and a control dAb (DOM1h-131-511) were analysed in the MRC5 cell assay for functional inhibition of TNF α mediated IL-8 release. The assay was performed as described and the curve corresponding to each dAb is indicated with an arrow. In the graph dAb concentration is plotted (using Graphpad Prism) against percentage neutralisation observed.

Figure 3. Receptor Binding Assay for dAbs from naïve selections to human TNFR1. Four purified dAbs (DOM1h-509, DOM1h-510, DOM1h-549 and DOM1h-574) from the naïve selections and a positive control dAb (DOM1h-131-511) were assayed in the receptor binding assay to determine competition with TNF α . The positive control dAb is known to be competitive with TNF α and shows a full inhibition curve. The selected anti-TNFR1 dAbs do not inhibit TNF α binding to the receptor. The assay was performed as described and the curve (using Graphpad Prism) corresponding to each dAb is indicated with an arrow. “% Neutralisation” on the y-axis indicates TNF alpha binding inhibition.

Figure 4. MRC5 cell assay for dAbs from error-prone test maturations to human TNFR1. Three purified dAbs (DOM1h-574-7, DOM1h-574-8 and DOM1h-574-10) from the naïve selections and a control dAb (DOM1h-131-511) were analysed in the MRC5 cell assay for functional inhibition of TNF α mediated IL-8 release. The assay was performed as described and the curve corresponding to each dAb is indicated with an arrow. In the graph dAb concentration is plotted (using Graphpad Prism) against percentage neutralisation observed. Compared to the parental DOM1h-574 shown in Figure 2, these dAbs demonstrate increased potency in the MRC5 cell assay.

Figure 5. Amino-acid sequence alignment for dAbs identified from error-prone libraries of DOM1h-574 and their subsequent recombinations. The error-prone, test maturation selections for improved DOM1h-574 dAbs identified positions responsible for affinity improvements in DOM1h-574-7, DOM1h-574-8, DOM1h-574-10, DOM1h-574-11, DOM1h-574-12 and DOM1h-574-13. Recombinations of these mutations (V30G, G44D, L45P, G55D, H56R and K94I) yielded DOM1h-574-14 to DOM1h-

- 13 -

574-19. A “.” at a particular position indicates the same amino as found in DOM1h-574 at that position. The CDRs are indicated by underlining and bold text (the first underlined sequence is CDR1, the second underlined sequence is CDR2 and the third underlined sequence is CDR3).

5

Figure 6. Amino-acid sequence alignment of the extracellular domain of TNFR1 from human, *Cynomologous* monkey, dog and mouse. The alignment highlights the limited conservation of sequence between human and mouse TNFR1. A “.” at a particular position indicates the same amino as found in human ECD TNFR1 at that position.

10

Figure 7. Monitoring of binding of DOM1h-574-16 and DOM1h-131-206 to dog TNFR1 as determined by BIAcore. A BIAcore SA chip was coated with biotinylated dog TNFR1. Subsequently, the purified dAbs DOM1h-574-16 and DOM1h-131-206, each at 100 nM, were injected over dog TNFR1. From the traces it is clear that whereas DOM1h-574-16 shows significant binding, only limited binding is observed for DOM1h-131-206.

15

Figure 8. Monitoring of binding of purified DOM1h-574-16 to mouse TNFR1 as determined by BIAcore. A BIAcore SA chip was coated with biotinylated mouse TNFR1. Subsequently, the purified dAb DOM1h-574-16, at 1 μ M, was injected over mouse TNFR1. The trace clearly demonstrates binding of DOM1h-574-16 for mouse TNFR1.

20

Figure 9. Functional activity of DOM1h-574-16 in a mouse L929 cell assay. Purified DOM1h-574-16 (black line, triangles) was assayed for functional cross-reactivity with mouse TNFR1 by testing its ability to protect mouse L929 cells from the cytotoxic effect of TNF α in the presence of actinomycine. As a positive control, the mouse TNFR1 binding dAb, DOM1m-21-23 (grey line, squares) was included and shown to be active. In the graph, dAb concentration is plotted (using Graphpad Prism) against percentage neutralisation of TNF α activity. The assay was performed as described in the examples.

25

- 14 -

Figure 10. Functional activity of DOM1h-574-16 in a *Cynomologous* monkey CYNOM-K1 cell assay. Purified DOM1h-574-16 (grey dashed line, triangles) was assayed for functional cross-reactivity with *Cynomologous* monkey TNFR1 by testing its ability to inhibit IL-8 release from CYNOM-K1 cells in response to TNF α . The assay was performed as described in the examples. As a positive control, DOM1h-131-511 (black solid line, squares) was included. Both dAbs showed full neutralisation. In the graph, dAb concentration is plotted (using Graphpad Prism) against percentage neutralisation of TNF α activity.

Figure 11A-C. Amino-acid sequence alignment for the most potent dAbs from the DOM1h-574 lineage identified during affinity maturation. The amino-acid sequences of the dAbs with the highest potency in the MRC5 cell assay are listed alongside the parental DOM1h-574, the template used for starting affinity maturation (DOM1h-574-14) and an earlier dAb identified with increased potency (DOM1h-574-72). A “.” at a particular position indicates the same amino as found in DOM1h-574 at that position. The CDRs are indicated by underlining and bold text (the first underlined sequence is CDR1, the second underlined sequence is CDR2 and the third underlined sequence is CDR3).

Figure 12 A-C. Amino-acid sequence alignment for the most protease stable dAbs from the DOM1h-574 lineage identified during affinity maturation. The amino-acid sequences of those dAbs identified after affinity maturation which were shown to be the most resistant to trypsin digestion. For alignment purposes, the parental dAb DOM1h-574 is also included. A “.” at a particular position indicates the same amino as found in DOM1h-574 at that position. The CDRs are indicated by underlining and bold text (the first underlined sequence is CDR1, the second underlined sequence is CDR2 and the third underlined sequence is CDR3).

Figure 13 A-C. Amino-acid sequence alignment for the dAbs chosen for detailed characterisation. The alignment contains the twelve dAbs chosen for detailed characterisation as well as DOM1h-574 (the parental dAb) and DOM1h-574-16, which was used early on for characterisation of the lineage. A “.” at a particular position

- 15 -

indicates the same amino as found in DOM1h-574 at that position. The CDRs are indicated by underlining and bold text (the first underlined sequence is CDR1, the second underlined sequence is CDR2 and the third underlined sequence is CDR3).

Figure 14. Epitope mapping by BIAcore for DOM1h-574-16 and DOM1h-131-511. A BIAcore SA chip was coated with biotinylated human TNFR1. Across this surface injections were performed of DOM1h-131-511 and DOM1h-574-16 (each at 200 nM and followed by a regeneration injection (not shown)). The number of RUs (response units) bound for each of the dAbs was determined. Subsequently, the same concentration of DOM1h-131-511 was injected, directly followed by an injection of DOM1h-574-16. As can clearly been seen, the number of binding units for the second injections of DOM1h-574-16 equals the first injection, indicating the dAbs bind non-competing epitopes.

Figure 15. Epitope mapping by BIAcore for DOM1h-574-16 and MAB225 (R&D Systems). A BIAcore SA chip was coated with biotinylated human TNFR1. Across the surface DOM1h-574-16 was injected and the binding quantified. After regeneration (not shown), MAB225 was injected followed again by injection of DOM1h-574-16. The level of binding for DOM1h-574-16 is very comparable to that seen in the absence of MAB225, indicating a binding epitope non-competitive with MAB225.

Figure 16. Epitope mapping by BIAcore for DOM1h-574-16 and the mAb Clone 4.12. A BIAcore SA chip was coated with biotinylated human TNFR1. Across the surface, Clone 4.12 (Invitrogen, Zymed) was injected and the binding quantified. After regeneration (not shown), DOM1h-574-16 was injected followed again by injection of Clone 4.12. The level of binding observed for the second injection of Clone 4.12 is about 20% less than that observed in the absence of DOM1h-574-16. This result indicates a limited competition for the binding epitope on human TNFR1. DOM1h-574-16 and Clone 4.12 might have slightly overlapping epitopes. The jumps in RU signal immediately before and after injections are buffer jumps, which have not been subtracted.

- 16 -

Figure 17. Epitope mapping by BIAcore for DOM1h-574-16 and DOM1h-510. A BIAcore SA chip was coated with biotinylated human TNFR1. Across the surface, DOM1h-510 was injected and the binding quantified. Subsequently, DOM1h-574-16 was injected followed again by injection of DOM1h-510. Clearly, the second injection of DOM1h-510 showed far less binding, indicating a competing epitope is being bound by DOM1h-510.

Figure 18. Epitope mapping by BIAcore for DOM1h-574-16 and DOM1m-21-23. A BIAcore SA chip was coated with biotinylated mouse TNFR1. Across the surface, DOM1h-574-16 was injected and the binding quantified. Subsequently, DOM1m-21-23 was injected followed again by injection of DOM1h-574-16. The number of bound RUs of DOM1h-574-16 after the second injection is very similar to that observed in the absence of DOM1m-12-23. This would indicate that DOM1m-21-23 and DOM1h-574-16 have different binding epitopes on mouse TNFR1.

Figure 19. Epitope mapping of DOM1h-574-16 to linear peptide fragments of TNFR1 by BIAcore. The four channels of a BIAcore SA chip were each coated with one of four biotinylated peptides. The peptides were: 1) a peptide fragment of human TNFR1 which did not show binding on the ForteBio and serves as a negative control, A3 (SGSGNDCPGPGQDTDCREC), 2) a domain-1 peptide D2 (SGSGNSICCTKCHKGTLY), 3) a domain-3 peptide D5 (SGSGCRKNQYRHYWSENLF) and 4) the overlapping domain-3 peptide E5 (SGSGNQYRHYWSENLFQCF). DOM1h-574-16 (2.5 μ M) was flowed over all four peptides and the amount of binding determined. No binding of DOM1h-574-16 was observed on the control peptide A3, while the dAb did bind the three other peptides. In the figure, the traces corresponding to the different peptides are indicated by the peptide identifier.

Figure 20. Evaluation of binding of DOM1m-21-23 to four linear peptide fragments of TNFR1 by BIAcore. The four channels of a BIAcore SA chip were each coated with one of four biotinylated peptides. The peptides were: 1) a peptide fragment of human TNFR1 which did not show binding to DOM1h-574-16 on the ForteBio and serves as a negative control, A3 (SGSGNDCPGPGQDTDCREC), 2) a domain-1 peptide D2 (SGSGNSICCTKCHKGTLY), 3) a domain-3 peptide D5

- 17 -

(SGSGCRKNQYRHYWSENLF) and 4) the overlapping domain-3 peptide E5 (SGSGNQYRHYWSENLFQCF). To establish if DOM1m-21-23 also binds these peptides, DOM1m-21-23 (2.5 μ M) was injected over all four peptides. As can be seen from the figure, DOM1m-21-23 did not show binding to any of the four peptides. The curves
 5 overlay each other.

Figure 21. Epitope mapping of DOM1h-131-511 to linear peptide fragments of TNFR1 by BIAcore. The four channels of a BIAcore SA chip were each coated with one of four biotinylated peptides. The peptides were: 1) a peptide fragment of human TNFR1 which did not show binding to DOM1h-574-16 on the ForteBio and serves as a
 10 negative control, A3 (SGSGNDCPGPGQDTDCREC), 2) a domain-1 peptide D2 (SGSGNSICCTKCHKGTLY), 3) a domain-3 peptide D5 (SGSGCRKNQYRHYWSENLF) and 4) the overlapping domain-3 peptide E5 (SGSGNQYRHYWSENLFQCF). DOM1h-131-511 (2.5 μ M) was flown over all four peptides and the amount of binding determined. As can be seen from the figure, DOM1h-131-511 did not show binding to
 15 any of the four peptides. The curves are close to overlaying and are indicated by arrows and the corresponding peptide number.

Figure 22. BIAcore analysis for binding of DOM0100-AlbudAb in-line fusions to mouse serum albumin (MSA). MSA (Sigma-Aldrich) was coated on a BIAcore CM5 chip using EDC/NHS chemistry according to manufacturer's instructions.
 20 Subsequently, the DMS constructs, each consisting N-terminally to C-terminally of an anti-TNFR1 dAb – Linker – AlbudAb and identified in Table 6, were injected at 1 μ M over the MSA surface and binding was monitored. As can be seen from the BIAcore traces, DMS0192 and DMS0188 had the best overall kinetics, while DMS0182 and DMS0184 were the weakest binders to MSA. The corresponding BIAcore trace for each
 25 DMS clone is indicated with an arrow.

Figure 23. BIAcore analysis for binding of DOM0100-AlbudAb in-line fusions to human serum albumin (HSA). HSA (Sigma-Aldrich) was coated on a BIAcore CM5 chip using EDC/NHS chemistry according to manufacturer's instructions. Subsequently, the DMS constructs, each consisting N-terminally to C-terminally of an

- 18 -

anti-TNFR1 dAb – Linker – AlbudAb and identified in Table 6, were injected at 1 μ M over the HSA surface and binding was monitored. As can be seen from the BIAcore traces, DMS0189 and DMS0190 had the best overall kinetics, while the other DMS clones shown in the figure (DMS0182, DMS0184, DMS0186 and DMS0188) were very similar and significantly weaker in their affinity for HSA. The corresponding BIAcore trace for each DMS clone is indicated with an arrow.

Figure 24. PK of DOM0100-AlbudAb fusions in mice. Mice were dosed with DMS0168 (2.5 mg/kg, intravenous), DMS0169 (2.5 mg/kg, intravenous) or DMS0182 (10 mg/kg, intraperitoneal). At each time point (0.17, 1, 4, 12, 24, 48 and 96h) three mice were sacrificed and their serum analysed for levels of the respective DOM0100-AlbudAb fusion. The average amount of each DOM0100-AlbudAb fusion was determined for each time point and plotted against time, DMS0168 (grey dashed line), DMS0182 (black dotted line) and DMS0169 (black solid line) (corresponding lines are also indicated by arrows). Using non-compartmental analysis (NCA) in the WinNonLin analysis package (eg version 5.1 (available from Pharsight Corp., Mountain View, CA94040, USA), the terminal half-life for each of the molecules was determined. DMS0182 had a terminal half-life of 5.9h, DMS0168 was 15.4h and DMS0169 was 17.8h. Due to the intraperitoneal dosing, the curve for DMS0182 has a different shape from that observed for DMS0168 and DMS0169 (the curve shown is by Biacore).

Figure 25. Arthritic score for Tg197/hp55 KI mice during saline and DMS0169 treatment. The transgenic mouse strain used in this study is a cross-bred of Tg197 (over-expressing human TNF α) and hp55 (knock-in of human TNFR1, also known as p55), which spontaneously develops arthritis. From week 6 till week 15, twelve mice in each group were treated twice a week with either 10 mg/kg of DMS0169 or saline. Each week the arthritic score was determined for the two hind joints per mouse and the average arthritic score, and standard error of the mean, over 12 mice was plotted in time. Clearly, the DMS0169 treated animals develop less arthritis.

Figure 26. Body weight Tg197/hp55 KI mice during saline and DMS0169 treatment. The transgenic mouse strain used in this study is a cross-bred of Tg197 (over-expressing human TNF α) and hp55 (knock-in of human TNFR1, also known as

- 19 -

p55), which spontaneously develops arthritis. From week 6 till week 15, twelve mice in each group were treated twice a week with either 10 mg/kg of DMS0169 or saline. Each week the mice were weighted and the average data plotted, with error bars indicating the standard error of the mean. From the figure, the trend for DMS0169 to be heavier, compared to saline treated animals is apparent, though not statistically significant.

Figure 27. Histology and arthritic scores for Tg197/hp55 KI mice at week 15 after saline and DMS0169 treatment. The transgenic mouse strain used in this study is a cross-bred of Tg197 (over-expressing human TNF α) and hp55 (knock-in of human TNFR1, also known as p55), which spontaneously develops arthritis. From week 6 till week 15, twelve mice in each group were treated twice a week with either 10 mg/kg of DMS0169 or saline. At week 15 the mice were sacrificed and both arthritic score (black bars) and histology (open bars) in the joint were scored (Keffer *et al.* *EMBO. J.* **10**, p4025 (1991)). Each group consisted of twelve animals and the standard error was calculated. The difference between the treatment groups is shown to be statistically significant ($p < 0.001$).

DETAILED DESCRIPTION OF THE INVENTION

Within this specification the invention has been described, with reference to embodiments, in a way which enables a clear and concise specification to be written. It is intended and should be appreciated that embodiments may be variously combined or separated without parting from the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, nucleic acid chemistry, hybridization techniques and biochemistry). Standard techniques are used for molecular, genetic and biochemical methods (see generally, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d

- 20 -

ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Ausubel *et al.*, Short Protocols in Molecular Biology (1999) 4th Ed, John Wiley & Sons, Inc. which are incorporated herein by reference) and chemical methods.

The immunoglobulin single variable domains (dAbs) described herein contain
 5 complementarity determining regions (CDR1, CDR2 and CDR3). The locations of CDRs and frame work (FR) regions and a numbering system have been defined by Kabat *et al.* (Kabat, E.A. *et al.*, *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). The amino acid sequences of the CDRs (CDR1, CDR2, CDR3) of the V_H and V_L (V_κ)
 10 dAbs disclosed herein will be readily apparent to the person of skill in the art based on the well known Kabat amino acid numbering system and definition of the CDRs. According to the Kabat numbering system heavy chain CDR-H3 have varying lengths, insertions are numbered between residue H100 and H101 with letters up to K (i.e. H100, H100A ... H100K, H101). CDRs can alternatively be determined using the
 15 system of Chothia (Chothia *et al.*, (1989) Conformations of immunoglobulin hypervariable regions; Nature 342, p877-883), according to AbM or according to the Contact method as follows. See <http://www.bioinf.org.uk/abs/> for suitable methods for determining CDRs.

Once each residue has been numbered, one can then apply the following CDR
 20 definitions ("-" means same residue numbers as shown for Kabat):

Kabat - most commonly used method based on sequence variability
 (using Kabat numbering):

25 CDR H1: 31-35/35A/35B
 CDR H2: 50-65
 CDR H3: 95-102
 CDR L1: 24-34
 CDR L2: 50-56
 CDR L3: 89-97

30 Chothia - based on location of the structural loop regions
 (using Chothia numbering):
 CDR H1: 26-32
 CDR H2: 52-56

- 21 -

	CDR H3: 95-102	
	CDR L1: 24-34	
	CDR L2: 50-56	
	CDR L3: 89-97	
5	AbM - compromise between Kabat and Chothia	
	(using Kabat numbering):	(using Chothia numbering):
	CDR H1: 26-35/35A/35B	26-35
	CDR H2: 50-58	-
10	CDR H3: 95-102	-
	CDR L1: 24-34	-
	CDR L2: 50-56	-
	CDR L3: 89-97	-
15	Contact - based on crystal structures and prediction of contact residues with antigen	
	(using Kabat numbering):	(using Chothia numbering):
	CDR H1: 30-35/35A/35B	30-35
	CDR H2: 47-58	-
	CDR H3: 93-101	-
20	CDR L1: 30-36	-
	CDR L2: 46-55	-
	CDR L3: 89-96	-

As used herein, the term “antagonist of Tumor Necrosis Factor Receptor 1 (TNFR1)” or “anti-TNFR1 antagonist” or the like refers to an agent (e.g., a molecule, a compound) which binds TNFR1 and can inhibit a (i.e., one or more) function of TNFR1. For example, an antagonist of TNFR1 can inhibit the binding of TNF α to TNFR1 and/or inhibit signal transduction mediated through TNFR1. Accordingly, TNFR1-mediated processes and cellular responses (e.g., TNF α -induced cell death in a standard L929 cytotoxicity assay) can be inhibited with an antagonist of TNFR1.

As used herein, “peptide” refers to about two to about 50 amino acids that are joined together via peptide bonds.

As used herein, “polypeptide” refers to at least about 50 amino acids that are joined together by peptide bonds. Polypeptides generally comprise tertiary structure and fold into functional domains.

As used herein, a peptide or polypeptide (e.g. a domain antibody (dAb)) that is “resistant to protease degradation” is not substantially degraded by a protease when

- 22 -

incubated with the protease under conditions suitable for protease activity. A polypeptide (*e.g.*, a dAb) is not substantially degraded when no more than about 25%, no more than about 20%, no more than about 15%, no more than about 14%, no more than about 13%, no more than about 12%, no more than about 11%, no more than about 10%, no more than about 9%, no more than about 8%, no more than about 7%, no more than about 6%, no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, or substantially none of the protein is degraded by protease after incubation with the protease for about one hour at a temperature suitable for protease activity, for example at 37 or 50 degrees C. Protein degradation can be assessed using any suitable method, for example, by SDS-PAGE or by functional assay (*e.g.*, ligand binding) as described herein.

As used herein, "display system" refers to a system in which a collection of polypeptides or peptides are accessible for selection based upon a desired characteristic, such as a physical, chemical or functional characteristic. The display system can be a suitable repertoire of polypeptides or peptides (*e.g.*, in a solution, immobilized on a suitable support). The display system can also be a system that employs a cellular expression system (*e.g.*, expression of a library of nucleic acids in, *e.g.*, transformed, infected, transfected or transduced cells and display of the encoded polypeptides on the surface of the cells) or an acellular expression system (*e.g.*, emulsion compartmentalization and display). Exemplary display systems link the coding function of a nucleic acid and physical, chemical and/or functional characteristics of a polypeptide or peptide encoded by the nucleic acid. When such a display system is employed, polypeptides or peptides that have a desired physical, chemical and/or functional characteristic can be selected and a nucleic acid encoding the selected polypeptide or peptide can be readily isolated or recovered. A number of display systems that link the coding function of a nucleic acid and physical, chemical and/or functional characteristics of a polypeptide or peptide are known in the art, for example, bacteriophage display (phage display, for example phagemid display), ribosome display, emulsion compartmentalization and display, yeast display, puromycin display, bacterial display, display on plasmid, covalent display and the like. (See, *e.g.*, EP

- 23 -

0436597 (Dyax), U.S. Patent No. 6,172,197 (McCafferty *et al.*), U.S. Patent No. 6,489,103 (Griffiths *et al.*).

As used herein, “repertoire” refers to a collection of polypeptides or peptides that are characterized by amino acid sequence diversity. The individual members of a repertoire can have common features, such as common structural features (*e.g.*, a common core structure) and/or common functional features (*e.g.*, capacity to bind a common ligand (*e.g.*, a generic ligand or a target ligand, TNFR1)).

As used herein, “functional” describes a polypeptide or peptide that has biological activity, such as specific binding activity. For example, the term “functional polypeptide” includes an antibody or antigen-binding fragment thereof that binds a target antigen through its antigen-binding site.

As used herein, “generic ligand” refers to a ligand that binds a substantial portion (*e.g.*, substantially all) of the functional members of a given repertoire. A generic ligand (*e.g.*, a common generic ligand) can bind many members of a given repertoire even though the members may not have binding specificity for a common target ligand. In general, the presence of a functional generic ligand-binding site on a polypeptide (as indicated by the ability to bind a generic ligand) indicates that the polypeptide is correctly folded and functional. Suitable examples of generic ligands include superantigens, antibodies that bind an epitope expressed on a substantial portion of functional members of a repertoire, and the like.

“Superantigen” is a term of art that refers to generic ligands that interact with members of the immunoglobulin superfamily at a site that is distinct from the target ligand-binding sites of these proteins. Staphylococcal enterotoxins are examples of superantigens which interact with T-cell receptors. Superantigens that bind antibodies include Protein G, which binds the IgG constant region (Bjorck and Kronvall, *J. Immunol.*, 133:969 (1984)); Protein A which binds the IgG constant region and V_H domains (Forsgren and Sjoquist, *J. Immunol.*, 97:822 (1966)); and Protein L which binds V_L domains (Bjorck, *J. Immunol.*, 140:1194 (1988)).

As used herein, “target ligand” refers to a ligand which is specifically or selectively bound by a polypeptide or peptide. For example, when a polypeptide is an

- 24 -

antibody or antigen-binding fragment thereof, the target ligand can be any desired antigen or epitope. Binding to the target antigen is dependent upon the polypeptide or peptide being functional.

As used herein an antibody refers to IgG, IgM, IgA, IgD or IgE or a fragment
5 (such as a Fab, F(ab')₂, Fv, disulphide linked Fv, scFv, closed conformation multispecific antibody, disulphide-linked scFv, diabody) whether derived from any species naturally producing an antibody, or created by recombinant DNA technology; whether isolated from serum, B-cells, hybridomas, transfectomas, yeast or bacteria.

As used herein, "antibody format", "formatted" or similar refers to any suitable
10 polypeptide structure in which one or more antibody variable domains can be incorporated so as to confer binding specificity for antigen on the structure. A variety of suitable antibody formats are known in the art, such as, chimeric antibodies, humanized antibodies, human antibodies, single chain antibodies, bispecific antibodies, antibody heavy chains, antibody light chains, homodimers and heterodimers of antibody
15 heavy chains and/or light chains, antigen-binding fragments of any of the foregoing (*e.g.*, a Fv fragment (*e.g.*, single chain Fv (scFv), a disulfide bonded Fv), a Fab fragment, a Fab' fragment, a F(ab')₂ fragment), a single antibody variable domain (*e.g.*, a dAb, V_H, V_{HH}, V_L), and modified versions of any of the foregoing (*e.g.*, modified by the covalent attachment of polyethylene glycol or other suitable polymer or a
20 humanized V_{HH}).

The phrase "immunoglobulin single variable domain" refers to an antibody variable domain (V_H, V_{HH}, V_L) that specifically binds an antigen or epitope independently of other V regions or domains. An immunoglobulin single variable domain can be present in a format (*e.g.*, homo- or hetero-multimer) with other variable
25 regions or variable domains where the other regions or domains are not required for antigen binding by the single immunoglobulin variable domain (*i.e.*, where the immunoglobulin single variable domain binds antigen independently of the additional variable domains). A "domain antibody" or "dAb" is the same as an "immunoglobulin single variable domain" as the term is used herein. A "single immunoglobulin variable
30 domain" is the same as an "immunoglobulin single variable domain" as the term is used

- 25 -

herein. A “single antibody variable domain” or an “antibody single variable domain” is the same as an “immunoglobulin single variable domain” as the term is used herein. An immunoglobulin single variable domain is in one embodiment a human antibody variable domain, but also includes single antibody variable domains from other species
5 such as rodent (for example, as disclosed in WO 00/29004, the contents of which are incorporated herein by reference in their entirety), nurse shark and *Camelid* V_{HH} dAbs. Camelid V_{HH} are immunoglobulin single variable domain polypeptides that are derived from species including camel, llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies naturally devoid of light chains. The V_{HH} may be humanized.

10 A “domain” is a folded protein structure which has tertiary structure independent of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain. A “single antibody variable domain” is a folded polypeptide
15 domain comprising sequences characteristic of antibody variable domains. It therefore includes complete antibody variable domains and modified variable domains, for example, in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains, or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of
20 variable domains which retain at least the binding activity and specificity of the full-length domain.

The term “library” refers to a mixture of heterogeneous polypeptides or nucleic acids. The library is composed of members, each of which has a single polypeptide or nucleic acid sequence. To this extent, “library” is synonymous with “repertoire.”

25 Sequence differences between library members are responsible for the diversity present in the library. The library may take the form of a simple mixture of polypeptides or nucleic acids, or may be in the form of organisms or cells, for example bacteria, viruses, animal or plant cells and the like, transformed with a library of nucleic acids. In one embodiment, each individual organism or cell contains only one or a limited number of
30 library members. In one embodiment, the nucleic acids are incorporated into expression

- 26 -

vectors, in order to allow expression of the polypeptides encoded by the nucleic acids. In an aspect, therefore, a library may take the form of a population of host organisms, each organism containing one or more copies of an expression vector containing a single member of the library in nucleic acid form which can be expressed to produce its
5 corresponding polypeptide member. Thus, the population of host organisms has the potential to encode a large repertoire of diverse polypeptides.

A “universal framework” is a single antibody framework sequence corresponding to the regions of an antibody conserved in sequence as defined by Kabat (“Sequences of Proteins of Immunological Interest”, US Department of Health and
10 Human Services) or corresponding to the human germline immunoglobulin repertoire or structure as defined by Chothia and Lesk, (1987) J. Mol. Biol. 196:910-917. Libraries and repertoires can use a single framework, or a set of such frameworks, which has been found to permit the derivation of virtually any binding specificity though variation in the hypervariable regions alone.

15 As used herein, the term “dose” refers to the quantity of ligand administered to a subject all at one time (unit dose), or in two or more administrations over a defined time interval. For example, dose can refer to the quantity of ligand (*e.g.*, ligand comprising an immunoglobulin single variable domain that binds target antigen) administered to a subject over the course of one day (24 hours) (daily dose), two days, one week, two
20 weeks, three weeks or one or more months (*e.g.*, by a single administration, or by two or more administrations). The interval between doses can be any desired amount of time.

As used herein, “hydrodynamic size” refers to the apparent size of a molecule (*e.g.*, a protein molecule, ligand) based on the diffusion of the molecule through an
25 aqueous solution. The diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the “Stokes radius” or “hydrodynamic radius” of the protein particle. The “hydrodynamic size” of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based
30 on the overall conformation of the protein.

- 27 -

As referred to herein, the term “competes” means that the binding of a first target to its cognate target binding domain is inhibited in the presence of a second binding domain that is specific for the cognate target. For example, binding may be inhibited sterically, for example by physical blocking of a binding domain or by
5 alteration of the structure or environment of a binding domain such that its affinity or avidity for a target is reduced. See WO2006038027 for details of how to perform competition ELISA and competition BiaCore experiments to determine competition between first and second binding domains.

Calculations of “homology” or “identity” or “similarity” between two sequences
10 (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In an embodiment, the length of a reference sequence aligned for comparison purposes is at
15 least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at
20 that position (as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. Amino acid and nucleotide sequence
25 alignments and homology, similarity or identity, as defined herein may be prepared and determined using the algorithm BLAST 2 Sequences, using default parameters (Tatusova, T. A. *et al.*, *FEMS Microbiol Lett*, 174:187-188 (1999)).

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1;
30 p55) immunoglobulin single variable domain comprising an amino acid sequence that is

- 28 -

at least 95, 96, 97, 98 or 99% identical to the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180. In one embodiment, the single variable domain is DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162, DOM1h-574-180, DOM1h-574-7, DOM1h-574-8, DOM1h-574-10, DOM1h-574-12, DOM1h-574-13, DOM1h-574-14, DOM1h-574-15, DOM1h-574-16, DOM1h-574-17, DOM1h-574-18 or DOM1h-574-19. In one embodiment, the variable domain according to this aspect can have one or more features of any of the other aspects of the invention and the disclosure of the present text is to be interpreted to enable such features to be combined, eg for inclusion in claims herein.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising an amino acid sequence that is at least 95, 96, 97, 98 or 99% identical to the amino acid sequence of DOM1h-510, DOM1h-543 or DOM1h-549. In one embodiment, the single variable domain is DOM1h-510, DOM1h-543 or DOM1h-549. In one embodiment, the variable domain according to this aspect can have one or more features of any of the other aspects of the invention and the disclosure of the present text is to be interpreted to enable such features to be combined, eg for inclusion in claims herein.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is a mutant of DOM1h-574-14 comprising one or more of the following mutations (numbering according to Kabat)

position 30 is L or F,
position 52 is A or T,
position 52a is D or E,
position 54 is A or R,
position 57 is R, K or A,
position 60 is D, S, T or K,
position 61 is E, H or G,

- 29 -

position 62 is A or T,

position 100 is R, G, N, K, Q, V, A, D, S or V, and

position 101 is A, Q, N, E, V, H or K.

In one embodiment of this aspect, the mutant amino acid sequence is at least 98
5 or 99% identical to, the amino acid sequence of DOM1h-574. In one embodiment, the
mutant amino acid sequence is identical to, or at least 98 or 99% identical to, the amino
acid sequence of DOM1h-574-14. In one embodiment, the variable domain according
to this aspect can have one or more features of any of the other aspects of the invention
and the disclosure of the present text is to be interpreted to enable such features to be
10 combined, eg for inclusion in claims herein.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1;
p55) immunoglobulin heavy chain single variable domain comprising valine at position
101 (numbering according to Kabat). The inventors surprisingly found that V101 was
often associated with a high KD for TNFR1 (eg, human TNFR1) binding. In one
15 embodiment, the variable domain according to this aspect can have one or more features
of any of the other aspects of the invention and the disclosure of the present text is to be
interpreted to enable such features to be combined, eg for inclusion in claims herein.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1;
p55) immunoglobulin heavy chain single variable domain comprising valine at position
20 101 (numbering according to Kabat). The inventors surprisingly found that V101 was
often associated with proteolytic stability. More details on proteolytic stability and
proteolytically stable immunoglobulin single variable domains can be found in
WO2008149144 and WO2008149148, the disclosures of which are incorporated herein
by reference in their entirety, particularly to provide tests for determining protease
25 stability of variable domains and other anti-TNFR1 ligands, antagonists and binding
domains. In one embodiment, the variable domain according to this aspect can have
one or more features of any of the other aspects of the invention and the disclosure of
the present text is to be interpreted to enable such features to be combined, eg for
inclusion in claims herein.

- 30 -

In one embodiment, the single variable domain according to any aspect comprises one or more of 30G, 44D, 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 55D, 56R, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 55D, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 45P, 55D, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 30G, 44D, 55D, 94I and 98R, wherein numbering is according to Kabat.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising one or more of 30G, 44D, 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat, wherein the amino acid sequence of the single variable domain is otherwise identical to the amino acid sequence of DOM1h-574. In one embodiment, the variable domain is provided for binding human, murine or *Cynomologus monkey* TNFR1. In one embodiment, the variable domain comprises 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 55D, 56R, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 55D, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 45P, 55D, 94I and 98R, wherein numbering is according to Kabat. In one embodiment, the variable domain comprises 30G, 44D, 55D, 94I and 98R, wherein numbering is according to Kabat.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is identical to, or at least 95, 96, 97, 98 or 99% identical to, the amino acid sequence of DOM1h-574-72, DOM1h-574-156, DOM1h-574-109, DOM1h-574-132, DOM1h-574-135, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180. This aspect provides variable domains that are potent neutralizers of TNFR1 (eg, at least human TNFR1) in cell assay, eg in a standard MRC5 assay as determined by inhibition of TNF

- 31 -

alpha-induced IL-8 secretion; or in a standard L929 assay as determined by inhibition of TNF alpha-induced cytotoxicity; in a standard Cynomologus KI assay as determined by inhibition of TNF alpha-induced IL-8 secretion. Details of standard assays for TNFR1 antagonists are known in the art, eg in WO2006038027, WO2008149144 and

5 WO2008149148. Details are also provided in the experimental section below. In one embodiment, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 95, 96, 97, 98 or 99% identical to the amino acid sequence of any one of the DOM1h variable domains shown in Table 11 below, with the exception of DOM1h-
10 574. In one embodiment, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 95,96, 97, 98 or 99% identical to the amino acid sequence of any one of DOM1h-574-89 to DOM1h-574-179.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is identical to, or at least 94, 95, 96, 97, 98 or 99% identical to, the amino acid sequence of DOM1h-574-109, DOM1h-574-93, DOM1h-574-123, DOM1h-574-125, DOM1h-574-126 or DOM1h-574-129, DOM1h-574-133, DOM1h-574-137 or DOM1h-574-160. This aspect provides variable domains that that are proteolytically stable.
20 Reference is made to the discussion above on protease stability.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is identical to, or at least 95, 96, 97, 98 or 99% identical to, to the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-125, DOM1h-574-126, DOM1h-574-133, DOM1h-574-135 or DOM1h-574-138, DOM1h-574-139, DOM1h-574-155, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180. This aspect provides variable domains that bind human TNFR1 with high affinity and optionally also display desirable affinity for murine TNFR1.
25

The single variable domain is, eg, a non-competitive inhibitor of TNFR1. In one embodiment, the anti-TNFR1 single variable of any aspect of the invention binds
30

- 32 -

TNFR1 (eg, human TNFR1) but does not (or does not substantially) compete with or inhibit TNF alpha for binding to TNFR1 (eg, in a standard receptor binding assay). In this embodiment, in one example the variable domain specifically binds to domain 1 of TNFR1, eg, human TNFR1. In this embodiment, in one example the variable domain
 5 specifically binds to the PLAD of TNFR1, eg, human TNFR1.

In one embodiment, the anti-TNFR1 single variable domain of any aspect of the invention comprises a binding site that specifically binds

- (i) human TNFR1 with a dissociation constant (KD) of (or of about) 500pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150
 10 pM or less as determined by surface plasmon resonance; or
- (ii) non-human primate TNFR1 (eg, *Cynomolgus* monkey, rhesus or baboon TNFR1) with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance; or
- 15 (iii) murine TNFR1 with a dissociation constant (KD) of (or of about) 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, or 1nM or less as determined by surface plasmon resonance. In one example, the variable domain specifically binds according to (i) and (ii); (i) and (iii); (i), (ii) and (iii), or (ii) and (iii).

In one embodiment, the single variable domain of any aspect of the invention
 20 comprises a binding site that specifically binds

- (a) human TNFR1 with an off-rate constant (Koff) of (or of about) $2 \times 10^{-4} \text{ S}^{-1}$ or less, or $1 \times 10^{-4} \text{ S}^{-1}$ or less, or $1 \times 10^{-5} \text{ S}^{-1}$ or less as determined by surface plasmon resonance;
- (b) non-human primate TNFR1 (eg, *Cynomolgus* monkey, rhesus or baboon
 25 TNFR1) with an off-rate constant (Koff) of (or of about) $2 \times 10^{-4} \text{ S}^{-1}$ or less, $1 \times 10^{-4} \text{ S}^{-1}$ or less, or $1 \times 10^{-5} \text{ S}^{-1}$ or less as determined by surface plasmon resonance; or
- (c) murine TNFR1 with an off-rate constant (Koff) of (or of about) $1 \times 10^{-3} \text{ S}^{-1}$ or less, or $1 \times 10^{-4} \text{ S}^{-1}$ or less as determined by surface plasmon resonance. In one example, the variable domain specifically binds according to (a) and (b); (a) and (c); (a),
 30 (b) and (c), or (b) and (c).

- 33 -

In one embodiment, the single variable domain of any aspect of the invention comprises a binding site that specifically binds

- (a') human TNFR1 with an on-rate constant (K_{on}) of (or of about) $5 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$ or more, $1 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $2 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $3 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $4 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, or $5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more as determined by surface plasmon resonance;
- (b') non-human primate TNFR1 (eg, *Cynomolgus* monkey, rhesus or baboon TNFR1) with an on-rate constant (K_{on}) of (or of about) $5 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$ or more, $1 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $2 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $3 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $4 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, or $5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more as determined by surface plasmon resonance; or
- (c') murine TNFR1 with an on-rate constant (K_{on}) of (or of about) $0.5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, $1 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more, or $2 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ or more as determined by surface plasmon resonance. In one example, the variable domain specifically binds according to (a') and (b'); (a') and (c'); (a'), (b') and (c'), or (b') and (c').

In one embodiment, the single variable domain of any aspect of the invention specifically binds human, *Cynomologus* monkey and optionally canine TNFR1. Specific binding is indicated by a dissociation constant K_D of 10 micromolar or less, optionally 1 micromolar or less. Specific binding of an antigen-binding protein to an antigen or epitope can be determined by a suitable assay, including, for example, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays such as ELISA and sandwich competition assays, and the different variants thereof. In one example, the variable domain also specifically binds murine TNFR1.

In one embodiment of any aspect of the invention, the single variable domain inhibits the binding of human, *Cynomologus* monkey and optionally canine TNFR1 to DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180, for example in a standard cell assay (eg, as described herein or in WO2006038027, WO2008149144 or WO2008149148. In an embodiment of any aspect of the invention, the single variable domain inhibits the binding of human, murine, *Cynomologus* monkey and optionally canine TNFR1 to DOM1h-574-72,

- 34 -

DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 or DOM1h-574-180, for example in a standard receptor binding assay (eg, as described herein or in WO2006038027, WO2008149144 or WO2008149148). In an example, “inhibits” in these embodiments is inhibition can be total (100% inhibition) or substantial (at least 90%, 95%, 98%, or 99%).

In one embodiment of any aspect of the invention, the anti-TNFR1 single variable, antagonist, ligand or polypeptide neutralizes TNFR1 (eg, human TNFR1) with an ND50 of (or about of) 5, 4, 3, 2 or 1 nM or less in a standard MRC5 assay as determined by inhibition of TNF alpha-induced IL-8 secretion.

10 In one embodiment of any aspect of the invention, the anti-TNFR1 single variable, antagonist, ligand or polypeptide neutralizes TNFR1 (eg, murine TNFR1) with an ND50 of 150, 100, 50, 40, 30 or 20 nM or less; or from (about) 150 to 10 nM; or from (about) 150 to 20 nM; or from (about) 110 to 10 nM; or from (about) 110 to 20 nM in a standard L929 assay as determined by inhibition of TNF alpha-induced cytotoxicity.

15 In one embodiment of any aspect of the invention, the anti-TNFR1 single variable, antagonist, ligand or polypeptide neutralises TNFR1 (eg, *Cynomologus* monkey TNFR1) with an ND50 of 5, 4, 3, 2 or 1 nM or less; or (about) 5 to (about) 1 nM in a standard *Cynomologus* KI assay as determined by inhibition of TNF alpha-induced IL-8 secretion.

20 In one embodiment of any aspect of the invention, the single variable domain comprises a terminal, optionally C-terminal, cysteine residue. For example, the cysteine residue can be used to attach PEG to the variable domain, eg, using a maleimide linkage (see, eg, WO04081026). In an embodiment of any aspect of the invention, the single variable domain is linked to a polyalkylene glycol moiety, optionally a polyethylene glycol moiety. See, eg, WO04081026, for suitable PEG moieties and conjugation methods and tests. These disclosures are incorporated herein in order to provide disclosure, for example of specific PEGs to be included in claims below.

- 35 -

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and
5 DOM1h-574-180 or differs from the selected amino acid sequence at no more than 25, 20, 15, 10 or 5 amino acid positions and has a CDR1 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98 % identical to, the CDR1 sequence of the selected amino acid sequence. In one embodiment, the immunoglobulin single variable domain comprises a CDR3 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98
10 % identical to, the CDR3 sequence of the selected amino acid sequence.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-
15 162 and DOM1h-574-180 or differs from the selected amino acid sequence at no more than 25, 20, 15, 10 or 5 amino acid positions and has a CDR2 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98 % identical to, the CDR2 sequence of the selected amino acid sequence. In one embodiment, the immunoglobulin single variable domain comprises a CDR2 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95
20 or 98 % identical to, the CDR2 sequence of the selected amino acid sequence.

Additionally, or alternatively, in one embodiment, the immunoglobulin single variable domain comprises a CDR3 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98 % identical to, the CDR3 sequence of the selected amino acid sequence.

Additionally, or alternatively, in one embodiment, the immunoglobulin single variable
25 domain comprises a CDR1 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98 % identical to, the CDR1 sequence of the selected amino acid sequence.

In one aspect, the invention provides an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprising an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of
30 DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-

- 36 -

162 and DOM1h-574-180 or differs from the selected amino acid sequence at no more than 25, 20, 15, 10 or 5 amino acid positions and has a CDR3 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98 % identical to, the CDR3 sequence of the selected amino acid sequence.

5 In one aspect, the invention provides a protease resistant anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is resistant to protease when incubated with

(i) a concentration (c) of at least 10 micrograms/ml protease at 37°C for time (t) of at least one hour; or

10 (ii) a concentration (c') of at least 40 micrograms/ml protease at 30°C for time (t) of at least one hour.

wherein the variable domain comprises an amino acid sequence that is at least 94, 95, 96, 97, 98 or 99% identical to the amino acid sequence of DOM1h-574-126 or DOM1h-574-133, and optionally comprises a valine at position 101 (Kabat numbering). In

15 another aspect, the invention provides a protease resistant anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is resistant to protease when incubated with

(i) a concentration (c) of at least 10 micrograms/ml protease at 37°C for time (t) of at least one hour; or

20 (ii) a concentration (c') of at least 40 micrograms/ml protease at 30°C for time (t) of at least one hour.

wherein the variable domain comprises an amino acid sequence that is at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to the amino acid sequence of DOM1h-574, DOM1h-574-93, DOM1h-574-123, DOM1h-574-125, DOM1h-574-126, 25 DOM1h-574-129, DOM1h-574-133, DOM1h-574-137 or DOM1h-574-160, and optionally comprises a valine at position 101 (Kabat numbering).

 In one embodiment of these aspects, the protease resistant anti-TNFR1 variable domain is a non-competitive variable domain (ie, it does not (substantially) inhibit the binding of TNF alpha to TNFR1). See the discussion above on non-competitive 30 variable domains, which applies to these embodiments too.

- 37 -

In one embodiment of these aspects the concentration (c or c') is at least 100 or 1000 micrograms/ml protease. In one embodiment, time (t) is one, three or 24 hours or overnight. In one example, the variable domain is resistant under conditions (i) and the concentration (c) is 10 or 100 micrograms/ml protease and time (t) is 1 hour. In one
5 example, the variable domain is resistant under conditions (ii) and the concentration (c') is 40 micrograms/ml protease and time (t) is 3 hours. In one embodiment, the protease is selected from trypsin, elastase, leucozyme and pancreatin. In one embodiment, the protease is trypsin. In one embodiment, the variable domain is resistant to trypsin and at least one other protease selected from elastase, leucozyme and pancreatin. In one
10 embodiment, the variable domain specifically binds TNFR1 following incubation under condition (i) or (ii). In one embodiment, the variable domain has an OD₄₅₀ reading in ELISA of at least 0.404 following incubation under condition (i) or (ii). In one embodiment, the variable domain specifically binds protein A or protein L following incubation under condition (i) or (ii). In one embodiment, the variable domain displays
15 substantially a single band in gel electrophoresis following incubation under condition (i) or (ii). In one embodiment, the single variable domain that has a T_m of at least 50°C. More details relating to protease resistance can be found in WO2008149144 and WO2008149148.

In one aspect, the invention relates to a polypeptide comprising an
20 immunoglobulin single variable domain of the present invention and an effector group or an antibody constant domain, optionally an antibody Fc region, optionally wherein the N-terminus of the Fc is linked (optionally directly linked) to the C-terminus of the variable domain. Any "effector group" as described in WO04058820 can be used in this aspect of the present invention, and the description of the effector groups in
25 WO04058820 and methods of linking them to variable domains disclosed in that publication are explicitly incorporated herein by reference to provide description herein that can be used, for example, in claims herein. In one embodiment, the polypeptide comprises an Fc fusion of DOM1h-574-16 or DOM1h-574-72.

In one aspect, the invention relates to a multispecific ligand comprising an
30 immunoglobulin single variable domain of the present invention and optionally at least

- 38 -

one immunoglobulin single variable domain that specifically binds serum albumin (SA). Surprisingly, the inventors found that fusion of an anti-TNFR1 single variable domain according to the invention to an anti-SA single variable domain provides the advantage of improved half-life (over an anti-TNFR1 dAb monomer alone), but also with the added benefit of an improvement in the affinity (KD) for TNFR1 binding. This observation has not been disclosed before in the state of the art. In this respect, the invention provides a multispecific ligand comprising an anti-TNFR1 immunoglobulin single variable domain of the invention and an anti-SA (eg, anti-human SA) immunoglobulin single variable domain for providing a ligand that has a longer half-life and a lower KD for TNFR1 binding (eg, human TNFR1 binding) than the anti-TNFR1 immunoglobulin single variable domain when provided as a variable domain monomer (ie, when the anti-TNFR1 variable domain is unformatted, eg, not PEGylated or fused to an antibody constant region such as an Fc region, and is not fused to any other domain). In one embodiment, the multispecific ligand binds TNFR1 (eg, human TNFR1) with a KD that is at least two-fold lower than the KD of the TNFR1 monomer. Additionally or alternatively, in one embodiment, the multispecific ligand has a half-life that is at least 5, 10, 20, 30, 40, 50 or 100 times that of the monomer. Additionally or alternatively, in one embodiment, the multispecific ligand has a terminal half-life of at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 days in man (for example as determined empirically in human volunteers or as calculated using conventional techniques familiar to the skilled person by extrapolating from the half-life of the ligand in an animal system such as mouse, dog and/or non-human primate (eg, *Cynomolgus* monkey, baboon, rhesus monkey)), for example where the anti-SA domain is cross-reactive between human SA and SA from the animal.

In one embodiment of the multispecific ligands of the invention, the ligand is an antagonist of TNFR1 (eg, human TNFR1), optionally of TNFR1-mediated signaling.

In one embodiment, the present invention provides the variable domain, multispecific ligand or antagonist according to the invention that has a $t_{1/2}$ half-life in the range of (or of about) 2.5 hours or more. In one embodiment, the lower end of the range is (or is about) 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 10 hours, 11 hours, or

- 39 -

12 hours. In addition, or alternatively, the $t_{1/2}$ half-life is (or is about) up to and including 21 or 25 days. In one embodiment, the upper end of the range is (or is about) 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days, 19 days, 20 days, 21 days or 22 days. For example, the variable domain or antagonist according to the invention will have a $t_{1/2}$ half life in the range 12 to 60 hours (or about 12 to 60 hours). In a further embodiment, it will be in the range 12 to 48 hours (or about 12 to 48 hours). In a further embodiment still, it will be in the range 12 to 26 hours (or about 12 to 26 hours).

As an alternative to using two-compartment modeling, the skilled person will be familiar with the use of non-compartmental modeling, which can be used to determine terminal half-lives (in this respect, the term "terminal half-life" as used herein means a terminal half-life determined using non-compartmental modeling). The WinNonlin analysis package, eg version 5.1 (available from Pharsight Corp., Mountain View, CA94040, USA) can be used, for example, to model the curve in this way. In this instance, in one embodiment the single variable domain, multispecific ligand or antagonist has a terminal half life of at least (or at least about) 8 hours, 10 hours, 12 hours, 15 hours, 28 hours, 20 hours, 1 day, 2 days, 3 days, 7 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days or 25 days. In one embodiment, the upper end of this range is (or is about) 24 hours, 48 hours, 60 hours or 72 hours or 120 hours. For example, the terminal half-life is (or is about) from 8 hours to 60 hours, or 8 hours to 48 hours or 12 to 120 hours, eg, in man.

In addition, or alternatively to the above criteria, the variable domain or antagonist according to the invention has an AUC value (area under the curve) in the range of (or of about) 1 mg.min/ml or more. In one embodiment, the lower end of the range is (or is about) 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, the variable domain, multispecific ligand or antagonist according to the invention has an AUC in the range of (or of about) up to 600 mg.min/ml. In one embodiment, the upper end of the range is (or is about) 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml. Advantageously the variable domain or antagonist will have a AUC

- 40 -

in (or about in) the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50mg.min/ml.

One or more of the t alpha, t beta and terminal half-lives as well as the AUCs quoted herein can be obtained in a human and/or animal (eg, mouse or non-human primate, eg, baboon, rhesus, *Cynomolgus* monkey) by providing one or more anti-TNFR1 single variable domains (or other binding moieties defined herein) linked to either a PEG or a single variable domain (or binding moiety) that specifically binds to serum albumin, eg mouse and/or human serum albumin (SA). The PEG size can be (or be about) at least 20 kDa, for example, 30, 40, 50, 60, 70 or 80 kDa. In one embodiment, the PEG is 40 kDa, eg 2x20kDa PEG. In one embodiment, to obtain a t alpha, t beta and terminal half-lives or an AUC quoted herein, there is provide an antagonist comprising an anti-TNFR1 immunoglobulin single variable domain linked to an anti-SA immunoglobulin single variable domain. In one embodiment, the PEG is 40 kDa, eg 2x20kDa PEG. For example, the antagonist comprises only one such anti-TNFR1 variable domains, for example one such domain linked to only one anti-SA variable domains. In one embodiment, to obtain a t alpha, t beta and terminal half-lives or a AUC quoted herein, there is provide an antagonist comprising an anti-TNFR1 immunoglobulin single variable domain linked to PEG, eg, 40-80 kDa PEG, eg, 40 kDa PEG. For example, the antagonist comprises only one such anti-TNFR1 variable domains, for example one such domain linked to 40 kDa PEG.

In one embodiment of the multispecific ligand of the invention, the ligand comprises an anti-SA (eg, HSA) single variable domain that comprises an amino acid sequence that is identical to, or at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to, the sequence of DOM7h-11, DOM7h-11-3, DOM7h-11-12, DOM7h-11-15, DOM7h-14, DOM7h-14-10, DOM7h-14-18 or DOM7m-16. Alternatively or additionally, in an embodiment, the multispecific ligand comprises a linker provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS. Alternatively, the linker is AS(G₄S)_n, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example AS(G₄S)₃. For example, the ligand comprises (N- to C- terminally) DOM1h-574-16-

- 41 -

AST-DOM7h-11; or DOM1h-574-72-ASTSGPS-DOM7m-16; or DOM1h-574-72-ASTSGPS-DOM7h-11-12.

In one aspect, the invention provides a multispecific ligand comprising (i) an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is identical to, or at least 93, 94, 95, 96, 97, 98 or 99% identical to, the amino acid sequence of DOM1h-574-156, (ii) at least one anti-serum albumin (SA) immunoglobulin single variable domain that specifically binds SA, wherein the anti-SA single variable domain comprises an amino acid sequence that is identical to, or at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to, the sequence of DOM7h-11-3, and (iii) optionally wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS. Alternatively, the linker is AS(G₄S)_n, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example AS(G₄S)₃. For example, the ligand comprises DOM1h-574-156 and DOM7h-11-3 optionally linked by AST or ASTSGPS. Alternatively, the linker is AS(G₄S)_n, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example AS(G₄S)₃. In this example or aspect, the ligand is optionally adapted for administration to a patient intravascularly, subcutaneously, intramuscularly, peritoneally or by inhalation. In one example, the ligand is provided as a dry-powder or lyophilized composition (which optionally is mixed with a diluent prior to administration).

In one aspect, the invention provides a multispecific ligand comprising (i) an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is identical to, or at least 93, 94, 95, 96, 97, 98 or 99% identical to, the amino acid sequence of DOM1h-574-156, (ii) at least one anti-serum albumin (SA) immunoglobulin single variable domain that specifically binds SA, wherein the anti-SA single variable domain comprises an amino acid sequence that is identical to, or at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to, the sequence of DOM7h-14-10, and (iii) optionally wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally

- 42 -

ASTSGPS. Alternatively, the linker is $AS(G_4S)_n$, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example $AS(G_4S)_3$. For example, the ligand comprises DOM1h-574-156 and DOM7h-14-10 optionally linked by AST or ASTSGPS. Alternatively, the linker is $AS(G_4S)_n$, where n is 1, 2, 3, 4, 5, 6, 7 or 8, for example $AS(G_4S)_3$. In this example or aspect, the
5 ligand is optionally adapted for administration to a patient by intravascularly, sub-cutaneously, intramuscularly, peritoneally or by inhalation. In one example, the ligand is provided as a dry-powder or lyophilized composition (which optionally is mixed with a diluent prior to administration).

The invention provides a TNFR1 antagonist comprising a single variable
10 domain, polypeptide or multispecific ligand of any aspect or embodiment of the invention. For example, the antagonist or variable domain of the invention is monovalent for TNFR1 binding. For example, the antagonist or variable domain of the invention is monovalent or substantially monovalent as determined by standard SEC-MALLS. Substantial monovalency is indicated by no more than 5, 4, 3, 2 or 1% of the
15 variable domain or antagonist being present in a non-monovalent form as determined by standard SEC-MALLS.

In one embodiment, the antagonist of the invention comprises first and second anti-TNFR1 immunoglobulin single variable domains, wherein each variable domain is according to any aspect or embodiment of the invention. The first and second
20 immunoglobulin single variable domains are in one example identical. In another example they are different.

In one example, the antagonist the amino acid sequence of the or each anti-TNFR1 single variable domain in an antagonist of the invention is identical to the amino acid sequence of DOM1h-574-16 or DOM1h-574-72.

25 In one aspect, the invention provides a $TN\alpha$ receptor type 1 (TNFR1; p55) antagonist comprising an anti-TNFR1 variable domain according to any aspect of the invention, for oral delivery, delivery to the GI tract of a patient, pulmonary delivery, delivery to the lung of a patient or systemic delivery. In another aspect, the invention provides the use of the TNFR1 antagonist of any aspect of the invention in the
30 manufacture of a medicament for oral delivery. In another aspect, the invention

- 43 -

provides the use of the TNFR1 antagonist of any aspect of the invention in the manufacture of a medicament for delivery to the GI tract of a patient. In one example of the antagonist or the variable domain is resistant to trypsin, elastase and/or pancreatin.

5 In one aspect, the invention provides the use of a TNFR1 antagonist of any aspect of the invention in the manufacture of a medicament for pulmonary delivery.

In another aspect, the invention provides the use of a TNFR1 antagonist of any aspect of the invention in the manufacture of a medicament for delivery to the lung of a patient. In one example the antagonist or the variable domain is resistant to leucozyme.

10 In one aspect, the invention provides a method of oral delivery or delivery of a medicament to the GI tract of a patient or to the lung or pulmonary tissue of a patient, wherein the method comprises administering to the patient a pharmaceutically effective amount of a TNFR1 antagonist of the invention.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55)
15 antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR1 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98% identical to, the CDR1 sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180. Optionally, the antagonist also has a CDR2 sequence that is identical to, or at least 50, 60, 70, 80, 90,
20 95 or 98% identical to, the CDR2 sequence of the selected sequence. Optionally, additionally or alternatively, the antagonist also has a CDR3 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98% identical to, the CDR3 sequence of the selected sequence.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55)
25 antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR2 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98% identical to, the CDR2 sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180. Optionally, the antagonist also has a CDR3 sequence that is identical to, or at least 50, 60, 70, 80, 90,
30 95 or 98% identical to, the CDR3 sequence of the selected sequence.

- 44 -

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR3 sequence that is identical to, or at least 50, 60, 70, 80, 90, 95 or 98% identical to, the CDR3 sequence of DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180.

In one aspect, the invention provides a TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist comprising an immunoglobulin single variable domain comprising the sequence of CDR1, CDR2, and/or CDR3 of a single variable domain selected from DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180.

The invention provides the TNFR1 antagonist of any aspect for treating and/or prophylaxis of an inflammatory condition. The invention provides the use of the TNFR1 antagonist of any aspect in the manufacture of a medicament for treating and/or prophylaxis of an inflammatory condition. In one embodiment of the antagonist or use, the condition is selected from the group consisting of arthritis, multiple sclerosis, inflammatory bowel disease and chronic obstructive pulmonary disease. In one example, the arthritis is rheumatoid arthritis or juvenile rheumatoid arthritis. In one example, the inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis. In one example, the chronic obstructive pulmonary disease is selected from the group consisting of chronic bronchitis, chronic obstructive bronchitis and emphysema. In one example, the pneumonia is bacterial pneumonia. In one example, the bacterial pneumonia is Staphylococcal pneumonia.

The invention provides a TNFR1 antagonist of any aspect for treating and/or prophylaxis of a respiratory disease. The invention provides the use of the TNFR1 antagonist of any aspect in the manufacture of a medicament for treating and/or prophylaxis of a respiratory disease. In one example the respiratory disease is selected from the group consisting of lung inflammation, chronic obstructive pulmonary disease, asthma, pneumonia, hypersensitivity pneumonitis, pulmonary infiltrate with eosinophilia, environmental lung disease, pneumonia, bronchiectasis, cystic fibrosis,

- 45 -

interstitial lung disease, primary pulmonary hypertension, pulmonary thromboembolism, disorders of the pleura, disorders of the mediastinum, disorders of the diaphragm, hypoventilation, hyperventilation, sleep apnea, acute respiratory distress syndrome, mesothelioma, sarcoma, graft rejection, graft versus host disease, lung
 5 cancer, allergic rhinitis, allergy, asbestosis, aspergilloma, aspergillosis, bronchiectasis, chronic bronchitis, emphysema, eosinophilic pneumonia, idiopathic pulmonary fibrosis, invasive pneumococcal disease, influenza, nontuberculous mycobacteria, pleural effusion, pneumoconiosis, pneumocytosis, pneumonia, pulmonary actinomycosis, pulmonary alveolar proteinosis, pulmonary anthrax, pulmonary edema, pulmonary
 10 embolus, pulmonary inflammation, pulmonary histiocytosis X, pulmonary hypertension, pulmonary nocardiosis, pulmonary tuberculosis, pulmonary veno-occlusive disease, rheumatoid lung disease, sarcoidosis, and Wegener's granulomatosis.

In one aspect, an anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand of any one aspect of the invention is provided for targeting one or
 15 more epitopic sequence of TNFR1 selected from the group consisting of NSICCTKCHKGTYLY, NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF. In one example, the anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand is provided for targeting NSICCTKCHKGTYLY. In one example, the anti-TNFR1 antagonist, single variable
 20 domain, polypeptide or multispecific ligand is provided for targeting NSICCTKCHKGTYL. In one example, the anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand is provided for targeting CRKNQYRHYWSENLF. In one example, the anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand is provided for targeting
 25 NQYRHYWSENLFQCF. In one example, the anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand is provided for targeting CRKNQYRHYWSENLF and NQYRHYWSENLFQCF. In one example, the anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand is provided for targeting NSICCTKCHKGTYLY, CRKNQYRHYWSENLF and
 30 NQYRHYWSENLFQCF. In one example, the anti-TNFR1 antagonist, single variable

- 46 -

domain, polypeptide or multispecific ligand is provided for targeting NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF. In one example, such targeting is to treat and/or prevent any condition or disease specified above. In one aspect, the invention provides a method of treating and/or preventing any
5 condition or disease specified above in a patient, the method comprising administering to the patient an anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand the invention for targeting one or more epitopic sequence of TNFR1 as described in any of the preceding embodiments.

10 POLYPEPTIDES, dAbs & ANTAGONISTS

The polypeptide, ligand, dAb, ligand or antagonist can be expressed in *E. coli* or in *Pichia* species (e.g., *P. pastoris*). In one embodiment, the ligand or dAb monomer is secreted in a quantity of at least about 0.5 mg/L when expressed in *E. coli* or in *Pichia*
15 species (e.g., *P. pastoris*). Although, the ligands and dAb monomers described herein can be secretable when expressed in *E. coli* or in *Pichia* species (e.g., *P. pastoris*), they can be produced using any suitable method, such as synthetic chemical methods or biological production methods that do not employ *E. coli* or *Pichia* species.

In some embodiments, the polypeptide, ligand, dAb, ligand or antagonist does
20 not comprise a *Camelid* immunoglobulin variable domain, or one or more framework amino acids that are unique to immunoglobulin variable domains encoded by *Camelid* germline antibody gene segments, eg at position 108, 37, 44, 45 and/or 47. In one embodiment, the anti-TNFR1 variable domain of the invention comprises a G residue at position 44 according to Kabat and optionally comprises one or more Camelid-specific
25 amino acids at other positions, eg at position 37 or 103.

Antagonists of TNFR1 according to the invention can be monovalent or multivalent. In some embodiments, the antagonist is monovalent and contains one binding site that interacts with TNFR1, the binding site provided by a polypeptide or dAb of the invention. Monovalent antagonists bind one TNFR1 and may not induce

- 47 -

cross-linking or clustering of TNFR1 on the surface of cells which can lead to activation of the receptor and signal transduction.

In other embodiments, the antagonist of TNFR1 is multivalent. Multivalent antagonists of TNFR1 can contain two or more copies of a particular binding site for
5 TNFR1 or contain two or more different binding sites that bind TNFR1, at least one of the binding sites being provided by a polypeptide or dAb of the invention. For example, as described herein the antagonist of TNFR1 can be a dimer, trimer or multimer comprising two or more copies of a particular polypeptide or dAb of the invention that binds TNFR1, or two or more different polypeptides or dAbs of the
10 invention that bind TNFR1. In one embodiment, a multivalent antagonist of TNFR1 does not substantially agonize TNFR1 (act as an agonist of TNFR1) in a standard cell assay (*i.e.*, when present at a concentration of 1 nM, 10 nM, 100 nM, 1 μ M, 10 μ M, 100 μ M, 1000 μ M or 5,000 μ M, results in no more than about 5% of the TNFR1-mediated activity induced by TNF α (100 pg/ml) in the assay).

15 In certain embodiments, the multivalent antagonist of TNFR1 contains two or more binding sites for a desired epitope or domain of TNFR1. For example, the multivalent antagonist of TNFR1 can comprise two or more binding sites that bind the same epitope in Domain 1 of TNFR1.

In other embodiments, the multivalent antagonist of TNFR1 contains two or
20 more binding sites provided by polypeptides or dAbs of the invention that bind to different epitopes or domains of TNFR1. In one embodiment, such multivalent antagonists do not agonize TNFR1 when present at a concentration of about 1 nM, or about 10 nM, or about 100 nM, or about 1 μ M, or about 10 μ M, in a standard L929 cytotoxicity assay or a standard HeLa IL-8 assay as described in WO2006038027.

25 Other antagonists of TNFR1 do not inhibit binding of TNF α to TNFR1. Such ligands (and antagonists) may have utility as diagnostic agents, because they can be used to bind and detect, quantify or measure TNFR1 in a sample and will not compete with TNF in the sample for binding to TNFR1. Accordingly, an accurate determination of whether or how much TNFR1 is in the sample can be made.

- 48 -

In other embodiments, the polypeptide, ligand, dAb or antagonist binds TNFR1 and antagonizes the activity of the TNFR1 in a standard cell assay with an ND_{50} of ≤ 100 nM, and at a concentration of $\leq 10\mu\text{M}$ the dAb agonizes the activity of the TNFR1 by $\leq 5\%$ in the assay.

5 In particular embodiments, the polypeptide, ligand, dAb or antagonist does not substantially agonize TNFR1 (act as an agonist of TNFR1) in a standard cell assay (*i.e.*, when present at a concentration of 1 nM, 10 nM, 100 nM, 1 μM , 10 μM , 100 μM , 1000 μM or 5,000 μM , results in no more than about 5% of the TNFR1-mediated activity induced by $\text{TNF}\alpha$ (100 pg/ml) in the assay).

10 In certain embodiments, the polypeptide, ligand, dAb or antagonist of the invention are efficacious in models of chronic inflammatory diseases when an effective amount is administered. Generally an effective amount is about 1 mg/kg to about 10 mg/kg (e.g., about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10
15 mg/kg). The models of chronic inflammatory disease (see those described in WO2006038027) are recognized by those skilled in the art as being predictive of therapeutic efficacy in humans.

In particular embodiments, the polypeptide, ligand, dAb or antagonist is efficacious in the standard mouse collagen-induced arthritis model (see
20 WO2006038027 for details of the model). For example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can reduce the average arthritic score of the summation of the four limbs in the standard mouse collagen-induced arthritis model, for example, by about 1 to about 16, about 3 to about 16, about 6 to about 16, about 9 to about 16, or about 12 to about 16, as compared to a suitable
25 control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can delay the onset of symptoms of arthritis in the standard mouse collagen-induced arthritis model, for example, by about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 14 days, about 21 days or about 28 days, as compared to a suitable control. In
30 another example, administering an effective amount of the polypeptide, ligand, dAb or

- 49 -

antagonist can result in an average arthritic score of the summation of the four limbs in the standard mouse collagen-induced arthritis model of 0 to about 3, about 3 to about 5, about 5 to about 7, about 7 to about 15, about 9 to about 15, about 10 to about 15, about 12 to about 15, or about 14 to about 15.

5 In other embodiments, the polypeptide, ligand, dAb or antagonist is efficacious in the mouse Δ ARE model of arthritis (see WO2006038027 for details of the model). For example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can reduce the average arthritic score in the mouse Δ ARE model of arthritis, for example, by about 0.1 to about 2.5, about 0.5 to about 2.5, about 1 to about 2.5,
10 about 1.5 to about 2.5, or about 2 to about 2.5, as compared to a suitable control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can delay the onset of symptoms of arthritis in the mouse Δ ARE model of arthritis by, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 14 days, about 21 days or about
15 28 days, as compared to a suitable control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can result in an average arthritic score in the mouse Δ ARE model of arthritis of 0 to about 0.5, about 0.5 to about 1, about 1 to about 1.5, about 1.5 to about 2, or about 2 to about 2.5.

 In other embodiments, the polypeptide, ligand, dAb or antagonist is efficacious
20 in the mouse Δ ARE model of inflammatory bowel disease (IBD) (see WO2006038027 for details of the model). For example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can reduce the average acute and/or chronic inflammation score in the mouse Δ ARE model of IBD, for example, by about 0.1 to about 2.5, about 0.5 to about 2.5, about 1 to about 2.5, about 1.5 to about 2.5, or about 2
25 to about 2.5, as compared to a suitable control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can delay the onset of symptoms of IBD in the mouse Δ ARE model of IBD by, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 14 days, about 21 days or about 28 days, as compared to a suitable

- 50 -

control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can result in an average acute and/or chronic inflammation score in the mouse Δ ARE model of IBD of 0 to about 0.5, about 0.5 to about 1, about 1 to about 1.5, about 1.5 to about 2, or about 2 to about 2.5.

5 In other embodiments, the polypeptide, ligand, dAb or antagonist is efficacious in the mouse dextran sulfate sodium (DSS) induced model of IBD (see WO2006038027 for details of the model). For example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can reduce the average severity score in the mouse DSS model of IBD, for example, by about 0.1 to about 2.5, about 0.5 to about
10 2.5, about 1 to about 2.5, about 1.5 to about 2.5, or about 2 to about 2.5, as compared to a suitable control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can delay the onset of symptoms of IBD in the mouse DSS model of IBD by, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 14 days,
15 about 21 days or about 28 days, as compared to a suitable control. In another example, administering an effective amount of the polypeptide, ligand, dAb or antagonist can result in an average severity score in the mouse DSS model of IBD of 0 to about 0.5, about 0.5 to about 1, about 1 to about 1.5, about 1.5 to about 2, or about 2 to about 2.5.

 In particular embodiments, the polypeptide, ligand, dAb or antagonist is
20 efficacious in the mouse tobacco smoke model of chronic obstructive pulmonary disease (COPD) (see WO2006038027 and WO2007049017 for details of the model). For example, administering an effective amount of the ligand can reduce or delay onset of the symptoms of COPD, as compared to a suitable control.

 Animal model systems which can be used to screen the effectiveness of the
25 antagonists of TNFR1 (e.g, ligands, antibodies or binding proteins thereof) in protecting against or treating the disease are available. Methods for the testing of systemic lupus erythematosus (SLE) in susceptible mice are known in the art (Knight *et al.* (1978) *J. Exp. Med.*, 147: 1653; Reinersten *et al.* (1978) *New Eng. J. Med.*, 299: 515). Myasthenia Gravis (MG) is tested in SJL/J female mice by inducing the disease with
30 soluble AchR protein from another species (Lindstrom *et al.* (1988) *Adv. Immunol.*, 42:

- 51 -

233). Arthritis is induced in a susceptible strain of mice by injection of Type II collagen (Stuart *et al.* (1984) *Ann. Rev. Immunol.*, 42: 233). A model by which adjuvant arthritis is induced in susceptible rats by injection of mycobacterial heat shock protein has been described (Van Eden *et al.* (1988) *Nature*, 331: 171). Thyroiditis is induced in mice by
5 administration of thyroglobulin as described (Maron *et al.* (1980) *J. Exp. Med.*, 152: 1115). Insulin dependent diabetes mellitus (IDDM) occurs naturally or can be induced in certain strains of mice such as those described by Kanasawa *et al.* (1984) *Diabetologia*, 27: 113. EAE in mouse and rat serves as a model for MS in human. In this model, the demyelinating disease is induced by administration of myelin basic
10 protein (see Paterson (1986) *Textbook of Immunopathology*, Mischer *et al.*, eds., Grune and Stratton, New York, pp. 179-213; McFarlin *et al.* (1973) *Science*, 179: 478: and Satoh *et al.* (1987) *J. Immunol.*, 138: 179).

Generally, the present ligands (e.g., antagonists) will be utilised in purified form together with pharmacologically appropriate carriers. Typically, these carriers include
15 aqueous or alcoholic/aqueous solutions, emulsions or suspensions, any including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's. Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin
20 and alginates.

Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringer's dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) *Remington's Pharmaceutical Sciences*, 16th Edition). A
25 variety of suitable formulations can be used, including extended release formulations.

The ligands (e.g., antagonists) of the present invention may be used as separately administered compositions or in conjunction with other agents. These can include various immunotherapeutic drugs, such as cyclosporine, methotrexate, adriamycin or cisplatin, and immunotoxins. Pharmaceutical compositions can include "cocktails"
30 of various cytotoxic or other agents in conjunction with the ligands of the present

- 52 -

invention, or even combinations of ligands according to the present invention having different specificities, such as ligands selected using different target antigens or epitopes, whether or not they are pooled prior to administration.

5 The route of administration of pharmaceutical compositions according to the invention may be any of those commonly known to those of ordinary skill in the art. For therapy, including without limitation immunotherapy, the selected ligands thereof of the invention can be administered to any patient in accordance with standard techniques.

10 The administration can be by any appropriate mode, including parenterally, intravenously, intramuscularly, intraperitoneally, subcutaneously, transdermally, *via* the pulmonary route, or also, appropriately, by direct infusion with a catheter. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician. Administration can be local (e.g., local delivery to the lung by pulmonary administration, e.g., intranasal administration)
15 or systemic as indicated.

The ligands of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immunoglobulins and art-known lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that
20 lyophilisation and reconstitution can lead to varying degrees of antibody activity loss (e.g. with conventional immunoglobulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted upward to compensate.

The compositions containing the present ligands (e.g., antagonists) or a cocktail
25 thereof can be administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, an adequate amount to accomplish at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a "therapeutically-effective dose". Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of
30 the patient's own immune system, but generally range from 0.005 to 10.0 mg of ligand,

- 53 -

e.g. dAb or antagonist *per* kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used. For prophylactic applications, compositions containing the present ligands or cocktails thereof may also be administered in similar or slightly lower dosages, to prevent, inhibit or delay onset of disease (e.g., to sustain remission or quiescence, or to prevent acute phase). The skilled clinician will be able to determine the appropriate dosing interval to treat, suppress or prevent disease. When an ligand of TNFR1 (e.g., antagonist) is administered to treat, suppress or prevent a chronic inflammatory disease, it can be administered up to four times per day, twice weekly, once weekly, once every two weeks, once a month, or once every two months, at a dose off, for example, about 10 µg/kg to about 80 mg/kg, about 100 µg/kg to about 80 mg/kg, about 1 mg/kg to about 80 mg/kg, about 1 mg/kg to about 70 mg/kg, about 1 mg/kg to about 60 mg/kg, about 1 mg/kg to about 50 mg/kg, about 1 mg/kg to about 40 mg/kg, about 1 mg/kg to about 30 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 10 mg/kg, about 10 µg/kg to about 10 mg/kg, about 10 µg/kg to about 5 mg/kg, about 10 µg/kg to about 2.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg or about 10 mg/kg. In particular embodiments, the ligand of TNFR1 (e.g., antagonist) is administered to treat, suppress or prevent a chronic inflammatory disease once every two weeks or once a month at a dose of about 10 µg/kg to about 10 mg/kg (e.g., about 10 µg/kg, about 100 µg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg or about 10 mg/kg.)

Treatment or therapy performed using the compositions described herein is considered “effective” if one or more symptoms are reduced (e.g., by at least 10% or at least one point on a clinical assessment scale), relative to such symptoms present before treatment, or relative to such symptoms in an individual (human or model animal) not treated with such composition or other suitable control. Symptoms will obviously vary depending upon the disease or disorder targeted, but can be measured by an ordinarily skilled clinician or technician. Such symptoms can be measured, for example, by monitoring the level of one or more biochemical indicators of the disease or disorder

- 54 -

(e.g., levels of an enzyme or metabolite correlated with the disease, affected cell numbers, etc.), by monitoring physical manifestations (e.g., inflammation, tumor size, etc.), or by an accepted clinical assessment scale, for example, the Expanded Disability Status Scale (for multiple sclerosis), the Irvine Inflammatory Bowel Disease

5 Questionnaire (32 point assessment evaluates quality of life with respect to bowel function, systemic symptoms, social function and emotional status - score ranges from 32 to 224, with higher scores indicating a better quality of life), the Quality of Life Rheumatoid Arthritis Scale, or other accepted clinical assessment scale as known in the field. A sustained (e.g., one day or more, or longer) reduction in disease or disorder
10 symptoms by at least 10% or by one or more points on a given clinical scale is indicative of "effective" treatment. Similarly, prophylaxis performed using a composition as described herein is "effective" if the onset or severity of one or more symptoms is delayed, reduced or abolished relative to such symptoms in a similar individual (human or animal model) not treated with the composition.

15 A composition containing a ligand (e.g., antagonist) or cocktail thereof according to the present invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal. In addition, the selected repertoires of polypeptides described herein may be used extracorporeally or *in vitro* selectively to kill, deplete or otherwise
20 effectively remove a target cell population from a heterogeneous collection of cells. Blood from a mammal may be combined extracorporeally with the ligands whereby the undesired cells are killed or otherwise removed from the blood for return to the mammal in accordance with standard techniques.

A composition containing a ligand (e.g., antagonist) according to the present
25 invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal.

The ligands (e.g., anti-TNFR1 antagonists, dAb monomers) can be administered and or formulated together with one or more additional therapeutic or active agents. When a ligand (eg, a dAb) is administered with an additional therapeutic agent, the
30 ligand can be administered before, simultaneously with or subsequent to administration

- 55 -

of the additional agent. Generally, the ligand and additional agent are administered in a manner that provides an overlap of therapeutic effect.

In one embodiment, the invention is a method for treating, suppressing or preventing a chronic inflammatory disease, comprising administering to a mammal in
5 need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of TNFR1 according to the invention.

In one embodiment, the invention is a method for treating, suppressing or preventing arthritis (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) comprising administering to a mammal in need thereof a
10 therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of TNFR1 according to the invention.

In another embodiment, the invention is a method for treating, suppressing or preventing psoriasis comprising administering to a mammal in need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of
15 TNFR1 according to the invention.

In another embodiment, the invention is a method for treating, suppressing or preventing inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) comprising administering to a mammal in need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of TNFR1 according to the
20 invention.

In another embodiment, the invention is a method for treating, suppressing or preventing chronic obstructive pulmonary disease (e.g., chronic bronchitis, chronic obstructive bronchitis, emphysema), comprising administering to a mammal in need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or
25 antagonist of TNFR1 according to the invention.

In another embodiment, the invention is a method for treating, suppressing or preventing pneumonia (e.g., bacterial pneumonia, such as Staphylococcal pneumonia) comprising administering to a mammal in need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of TNFR1 according to the
30 invention.

- 56 -

The invention provides a method for treating, suppressing or preventing other pulmonary diseases in addition to chronic obstructive pulmonary disease, and pneumonia. Other pulmonary diseases that can be treated, suppressed or prevented in accordance with the invention include, for example, cystic fibrosis and asthma (e.g.,
5 steroid resistant asthma). Thus, in another embodiment, the invention is a method for treating, suppressing or preventing a pulmonary disease (e.g., cystic fibrosis, asthma) comprising administering to a mammal in need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of TNFR1 according to the invention.

10 In particular embodiments, an antagonist of TNFR1 is administered via pulmonary delivery, such as by inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) or by systemic delivery (e.g., parenteral, intravenous, intramuscular, intraperitoneal, subcutaneous).

In another embodiment, the invention is a method treating, suppressing or
15 preventing septic shock comprising administering to a mammal in need thereof a therapeutically-effective dose or amount of a polypeptide, ligand, dAb or antagonist of TNFR1 according to the invention.

In a further aspect of the invention, there is provided a composition comprising a a polypeptide, ligand, dAb or antagonist of TNFR1 according to the invention and a
20 pharmaceutically acceptable carrier, diluent or excipient.

Moreover, the present invention provides a method for the treatment of disease using a polypeptide, ligand, dAb or antagonist of TNFR1 or a composition according to the present invention. In an embodiment the disease is cancer or an inflammatory disease, eg rheumatoid arthritis, asthma or Crohn's disease.

25 In a further aspect of the invention, there is provided a composition comprising a polypeptide, single variable domain, ligand or antagonist according to the invention and a pharmaceutically acceptable carrier, diluent or excipient.

In particular embodiments, the polypeptide, ligand, single variable domain, antagonist or composition is administered via pulmonary delivery, such as by inhalation

- 57 -

(e.g, intrabronchial, intranasal or oral inhalation, intranasal drops) or by systemic delivery (e.g, parenteral, intravenous, intramuscular, intraperitoneal, subcutaneous).

An aspect of the invention provides a pulmonary delivery device containing a polypeptide, single variable domain, ligand, composition or antagonist according to the
5 invention. The device can be an inhaler or an intranasal administration device.

In other embodiments, any of the ligands described herein (eg., antagonist or single variable domain) further comprises a half-life extending moiety, such as a polyalkylene glycol moiety, serum albumin or a fragment thereof, transferrin receptor or a transferrin-binding portion thereof, or a moiety comprising a binding site for a
10 polypeptide that enhance half-life *in vivo*. In some embodiments, the half-life extending moiety is a moiety comprising a binding site for a polypeptide that enhances half-life *in vivo* selected from the group consisting of an affibody, a SpA domain, an LDL receptor class A domain, an EGF domain, and an avimer.

In other embodiments, the half-life extending moiety is a polyethylene glycol
15 moiety. In one embodiment, the antagonist comprises (optionally consists of) a single variable domain of the invention linked to a polyethylene glycol moiety (optionally, wherein the moiety has a size of about 20 to about 50 kDa, optionally about 40 kDa linear or branched PEG). Reference is made to WO04081026 for more detail on PEGylation of dAbs and binding moieties. In one embodiment, the antagonist consists
20 of a dAb monomer linked to a PEG, wherein the dAb monomer is a single variable domain according to the invention. This antagonist can be provided for treatment of inflammatory disease, a lung condition (e.g., asthma, influenza or COPD) or cancer or optionally is for intravenous administration.

In other embodiments, the half-life extending moiety is an antibody or antibody
25 fragment (e.g, an immunoglobulin single variable domain) comprising a binding site for serum albumin or neonatal Fc receptor.

The invention also relates to a composition (e.g, pharmaceutical composition) comprising a ligand of the invention (eg., antagonist, or single variable domain) and a physiologically acceptable carrier. In some embodiments, the composition comprises a

- 58 -

vehicle for intravenous, intramuscular, intraperitoneal, intraarterial, intrathecal, intraarticular, subcutaneous administration, pulmonary, intranasal, vaginal, or rectal administration.

The invention also relates to a drug delivery device comprising the composition
5 (e.g, pharmaceutical composition) of the invention. In some embodiments, the drug delivery device comprises a plurality of therapeutically effective doses of ligand. In other embodiments, the drug delivery device is selected from the group consisting of parenteral delivery device, intravenous delivery device, intramuscular delivery device, intraperitoneal delivery device, transdermal delivery device, pulmonary delivery device,
10 intraarterial delivery device, intrathecal delivery device, intraarticular delivery device, subcutaneous delivery device, intranasal delivery device, vaginal delivery device, rectal delivery device, syringe, a transdermal delivery device, a capsule, a tablet, a nebulizer, an inhaler, an atomizer, an aerosolizer, a mister, a dry powder inhaler, a metered dose inhaler, a metered dose sprayer, a metered dose mister, a metered dose atomizer, and a
15 catheter.

The ligand (eg, single variable domain, antagonist or multispecific ligand) of the invention can be formatted as described herein. For example, the ligand of the invention can be formatted to tailor *in vivo* serum half-life. If desired, the ligand can further comprise a toxin or a toxin moiety as described herein. In some embodiments,
20 the ligand comprises a surface active toxin, such as a free radical generator (e.g, selenium containing toxin) or a radionuclide. In other embodiments, the toxin or toxin moiety is a polypeptide domain (e.g, a dAb) having a binding site with binding specificity for an intracellular target. In particular embodiments, the ligand is an IgG-like format that has binding specificity for TNFR1 (e.g, human TNFR1).

25 In an aspect, the invention provides a fusion protein comprising the single variable domain of the invention. The variable domain can be fused, for example, to a peptide or polypeptide or protein. In one embodiment, the variable domain is fused to an antibody or antibody fragment, eg a monoclonal antibody. Generally, fusion can be achieved by expressing the fusion product from a single nucleic acid sequence or by

- 59 -

expressing a polypeptide comprising the single variable domain and then assembling this polypeptide into a larger protein or antibody format using techniques that are conventional.

In one embodiment, the immunoglobulin single variable domain, antagonist or the fusion protein comprises an antibody constant domain. In one embodiment, the immunoglobulin single variable domain, antagonist or the fusion protein comprises an antibody Fc, optionally wherein the N-terminus of the Fc is linked (optionally directly linked) to the C-terminus of the variable domain. In one embodiment, the immunoglobulin single variable domain, antagonist or the fusion protein comprises a half-life extending moiety. The half-life extending moiety can be a polyethylene glycol moiety, serum albumin or a fragment thereof, transferrin receptor or a transferrin-binding portion thereof, or an antibody or antibody fragment comprising a binding site for a polypeptide that enhances half-life *in vivo*. The half-life extending moiety can be an antibody or antibody fragment comprising a binding site for serum albumin or neonatal Fc receptor. The half-life extending moiety can be a dAb, antibody or antibody fragment. In one embodiment, the immunoglobulin single variable domain or the antagonist or the fusion protein is provided such that the variable domain (or the variable domain comprised by the antagonist or fusion protein) further comprises a polyalkylene glycol moiety. The polyalkylene glycol moiety can be a polyethylene glycol moiety. Further discussion is provided below.

In one aspect, the present invention provides the single variable domain, protein, polypeptide, antagonist, composition or device of any aspect or embodiment of the invention for providing one or more of the following (an explicit combination of two or more of the following purposes is hereby disclosed and can be the subject of a claim):-

- (i) Potent binding of human TNFR1 (*e.g.*, with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or

- 60 -

less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance;

- 5 (ii) Potent binding of a non-human primate TNFR1 (*e.g.*, *Cynomolgus* monkey, rhesus or baboon TNFR1) (*e.g.*, with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance;
- 10 (iii) Potent binding of human TNFR1 (*e.g.*, with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance) and potent binding of a non-human primate TNFR1 (*e.g.*, *Cynomolgus* monkey, rhesus or baboon TNFR1) (*e.g.*, with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance);
- 15 (iv) Potent binding of human, *Cynomolgus* monkey and murine TNFR1 (*e.g.*, binding human TNFR1 with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance; binding of *Cynomolgus* monkey TNFR1 with a dissociation constant (KD) of (or of about) 500 pM or less, 400 pM or less, 350 pM or less, 300 pM or less, 250 pM or less, 200 pM or less, or 150 pM or less as determined by surface plasmon resonance; and binding murine TNFR1 with a dissociation constant (KD) of (or of about) 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, or 1nM or less as determined by surface plasmon resonance);
- 20 25 (v) Potent neutralization of human TNFR1 in a patient, *e.g.*, neutralization using a single variable domain, protein, polypeptide, antagonist, ligand or composition of the invention that neutralises human TNFR1 with an ND50

- 61 -

of (or about of) 5, 4, 3, 2 or 1 nM or less in a standard MRC5 assay as determined by inhibition of TNF alpha-induced IL-8 secretion;

(vi) Potent neutralization of human TNFR1 in a patient, *e.g.*, neutralization using a single variable domain, protein, polypeptide, antagonist or composition of the invention that neutralises *Cynomolgus* monkey TNFR1 with an ND50 of 5, 4, 3, 2 or 1 nM or less; or (about) 5 to (about) 1 nM in a standard *Cynomologus* KI assay as determined by inhibition of TNF alpha-induced IL-8 secretion;

(vii) Potent neutralization of human TNFR1 in a patient, *e.g.*, neutralization using a single variable domain, protein, polypeptide, antagonist or composition of the invention that neutralises murine TNFR1 with an ND50 of 150, 100, 50, 40, 30 or 20 nM or less; or from (about) 150 to 10 nM; or from (about) 150 to 20 nM; or from (about) 110 to 10 nM; or from (about) 110 to 20 nM in a standard L929 assay as determined by inhibition of TNF alpha-induced cytotoxicity;

(viii) Potent neutralization of human TNFR1 in a patient, *e.g.*, neutralization using a single variable domain, protein, polypeptide, antagonist or composition that neutralises *Cynomolgus* monkey TNFR1 with an ND50 of 5, 4, 3, 2 or 1 nM or less; or (about) 5 to (about) 1 nM in a standard *Cynomologus* KI assay as determined by inhibition of TNF alpha-induced IL-8 secretion; and neutralizes murine TNFR1 with an ND50 of 150, 100, 50, 40, 30 or 20 nM or less; or from (about) 150 to 10 nM; or from (about) 150 to 20 nM; or from (about) 110 to 10 nM; or from (about) 110 to 20 nM in a standard L929 assay as determined by inhibition of TNF alpha-induced cytotoxicity;

(ix) Providing cross-reactivity between more than one species of primate TNFR1 (optionally, human and *Cynomolgus* monkey and/or rhesus TNFR1 and/or baboon TNFR1, *e.g.*, human and *Cynomolgus* monkey TNFR1) and optionally murine TNFR1; and

(x) Providing protease stability (optionally, trypsin stability).

- 62 -

In one aspect, the present invention provides the use of the single variable domain, protein, polypeptide, antagonist, ligand, composition or device of any aspect or embodiment of the invention for providing one or more of (i) to (x) in the immediately preceding paragraph. The invention also provides corresponding methods.

5 Reference is made to WO2006038027, which discloses anti-TNFR1 immunoglobulin single variable domains. The disclosure of this document is incorporated herein in its entirety, in particular to provide for uses, formats, methods of selection, methods of production, methods of formulation and assays for anti- TNFR1 single variable domains, ligands, antagonists and the like, so that these disclosures can
10 be applied specifically and explicitly in the context of the present invention, including to provide explicit description for importation into claims of the present disclosure.

The anti- TNFR1 of the invention is an immunoglobulin single variable domain that optionally is a human variable domain or a variable domain that comprises or are derived from human framework regions (e.g., DP47 or DPK9 framework regions). In
15 certain embodiments, the variable domain is based on a universal framework, as described herein.

In certain embodiments, a polypeptide domain (e.g., immunoglobulin single variable domain) that has a binding site with binding specificity for TNFR1 resists aggregation, unfolds reversibly (see WO04101790, the teachings of which are
20 incorporated herein by reference).

NUCLEIC ACID MOLECULES, VECTORS AND HOST CELLS

The invention also provides isolated and/or recombinant nucleic acid molecules
25 encoding ligands (single variable domains, fusion proteins, polypeptides, dual-specific ligands and multispecific ligands) as described herein.

In one aspect, the invention provides an isolated or recombinant nucleic acid encoding a polypeptide comprising an immunoglobulin single variable domain

- 63 -

according to the invention. In one embodiment, the nucleic acid comprises the nucleotide sequence of DOM1h-574-156, DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180. In one embodiment, the nucleic acid comprises the nucleotide sequence of DOM1h-574-156, DOM1h-574-72, DOM1h-574-109, DOM1h-574-132, DOM1h-574-135, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180. In one embodiment, the nucleic acid comprises the nucleotide sequence of DOM1h-574-109, DOM1h-574-93, DOM1h-574-123, DOM1h-574-125, DOM1h-574-126 or DOM1h-574-129, DOM1h-574-133, DOM1h-574-137 or DOM1h-574-160. In one embodiment, the nucleic acid comprises the nucleotide sequence of DOM1h-574-156, DOM1h-574-72, DOM1h-574-109, DOM1h-574-125, DOM1h-574-126, DOM1h-574-133, DOM1h-574-135 or DOM1h-574-138, DOM1h-574-139, DOM1h-574-155, DOM1h-574-162 or DOM1h-574-180. In one embodiment, the nucleic acid comprises the nucleotide sequence of DOM1h-574-126 or DOM1h-574-133.

15 In one aspect, the invention provides an isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleotide sequence that is at least 80, 85, 90, 95, 98 or 99% identical to the nucleotide sequence of DOM1h-574-156, DOM1h-574-72, DOM1h-574-109, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180 and wherein the nucleic acid encodes a polypeptide comprising an immunoglobulin single
20 variable domain that specifically binds to TNFR1. In one aspect, the invention provides an isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleotide sequence that is at least 80, 85, 90, 95, 98 or 99% identical to the nucleotide sequence of DOM1h-574-156, DOM1h-574-72, DOM1h-574-109, DOM1h-574-132, DOM1h-574-135, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180 and wherein the
25 nucleic acid encodes a polypeptide comprising an immunoglobulin single variable domain that specifically binds to TNFR1. In one aspect, the invention provides an isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleotide sequence that is at least 80, 85, 90, 95, 98 or 99% identical to the nucleotide sequence of DOM1h-574-109, DOM1h-574-93, DOM1h-574-123, DOM1h-574-125, DOM1h-
30 574-126 or DOM1h-574-129, DOM1h-574-133, DOM1h-574-137 or DOM1h-574-160

- 64 -

and wherein the nucleic acid encodes a polypeptide comprising an immunoglobulin single variable domain that specifically binds to TNFR1. In one aspect, the invention provides an isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleotide sequence that is at least 80, 85, 90, 95, 98 or 99% identical to the nucleotide
5 sequence of DOM1h-574-156, DOM1h-574-72, DOM1h-574-109, DOM1h-574-125, DOM1h-574-126, DOM1h-574-133, DOM1h-574-135 or DOM1h-574-138, DOM1h-574-139, DOM1h-574-155, DOM1h-574-162 or DOM1h-574-180 and wherein the nucleic acid encodes a polypeptide comprising an immunoglobulin single variable domain that specifically binds to TNFR1. In one aspect, the invention provides an
10 isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleotide sequence that is at least 80, 85, 90, 95, 98 or 99% identical to the nucleotide sequence of DOM1h-574-126 or DOM1h-574-133 and wherein the nucleic acid encodes a polypeptide comprising an immunoglobulin single variable domain that specifically binds to TNFR1.

15 In one aspect, the invention provides a vector comprising a nucleic acid of the invention. In one aspect, the invention provides a host cell comprising a nucleic acid of the invention or the vector. There is provided a method of producing polypeptide comprising an immunoglobulin single variable domain, the method comprising maintaining the host cell under conditions suitable for expression of the nucleic acid or
20 vector, whereby a polypeptide comprising an immunoglobulin single variable domain is produced. Optionally, the method further comprises the step of isolating the polypeptide and optionally producing a variant, eg a mutated variant, having an improved affinity (KD); ND₅₀ for TNFR1 neutralization in a standard MRC5, L929 or *Cynomolgus* KI assay than the isolated polypeptide.

25 Nucleic acids referred to herein as "isolated" are nucleic acids which have been separated away from the nucleic acids of the genomic DNA or cellular RNA of their source of origin (*e.g.*, as it exists in cells or in a mixture of nucleic acids such as a library), and include nucleic acids obtained by methods described herein or other suitable methods, including essentially pure nucleic acids, nucleic acids produced by chemical
30 synthesis, by combinations of biological and chemical methods, and recombinant

- 65 -

nucleic acids which are isolated (see *e.g.*, Daugherty, B.L. *et al.*, *Nucleic Acids Res.*, 19(9): 2471-2476 (1991); Lewis, A.P. and J.S. Crowe, *Gene*, 101: 297-302 (1991)).

Nucleic acids referred to herein as "recombinant" are nucleic acids which have been produced by recombinant DNA methodology, including those nucleic acids that are
5 generated by procedures which rely upon a method of artificial recombination, such as the polymerase chain reaction (PCR) and/or cloning into a vector using restriction enzymes.

In certain embodiments, the isolated and/or recombinant nucleic acid comprises a nucleotide sequence encoding a ligand, as described herein, wherein the ligand
10 comprises an amino acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence of a dAb that binds TNFR1 disclosed herein, eg, DOM1h-574-156, DOM1h-574-72,
15 DOM1h-574-109, DOM1h-574-138, DOM1h-574-162 or DOM1h-574-180. Nucleotide sequence identity can be determined over the whole length of the nucleotide sequence that encodes the selected anti-TNFR1 dAb.

The invention also provides a vector comprising a recombinant nucleic acid molecule of the invention. In certain embodiments, the vector is an expression vector
20 comprising one or more expression control elements or sequences that are operably linked to the recombinant nucleic acid of the invention. The invention also provides a recombinant host cell comprising a recombinant nucleic acid molecule or vector of the invention. Suitable vectors (*e.g.*, plasmids, phagemids), expression control elements, host cells and methods for producing recombinant host cells of the invention are well-
25 known in the art, and examples are further described herein.

Suitable expression vectors can contain a number of components, for example, an origin of replication, a selectable marker gene, one or more expression control elements, such as a transcription control element (*e.g.*, promoter, enhancer, terminator) and/or one or more translation signals, a signal sequence or leader sequence, and the
30 like. Expression control elements and a signal sequence, if present, can be provided by

- 66 -

the vector or other source. For example, the transcriptional and/or translational control sequences of a cloned nucleic acid encoding an antibody chain can be used to direct expression.

A promoter can be provided for expression in a desired host cell. Promoters can be constitutive or inducible. For example, a promoter can be operably linked to a nucleic acid encoding an antibody, antibody chain or portion thereof, such that it directs transcription of the nucleic acid. A variety of suitable promoters for prokaryotic (e.g, lac, tac, T3, T7 promoters for *E. coli*) and eukaryotic (e.g, Simian Virus 40 early or late promoter, Rous sarcoma virus long terminal repeat promoter, cytomegalovirus promoter, adenovirus late promoter) hosts are available.

In addition, expression vectors typically comprise a selectable marker for selection of host cells carrying the vector, and, in the case of a replicable expression vector, an origin of replication. Genes encoding products which confer antibiotic or drug resistance are common selectable markers and may be used in prokaryotic (e.g, lactamase gene (ampicillin resistance), *Tet* gene for tetracycline resistance) and eukaryotic cells (e.g, neomycin (G418 or geneticin), gpt (mycophenolic acid), ampicillin, or hygromycin resistance genes). Dihydrofolate reductase marker genes permit selection with methotrexate in a variety of hosts. Genes encoding the gene product of auxotrophic markers of the host (e.g, *LEU2*, *URA3*, *HIS3*) are often used as selectable markers in yeast. Use of viral (e.g, baculovirus) or phage vectors, and vectors which are capable of integrating into the genome of the host cell, such as retroviral vectors, are also contemplated. Suitable expression vectors for expression in mammalian cells and prokaryotic cells (*E. coli*), insect cells (*Drosophila* Schnieder S2 cells, Sf9) and yeast (*P. methanolica*, *P. pastoris*, *S. cerevisiae*) are well-known in the art.

Suitable host cells can be prokaryotic, including bacterial cells such as *E. coli*, *B. subtilis* and/or other suitable bacteria; eukaryotic cells, such as fungal or yeast cells (e.g., *Pichia pastoris*, *Aspergillus sp.*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Neurospora crassa*), or other lower eukaryotic cells, and cells of higher eukaryotes such as those from insects (e.g., *Drosophila* Schnieder S2 cells, Sf9 insect

- 67 -

cells (WO 94/26087 (O'Connor)), mammals (e.g., COS cells, such as COS-1 (ATCC Accession No. CRL-1650) and COS-7 (ATCC Accession No. CRL-1651), CHO (e.g., ATCC Accession No. CRL-9096, CHO DG44 (Urlaub, G. and Chasin, LA., *Proc. Natl. Acad. Sci. USA*, 77(7):4216-4220 (1980))), 293 (ATCC Accession No. CRL-1573),

5 HeLa (ATCC Accession No. CCL-2), CV1 (ATCC Accession No. CCL-70), WOP (Dailey, L., *et al.*, *J. Virol.*, 54:739-749 (1985), 3T3, 293T (Pear, W. S., *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 90:8392-8396 (1993)) NS0 cells, SP2/0, HuT 78 cells and the like, or plants (e.g., tobacco). (See, for example, Ausubel, F.M. *et al.*, eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons

10 Inc. (1993).) In some embodiments, the host cell is an isolated host cell and is not part of a multicellular organism (e.g., plant or animal). In certain embodiments, the host cell is a non-human host cell.

The invention also provides a method for producing a ligand (e.g, dual-specific ligand, multispecific ligand) of the invention, comprising maintaining a recombinant

15 host cell comprising a recombinant nucleic acid of the invention under conditions suitable for expression of the recombinant nucleic acid, whereby the recombinant nucleic acid is expressed and a ligand is produced. In some embodiments, the method further comprises isolating the ligand.

Reference is made to WO2006038027, for details of disclosure that is applicable

20 to embodiments of the present invention. For example, relevant disclosure relates to the preparation of immunoglobulin single variable domain-based ligands, library vector systems, library construction, combining single variable domains, characterisation of ligands, structure of ligands, skeletons, protein scaffolds, diversification of the canonical sequence, assays and therapeutic and diagnostic compositions and uses, as

25 well as definitions of "operably linked", "naive", "prevention", "suppression", "treatment" and "therapeutically-effective dose".

30 FORMATS

- 68 -

Increased half-life is useful in *in vivo* applications of immunoglobulins, especially antibodies and most especially antibody fragments of small size. Such fragments (Fvs, disulphide bonded Fvs, Fabs, scFvs, dAbs) suffer from rapid clearance from the body; thus, whilst they are able to reach most parts of the body rapidly, and are quick to produce and easier to handle, their *in vivo* applications have been limited by their only brief persistence *in vivo*. One embodiment of the invention solves this problem by providing increased half-life of the ligands *in vivo* and consequently longer persistence times in the body of the functional activity of the ligand.

Methods for pharmacokinetic analysis and determination of ligand half-life will be familiar to those skilled in the art. Details may be found in *Kenneth, A et al*: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and in *Peters et al*, Pharmacokinetic analysis: A Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D Perron, published by Marcel Dekker, 2nd Rev. ex edition (1982), which describes pharmacokinetic parameters such as t_{α} and t_{β} half lives and area under the curve (AUC). Half-life and AUC definitions are provided above.

In one embodiment, the present invention provides a ligand (eg, polypeptide, variable domain, antagonist, multispecific ligand) or a composition comprising a ligand according to the invention having a t_{α} half-life in the range of 15 minutes or more. In one embodiment, the lower end of the range is 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 10 hours, 11 hours or 12 hours. In addition, or alternatively, a ligand or composition according to the invention will have a t_{α} half life in the range of up to and including 12 hours. In one embodiment, the upper end of the range is 11, 10, 9, 8, 7, 6 or 5 hours. An example of a suitable range is 1 to 6 hours, 2 to 5 hours or 3 to 4 hours.

In one embodiment, the present invention provides a ligand (eg, polypeptide, variable domain, antagonist, multispecific ligand) or a composition comprising a ligand according to the invention having a t_{β} half-life in the range of about 2.5 hours or more.

In one embodiment, the lower end of the range is about 3 hours, about 4 hours, about 5

- 69 -

hours, about 6 hours, about 7 hours, about 10 hours, about 11 hours, or about 12 hours. In addition, or alternatively, a ligand or composition according to the invention has a $t_{1/2}$ half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is about 12 hours, about 24 hours, about 2 days, about 3 days, about 5 days, about 10 days, about 15 days or about 20 days. In one embodiment a ligand or composition according to the invention will have a $t_{1/2}$ half life in the range about 12 to about 60 hours. In a further embodiment, it will be in the range about 12 to about 48 hours. In a further embodiment still, it will be in the range about 12 to about 26 hours.

In addition, or alternatively to the above criteria, the present invention provides a ligand or a composition comprising a ligand according to the invention having an AUC value (area under the curve) in the range of about 1 mg·min/ml or more. In one embodiment, the lower end of the range is about 5, about 10, about 15, about 20, about 30, about 100, about 200 or about 300 mg·min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to about 600 mg·min/ml. In one embodiment, the upper end of the range is about 500, about 400, about 300, about 200, about 150, about 100, about 75 or about 50 mg·min/ml. In one embodiment a ligand according to the invention will have a AUC in the range selected from the group consisting of the following: about 15 to about 150 mg·min/ml, about 15 to about 100 mg·min/ml, about 15 to about 75 mg·min/ml, and about 15 to about 50mg·min/ml.

Polypeptides and dAbs of the invention and antagonists comprising these can be formatted to have a larger hydrodynamic size, for example, by attachment of a PEG group, serum albumin, transferrin, transferrin receptor or at least the transferrin-binding portion thereof, an antibody Fc region, or by conjugation to an antibody domain. For example, polypeptides dAbs and antagonists formatted as a larger antigen-binding fragment of an antibody or as an antibody (e.g, formatted as a Fab, Fab', F(ab)₂, F(ab')₂, IgG, scFv).

Hydrodynamic size of the ligands (e.g, dAb monomers and multimers) of the invention may be determined using methods which are well known in the art. For example, gel filtration chromatography may be used to determine the hydrodynamic

- 70 -

size of a ligand. Suitable gel filtration matrices for determining the hydrodynamic sizes of ligands, such as cross-linked agarose matrices, are well known and readily available.

The size of a ligand format (*e.g.*, the size of a PEG moiety attached to a dAb monomer), can be varied depending on the desired application. For example, where
5 ligand is intended to leave the circulation and enter into peripheral tissues, it is desirable to keep the hydrodynamic size of the ligand low to facilitate extravasation from the blood stream. Alternatively, where it is desired to have the ligand remain in the systemic circulation for a longer period of time the size of the ligand can be increased, for example by formatting as an Ig like protein.

10

Half-life extension by targeting an antigen or epitope that increases half-life *in vivo*

The hydrodynamic size of a ligand and its serum half-life can also be increased by conjugating or associating an TNFR1 binding polypeptide, dAb or antagonist of the
15 invention to a binding domain (*e.g.*, antibody or antibody fragment) that binds an antigen or epitope that increases half-life *in vivo*, as described herein. For example, the TNFR1 binding agent (*e.g.*, polypeptide) can be conjugated or linked to an anti-serum albumin or anti-neonatal Fc receptor antibody or antibody fragment, *eg* an anti-SA or anti-neonatal Fc receptor dAb, Fab, Fab' or scFv, or to an anti-SA affibody or anti-
20 neonatal Fc receptor Affibody or an anti-SA avimer, or an anti-SA binding domain which comprises a scaffold selected from, but not limited to, the group consisting of CTLA-4, lipocalin, SpA, an affibody, an avimer, GroEl and fibronectin (see WO2008096158 for disclosure of these binding domains, which domains and their sequences are incorporated herein by reference and form part of the disclosure of the
25 present text). Conjugating refers to a composition comprising polypeptide, dAb or antagonist of the invention that is bonded (covalently or noncovalently) to a binding domain that binds serum albumin.

Suitable polypeptides that enhance serum half-life *in vivo* include, for example, transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (see U.S.
30 Patent No. 5,977,307, the teachings of which are incorporated herein by reference),

- 71 -

brain capillary endothelial cell receptor, transferrin, transferrin receptor (*e.g.*, soluble transferrin receptor), insulin, insulin-like growth factor 1 (IGF 1) receptor, insulin-like growth factor 2 (IGF 2) receptor, insulin receptor, blood coagulation factor X, α 1-antitrypsin and HNF 1 α . Suitable polypeptides that enhance serum half-life also

5 include alpha-1 glycoprotein (orosomucoid; AAG), alpha-1 antichymotrypsin (ACT), alpha-1 microglobulin (protein HC; AIM), antithrombin III (AT III), apolipoprotein A-1 (Apo A-1), apolipoprotein B (Apo B), ceruloplasmin (Cp), complement component C3 (C3), complement component C4 (C4), C1 esterase inhibitor (C1 INH), C-reactive protein (CRP), ferritin (FER), hemopexin (HPX), lipoprotein(a) (Lp(a)), mannose-

10 binding protein (MBP), myoglobin (Myo), prealbumin (transthyretin; PAL), retinol-binding protein (RBP), and rheumatoid factor (RF).

Suitable proteins from the extracellular matrix include, for example, collagens, laminins, integrins and fibronectin. Collagens are the major proteins of the extracellular matrix. About 15 types of collagen molecules are currently known, found in different

15 parts of the body, *e.g.*, type I collagen (accounting for 90% of body collagen) found in bone, skin, tendon, ligaments, cornea, internal organs or type II collagen found in cartilage, vertebral disc, notochord, and vitreous humor of the eye.

Suitable proteins from the blood include, for example, plasma proteins (*e.g.*, fibrin, α -2 macroglobulin, serum albumin, fibrinogen (*e.g.*, fibrinogen A, fibrinogen B),

20 serum amyloid protein A, haptoglobin, profilin, ubiquitin, uteroglobulin and β -2-microglobulin), enzymes and enzyme inhibitors (*e.g.*, plasminogen, lysozyme, cystatin C, alpha-1-antitrypsin and pancreatic trypsin inhibitor), proteins of the immune system, such as immunoglobulin proteins (*e.g.*, IgA, IgD, IgE, IgG, IgM, immunoglobulin light chains (kappa/lambda)), transport proteins (*e.g.*, retinol binding protein, α -1

25 microglobulin), defensins (*e.g.*, beta-defensin 1, neutrophil defensin 1, neutrophil defensin 2 and neutrophil defensin 3) and the like.

Suitable proteins found at the blood brain barrier or in neural tissue include, for example, melanocortin receptor, myelin, ascorbate transporter and the like.

Suitable polypeptides that enhance serum half-life *in vivo* also include proteins

30 localized to the kidney (*e.g.*, polycystin, type IV collagen, organic anion transporter K1,

- 72 -

Heymann's antigen), proteins localized to the liver (*e.g.*, alcohol dehydrogenase, G250), proteins localized to the lung (*e.g.*, secretory component, which binds IgA), proteins localized to the heart (*e.g.*, HSP 27, which is associated with dilated cardiomyopathy), proteins localized to the skin (*e.g.*, keratin), bone specific proteins such as morphogenic proteins (BMPs), which are a subset of the transforming growth factor β superfamily of proteins that demonstrate osteogenic activity (*e.g.*, BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8), tumor specific proteins (*e.g.*, trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins (*e.g.*, cathepsin B, which can be found in liver and spleen)).

10 Suitable disease-specific proteins include, for example, antigens expressed only on activated T-cells, including LAG-3 (lymphocyte activation gene), osteoprotegerin ligand (OPGL; see *Nature* 402, 304-309 (1999)), OX40 (a member of the TNF receptor family, expressed on activated T cells and specifically up-regulated in human T cell leukemia virus type-I (HTLV-I)-producing cells; see *Immunol.* 165 (1):263-70 (2000)).

15 Suitable disease-specific proteins also include, for example, metalloproteases (associated with arthritis/cancers) including CG6512 *Drosophila*, human paraplegin, human FtsH, human AFG3L2, murine ftsH; and angiogenic growth factors, including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), vascular endothelial growth factor/vascular permeability factor (VEGF/VPF),
20 transforming growth factor- α (TGF α), tumor necrosis factor-alpha (TNF- α), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-ECGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BB (PDGF), and fractalkine.

 Suitable polypeptides that enhance serum half-life *in vivo* also include stress
25 proteins such as heat shock proteins (HSPs). HSPs are normally found intracellularly. When they are found extracellularly, it is an indicator that a cell has died and spilled out its contents. This unprogrammed cell death (necrosis) occurs when as a result of trauma, disease or injury, extracellular HSPs trigger a response from the immune system. Binding to extracellular HSP can result in localizing the compositions of the invention
30 to a disease site.

- 73 -

Suitable proteins involved in Fc transport include, for example, Brambell receptor (also known as FcRB). This Fc receptor has two functions, both of which are potentially useful for delivery. The functions are (1) transport of IgG from mother to child across the placenta (2) protection of IgG from degradation thereby prolonging its serum half-life. It is thought that the receptor recycles IgG from endosomes. (See, Holliger *et al*, *Nat Biotechnol* 15(7):632-6 (1997).)

dAbs that Bind Serum Albumin

The invention in one embodiment provides a ligand, polypeptide or antagonist (*e.g.*, dual specific ligand comprising an anti-TNFR1 dAb (a first dAb)) that binds to TNFR1 and a second dAb that binds serum albumin (SA), the second dAb binding SA with a KD as determined by surface plasmon resonance of about 1nM to about 1, about 2, about 3, about 4, about 5, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 100, about 200, about 300, about 400 or about 500 μ M (*i.e.*, $\times 10^{-9}$ to 5×10^{-4} M), or about 100 nM to about 10 μ M, or about 1 to about 5 μ M or about 3 to about 70 nM or about 10nM to about 1, about 2, about 3, about 4 or about 5 μ M. For example about 30 to about 70 nM as determined by surface plasmon resonance. In one embodiment, the first dAb (or a dAb monomer) binds SA (*e.g.*, HSA) with a KD as determined by surface plasmon resonance of approximately about 1, about 50, about 70, about 100, about 150, about 200, about 300 nM or about 1, about 2 or about 3 μ M. In one embodiment, for a dual specific ligand comprising a first anti-SA dAb and a second dAb to TNFR1, the affinity (*e.g.*, KD and/or K_{off} as measured by surface plasmon resonance, *e.g.*, using BiaCore) of the second dAb for its target is from about 1 to about 100000 times (*e.g.*, about 100 to about 100000, or about 1000 to about 100000, or about 10000 to about 100000 times) the affinity of the first dAb for SA. In one embodiment, the serum albumin is human serum albumin (HSA). For example, the first dAb binds SA with an affinity of approximately about 10 μ M, while the second dAb binds its target with an affinity of about 100 pM. In one embodiment, the serum albumin is human serum albumin (HSA). In one embodiment, the first dAb binds SA

- 74 -

(*e.g.*, HSA) with a KD of approximately about 50, for example about 70, about 100, about 150 or about 200 nM. Details of dual specific ligands are found in WO03002609, WO04003019, WO2008096158 and WO04058821.

The ligands of the invention can in one embodiment comprise a dAb that binds
 5 serum albumin (SA) with a KD as determined by surface plasmon resonance of about 1 nM to about 1, about 2, about 3, about 4, about 5, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 100, about 200, about 300, about 400 or about 500 μ M (*i.e.*, $\times$ about 10^{-9} to about 5×10^{-4} M), or about 100 nM to about 10 μ M, or about 1 to about 5 μ M or about 3 to about 70 nM or about 10 nM to about 1, about 2,
 10 about 3, about 4 or about 5 μ M. For example about 30 to about 70 nM as determined by surface plasmon resonance. In one embodiment, the first dAb (or a dAb monomer) binds SA (*e.g.*, HSA) with a KD as determined by surface plasmon resonance of approximately about 1, about 50, about 70, about 100, about 150, about 200, about 300 nM or about 1, about 2 or about 3 μ M. In one embodiment, the first and second dAbs
 15 are linked by a linker, for example a linker of from 1 to 4 amino acids or from 1 to 3 amino acids, or greater than 3 amino acids or greater than 4, 5, 6, 7, 8, 9, 10, 15 or 20 amino acids. In one embodiment, a longer linker (greater than 3 amino acids) is used to enhance potency (KD of one or both dAbs in the antagonist).

In particular embodiments of the ligands and antagonists, the dAb binds human
 20 serum albumin and competes for binding to albumin with a dAb selected from the group consisting of DOM7h-11, DOM7h-11-3, DOM7h-11-12, DOM7h-11-15, DOM7h-14, DOM7h-14-10, DOM7h-14-18 and DOM7m-16.

In particular embodiments of the ligands and antagonists, the dAb binds human serum albumin and competes for binding to albumin with a dAb selected from the group
 25 consisting of

MSA-16, MSA-26 (See WO04003019 for disclosure of these sequences, which sequences and their nucleic acid counterpart are incorporated herein by reference and form part of the disclosure of the present text),

DOM7m-16 (SEQ ID NO: 473), DOM7m-12 (SEQ ID NO: 474), DOM7m-26
 30 (SEQ ID NO: 475), DOM7r-1 (SEQ ID NO: 476), DOM7r-3 (SEQ ID NO: 477),

- 75 -

DOM7r-4 (SEQ ID NO: 478), DOM7r-5 (SEQ ID NO: 479), DOM7r-7 (SEQ ID NO: 480), DOM7r-8 (SEQ ID NO: 481), DOM7h-2 (SEQ ID NO: 482), DOM7h-3 (SEQ ID NO: 483), DOM7h-4 (SEQ ID NO: 484), DOM7h-6 (SEQ ID NO: 485), DOM7h-1 (SEQ ID NO: 486), DOM7h-7 (SEQ ID NO: 487), DOM7h-22 (SEQ ID NO: 489),
 5 DOM7h-23 (SEQ ID NO: 490), DOM7h-24 (SEQ ID NO: 491), DOM7h-25 (SEQ ID NO: 492), DOM7h-26 (SEQ ID NO: 493), DOM7h-21 (SEQ ID NO: 494), DOM7h-27 (SEQ ID NO: 495), DOM7h-8 (SEQ ID NO: 496), DOM7r-13 (SEQ ID NO: 497), DOM7r-14 (SEQ ID NO: 498), DOM7r-15 (SEQ ID NO: 499), DOM7r-16 (SEQ ID NO: 500), DOM7r-17 (SEQ ID NO: 501), DOM7r-18 (SEQ ID NO: 502), DOM7r-19 (SEQ ID NO: 503), DOM7r-20 (SEQ ID NO: 504), DOM7r-21 (SEQ ID NO: 505), DOM7r-22 (SEQ ID NO: 506), DOM7r-23 (SEQ ID NO: 507), DOM7r-24 (SEQ ID NO: 508), DOM7r-25 (SEQ ID NO: 509), DOM7r-26 (SEQ ID NO: 510), DOM7r-27 (SEQ ID NO: 511), DOM7r-28 (SEQ ID NO: 512), DOM7r-29 (SEQ ID NO: 513), DOM7r-30 (SEQ ID NO: 514), DOM7r-31 (SEQ ID NO: 515), DOM7r-32 (SEQ ID NO: 516), DOM7r-33 (SEQ ID NO: 517) (See WO2007080392 for disclosure of these sequences, which sequences and their nucleic acid counterpart are incorporated herein by reference and form part of the disclosure of the present text; the SEQ ID No's in this paragraph are those that appear in WO2007080392),

dAb8 (dAb10), dAb 10, dAb36, dAb7r20 (DOM7r20), dAb7r21 (DOM7r21),
 20 dAb7r22 (DOM7r22), dAb7r23 (DOM7r23), dAb7r24 (DOM7r24), dAb7r25 (DOM7r25), dAb7r26 (DOM7r26), dAb7r27 (DOM7r27), dAb7r28 (DOM7r28), dAb7r29 (DOM7r29), dAb7r29 (DOM7r29), dAb7r31 (DOM7r31), dAb7r32 (DOM7r32), dAb7r33 (DOM7r33), dAb7r33 (DOM7r33), dAb7h22 (DOM7h22), dAb7h23 (DOM7h23), dAb7h24 (DOM7h24), dAb7h25 (DOM7h25), dAb7h26 (DOM7h26), dAb7h27 (DOM7h27), dAb7h30 (DOM7h30), dAb7h31 (DOM7h31),
 25 dAb2 (dAbs 4,7,41), dAb4, dAb7, dAb11, dAb12 (dAb7m12), dAb13 (dAb 15), dAb15, dAb16 (dAb21, dAb7m16) , dAb17, dAb18, dAb19, dAb21, dAb22, dAb23, dAb24, dAb25 (dAb26, dAb7m26), dAb27, dAb30 (dAb35), dAb31, dAb33, dAb34, dAb35, dAb38 (dAb54), dAb41, dAb46 (dAbs 47, 52 and 56), dAb47, dAb52, dAb53, dAb54,
 30 dAb55, dAb56, dAb7m12, dAb7m16, dAb7m26, dAb7r1 (DOM 7r1), dAb7r3

- 76 -

(DOM7r3), dAb7r4 (DOM7r4), dAb7r5 (DOM7r5), dAb7r7 (DOM7r7), dAb7r8 (DOM7r8), dAb7r13 (DOM7r13), dAb7r14 (DOM7r14), dAb7r15 (DOM7r15), dAb7r16 (DOM7r16), dAb7r17 (DOM7r17), dAb7r18 (DOM7r18), dAb7r19 (DOM7r19), dAb7h1 (DOM7h1), dAb7h2 (DOM7h2), dAb7h6 (DOM7h6), dAb7h7 (DOM7h7), dAb7h8 (DOM7h8), dAb7h9 (DOM7h9), dAb7h10 (DOM7h10), dAb7h11 (DOM7h11), dAb7h12 (DOM7h12), dAb7h13 (DOM7h13), dAb7h14 (DOM7h14), dAb7p1 (DOM7p1), and dAb7p2 (DOM7p2) (see WO2008096158 for disclosure of these sequences, which sequences and their nucleic acid counterpart are incorporated herein by reference and form part of the disclosure of the present text). Alternative names are shown in brackets after the dAb, e.g., dAb8 has an alternative name which is dAb10 i.e. dAb8 (dAb10).

In certain embodiments, the dAb binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence of a dAb selected from the group consisting of DOM7h-11, DOM7h-11-3, DOM7h-11-12, DOM7h-11-15, DOM7h-14, DOM7h-14-10, DOM7h-14-18 and DOM7m-16.

In certain embodiments, the dAb binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence of a dAb selected from the group consisting of

MSA-16, MSA-26,
DOM7m-16 (SEQ ID NO: 473), DOM7m-12 (SEQ ID NO: 474), DOM7m-26 (SEQ ID NO: 475), DOM7r-1 (SEQ ID NO: 476), DOM7r-3 (SEQ ID NO: 477), DOM7r-4 (SEQ ID NO: 478), DOM7r-5 (SEQ ID NO: 479), DOM7r-7 (SEQ ID NO: 480), DOM7r-8 (SEQ ID NO: 481), DOM7h-2 (SEQ ID NO: 482), DOM7h-3 (SEQ ID NO: 483), DOM7h-4 (SEQ ID NO: 484), DOM7h-6 (SEQ ID NO: 485), DOM7h-1 (SEQ ID NO: 486), DOM7h-7 (SEQ ID NO: 487), DOM7h-22 (SEQ ID NO: 489),

- 77 -

DOM7h-23 (SEQ ID NO: 490), DOM7h-24 (SEQ ID NO: 491), DOM7h-25 (SEQ ID NO: 492), DOM7h-26 (SEQ ID NO: 493), DOM7h-21 (SEQ ID NO: 494), DOM7h-27 (SEQ ID NO: 495), DOM7h-8 (SEQ ID NO: 496), DOM7r-13 (SEQ ID NO: 497), DOM7r-14 (SEQ ID NO: 498), DOM7r-15 (SEQ ID NO: 499), DOM7r-16 (SEQ ID NO: 500), DOM7r-17 (SEQ ID NO: 501), DOM7r-18 (SEQ ID NO: 502), DOM7r-19 (SEQ ID NO: 503), DOM7r-20 (SEQ ID NO: 504), DOM7r-21 (SEQ ID NO: 505), DOM7r-22 (SEQ ID NO: 506), DOM7r-23 (SEQ ID NO: 507), DOM7r-24 (SEQ ID NO: 508), DOM7r-25 (SEQ ID NO: 509), DOM7r-26 (SEQ ID NO: 510), DOM7r-27 (SEQ ID NO: 511), DOM7r-28 (SEQ ID NO: 512), DOM7r-29 (SEQ ID NO: 513), DOM7r-30 (SEQ ID NO: 514), DOM7r-31 (SEQ ID NO: 515), DOM7r-32 (SEQ ID NO: 516), DOM7r-33 (SEQ ID NO: 517) (the SEQ ID No's in this paragraph are those that appear in WO2007080392),

dAb8, dAb 10, dAb36, dAb7r20, dAb7r21, dAb7r22, dAb7r23, dAb7r24, dAb7r25, dAb7r26, dAb7r27, dAb7r28, dAb7r29, dAb7r30, dAb7r31, dAb7r32, dAb7r33, dAb7h21, dAb7h22, dAb7h23, Ab7h24, Ab7h25, Ab7h26, dAb7h27, dAb7h30, dAb7h31, dAb2, dAb4, dAb7, dAb11, dAb12, dAb13, dAb15, dAb16, dAb17, dAb18, dAb19, dAb21, dAb22, dAb23, dAb24, dAb25, dAb26, dAb27, dAb30, dAb31, dAb33, dAb34, dAb35, dAb38, dAb41, dAb46, dAb47, dAb52, dAb53, dAb54, dAb55, dAb56, dAb7m12, dAb7m16, dAb7m26, dAb7r1, dAb7r3, dAb7r4, dAb7r5, dAb7r7, dAb7r8, dAb7r13, dAb7r14, dAb7r15, dAb7r16, dAb7r17, dAb7r18, dAb7r19, dAb7h1, dAb7h2, dAb7h6, dAb7h7, dAb7h8, dAb7h9, dAb7h10, dAb7h11, dAb7h12, dAb7h13, dAb7h14, dAb7p1, and dAb7p2.

For example, the dAb that binds human serum albumin can comprise an amino acid sequence that has at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with DOM7h-11-3 or DOM7h-14-10.

For example, the dAb that binds human serum albumin can comprise an amino acid sequence that has at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with

- 78 -

DOM7h-2 (SEQ ID NO:482), DOM7h-3 (SEQ ID NO:483), DOM7h-4 (SEQ ID NO:484), DOM7h-6 (SEQ ID NO:485), DOM7h-1 (SEQ ID NO:486), DOM7h-7 (SEQ ID NO:487), DOM7h-8 (SEQ ID NO:496), DOM7r-13 (SEQ ID NO:497), DOM7r-14 (SEQ ID NO:498), DOM7h-22 (SEQ ID NO:489), DOM7h-23 (SEQ ID NO:490), DOM7h-24 (SEQ ID NO:491), DOM7h-25 (SEQ ID NO:492), DOM7h-26 (SEQ ID NO:493), DOM7h-21 (SEQ ID NO:494) or DOM7h-27 (SEQ ID NO:495) (the SEQ ID No's in this paragraph are those that appear in WO2007080392), or

dAb8, dAb 10, dAb36, dAb7h21, dAb7h22, dAb7h23, Ab7h24, Ab7h25, Ab7h26, dAb7h27, dAb7h30, dAb7h31, dAb2, dAb4, dAb7, dAb11, dAb12, dAb13, dAb15, dAb16, dAb17, dAb18, dAb19, dAb21, dAb22, dAb23, dAb24, dAb25, dAb26, dAb27, dAb30, dAb31, dAb33, dAb34, dAb35, dAb38, dAb41, dAb46, dAb47, dAb52, dAb53, dAb54, dAb55, dAb56, dAb7h1, dAb7h2, dAb7h6, dAb7h7, dAb7h8, dAb7h9, dAb7h10, dAb7h11, dAb7h12, dAb7h13 or dAb7h14.

In certain embodiments, the dAb binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence of a dAb selected from the group consisting of

DOM7h-2 (SEQ ID NO:482), DOM7h-6 (SEQ ID NO:485), DOM7h-1 (SEQ ID NO:486), DOM7h-7 (SEQ ID NO:487), DOM7h-8 (SEQ ID NO:496), DOM7h-22 (SEQ ID NO:489), DOM7h-23 (SEQ ID NO:490), DOM7h-24 (SEQ ID NO:491), DOM7h-25 (SEQ ID NO:492), DOM7h-26 (SEQ ID NO:493), DOM7h-21 (SEQ ID NO:494), DOM7h-27 (SEQ ID NO:495) (the SEQ ID No's in this paragraph are those that appear in WO2007080392),

dAb7h21, dAb7h22, dAb7h23, Ab7h24, Ab7h25, Ab7h26, dAb7h27, dAb7h30, dAb7h31, dAb2, dAb4, dAb7, dAb38, dAb41, dAb7h1, dAb7h2, dAb7h6, dAb7h7, dAb7h8, dAb7h9, dAb7h10, dAb7h11, dAb7h12, dAb7h13 and dAb7h14.

In more particular embodiments, the dAb is a V_K dAb that binds human serum albumin and has an amino acid sequence selected from the group consisting of

- 79 -

DOM7h-2 (SEQ ID NO:482), DOM7h-6 (SEQ ID NO:485), DOM7h-1 (SEQ ID NO:486), DOM7h-7 (SEQ ID NO:487), DOM7h-8 (SEQ ID NO:496) (the SEQ ID No's in this paragraph are those that appear in WO2007080392),

dAb2, dAb4, dAb7, dAb38, dAb41, dAb54, dAb7h1, dAb7h2, dAb7h6,
5 dAb7h7, dAb7h8, dAb7h9, dAb7h10, dAb7h11, dAb7h12, dAb7h13 and dAb7h14.

In more particular embodiments, the dAb is a V_H dAb that binds human serum albumin and has an amino acid sequence selected from dAb7h30 and dAb7h31.

In more particular embodiments, the dAb is dAb7h11 or dAb7h14. In an example, the dAb is DOM7h-11-3. In another example, the dAb is DOM7h-14-10.

10 In other embodiments, the dAb, ligand or antagonist binds human serum albumin and comprises one, two or three of the CDRs of any of the foregoing amino acid sequences, eg one, two or three of the CDRs of DOM7h-11-3, DOM7h-14-10, dAb7h11 or dAb7h14.

Suitable *Camelid* V_{HH} that bind serum albumin include those disclosed in WO
15 2004/041862 (Ablynx N.V.) and in WO2007080392 (which V_{HH} sequences and their nucleic acid counterpart are incorporated herein by reference and form part of the disclosure of the present text), such as Sequence A (SEQ ID NO:518), Sequence B (SEQ ID NO:519), Sequence C (SEQ ID NO:520), Sequence D (SEQ ID NO:521), Sequence E (SEQ ID NO:522), Sequence F (SEQ ID NO:523), Sequence G (SEQ ID
20 NO:524), Sequence H (SEQ ID NO:525), Sequence I (SEQ ID NO:526), Sequence J (SEQ ID NO:527), Sequence K (SEQ ID NO:528), Sequence L (SEQ ID NO:529), Sequence M (SEQ ID NO:530), Sequence N (SEQ ID NO:531), Sequence O (SEQ ID NO:532), Sequence P (SEQ ID NO:533), Sequence Q (SEQ ID NO:534), these sequence numbers corresponding to those cited in WO2007080392 or WO 2004/041862
25 (Ablynx N.V.). In certain embodiments, the *Camelid* V_{HH} binds human serum albumin and comprises an amino acid sequence that has at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% amino acid sequence identity with ALB1 disclosed in WO2007080392 or any one of SEQ ID NOS:518-534,

- 80 -

these sequence numbers corresponding to those cited in WO2007080392 or WO 2004/041862.

In some embodiments, the ligand or antagonist comprises an anti-serum albumin dAb that competes with any anti-serum albumin dAb disclosed herein for binding to serum albumin (*e.g.*, human serum albumin).

In an alternative embodiment, the antagonist or ligand comprises a binding moiety specific for SA (*e.g.*, human SA), wherein the moiety comprises non-immunoglobulin sequences as described in WO2008096158, the disclosure of these binding moieties, their methods of production and selection (*e.g.*, from diverse libraries) and their sequences are incorporated herein by reference as part of the disclosure of the present text)

Conjugation to a half-life extending moiety (*e.g.*, albumin)

15

In one embodiment, a (one or more) half-life extending moiety (*e.g.*, albumin, transferrin and fragments and analogues thereof) is conjugated or associated with the TNFR1-binding polypeptide, dAb or antagonist of the invention. Examples of suitable albumin, albumin fragments or albumin variants for use in a TNFR1-binding format are described in WO 2005077042, which disclosure is incorporated herein by reference and forms part of the disclosure of the present text. In particular, the following albumin, albumin fragments or albumin variants can be used in the present invention:

- SEQ ID NO:1 (as disclosed in WO 2005077042, this sequence being explicitly incorporated into the present disclosure by reference);
- Albumin fragment or variant comprising or consisting of amino acids 1-387 of SEQ ID NO:1 in WO 2005077042;
- Albumin, or fragment or variant thereof, comprising an amino acid sequence selected from the group consisting of: (a) amino acids 54 to 61 of SEQ ID NO:1 in WO 2005077042; (b) amino acids 76 to 89 of SEQ ID NO:1 in WO

- 81 -

2005077042; (c) amino acids 92 to 100 of SEQ ID NO:1 in WO 2005077042; (d) amino acids 170 to 176 of SEQ ID NO:1 in WO 2005077042; (e) amino acids 247 to 252 of SEQ ID NO:1 in WO 2005077042; (f) amino acids 266 to 277 of SEQ ID NO:1 in WO 2005077042; (g) amino acids 280 to 288 of SEQ ID NO:1 in WO 2005077042; (h) amino acids 362 to 368 of SEQ ID NO:1 in WO 2005077042; (i) amino acids 439 to 447 of SEQ ID NO:1 in WO 2005077042; (j) amino acids 462 to 475 of SEQ ID NO:1 in WO 2005077042; (k) amino acids 478 to 486 of SEQ ID NO:1 in WO 2005077042; and (l) amino acids 560 to 566 of SEQ ID NO:1 in WO 2005077042.

Further examples of suitable albumin, fragments and analogs for use in a TNFR1-binding format are described in WO 03076567, which disclosure is incorporated herein by reference and which forms part of the disclosure of the present text. In particular, the following albumin, fragments or variants can be used in the present invention:

- Human serum albumin as described in WO 03076567, e.g., in figure 3 (this sequence information being explicitly incorporated into the present disclosure by reference);
- Human serum albumin (HA) consisting of a single non-glycosylated polypeptide chain of 585 amino acids with a formula molecular weight of 66,500 (See, Meloun, *et al.*, *FEBS Letters* 58:136 (1975); Behrens, *et al.*, *Fed. Proc.* 34:591 (1975); Lawn, *et al.*, *Nucleic Acids Research* 9:6102-6114 (1981); Minghetti, *et al.*, *J. Biol. Chem.* 261:6747 (1986));
- A polymorphic variant or analog or fragment of albumin as described in Weitkamp, *et al.*, *Ann. Hum. Genet.* 37:219 (1973);
- An albumin fragment or variant as described in EP 322094, e.g., HA(1-373., HA(1-388), HA(1-389), HA(1-369), and HA(1-419) and fragments between 1-369 and 1-419;
- An albumin fragment or variant as described in EP 399666, e.g., HA(1-177) and HA(1-200) and fragments between HA(1-X), where X is any number from 178 to 199.

- 82 -

Where a (one or more) half-life extending moiety (e.g., albumin, transferrin and fragments and analogues thereof) is used to format the TNFR1-binding polypeptides, dAbs and antagonists of the invention, it can be conjugated using any suitable method, such as, by direct fusion to the TNFR1-binding moiety (e.g., anti-
5 TNFR1dAb), for example by using a single nucleotide construct that encodes a fusion protein, wherein the fusion protein is encoded as a single polypeptide chain with the half-life extending moiety located N- or C-terminally to the TNFR1 binding moiety. Alternatively, conjugation can be achieved by using a peptide linker between moieties, e.g., a peptide linker as described in WO 03076567 or WO 2004003019 (these linker
10 disclosures being incorporated by reference in the present disclosure to provide examples for use in the present invention). Typically, a polypeptide that enhances serum half-life *in vivo* is a polypeptide which occurs naturally *in vivo* and which resists degradation or removal by endogenous mechanisms which remove unwanted material from the organism (e.g, human). For example, a polypeptide that enhances serum half-
15 life *in vivo* can be selected from proteins from the extracellular matrix, proteins found in blood, proteins found at the blood brain barrier or in neural tissue, proteins localized to the kidney, liver, lung, heart, skin or bone, stress proteins, disease-specific proteins, or proteins involved in Fc transport.

In embodiments of the invention described throughout this disclosure, instead of the
20 use of an anti- TNFR1 single variable domain (“dAb”) in an antagonist or ligand of the invention, it is contemplated that the skilled addressee can use a polypeptide or domain that comprises one or more or all 3 of the CDRs of a dAb of the invention that binds TNFR1 (e.g, CDRs grafted onto a suitable protein scaffold or skeleton, eg an affibody, an SpA scaffold, an LDL receptor class A domain or an EGF domain). The disclosure
25 as a whole is to be construed accordingly to provide disclosure of antagonists using such domains in place of a dAb. In this respect, see WO2008096158 for details of how to produce diverse libraries based on protein scaffolds and selection and characterization of domains from such libraries, the disclosure of which is incorporated by reference.

- 83 -

In one embodiment, therefore, an antagonist of the invention comprises an immunoglobulin single variable domain or domain antibody (dAb) that has binding specificity for TNFR1 or the complementarity determining regions of such a dAb in a suitable format. The antagonist can be a polypeptide that consists of such a dAb, or
5 consists essentially of such a dAb. The antagonist can be a polypeptide that comprises a dAb (or the CDRs of a dAb) in a suitable format, such as an antibody format (e.g, IgG-like format, scFv, Fab, Fab', F(ab')₂), or a dual specific ligand that comprises a dAb that binds TNFR1 and a second dAb that binds another target protein, antigen or epitope (e.g, serum albumin).

10 Polypeptides, dAbs and antagonists according to the invention can be formatted as a variety of suitable antibody formats that are known in the art, such as, IgG-like formats, chimeric antibodies, humanized antibodies, human antibodies, single chain antibodies, bispecific antibodies, antibody heavy chains, antibody light chains, homodimers and heterodimers of antibody heavy chains and/or light chains, antigen-binding fragments of
15 any of the foregoing (e.g, a Fv fragment (e.g, single chain Fv (scFv), a disulfide bonded Fv), a Fab fragment, a Fab' fragment, a F(ab')₂ fragment), a single variable domain (e.g, V_H, V_L), a dAb, and modified versions of any of the foregoing (e.g, modified by the covalent attachment of polyalkylene glycol (e.g, polyethylene glycol, polypropylene glycol, polybutylene glycol) or other suitable polymer).

20 In some embodiments, the invention provides a ligand (e.g., an anti-TNFR1 antagonist) that is an IgG-like format. Such formats have the conventional four chain structure of an IgG molecule (2 heavy chains and two light chains), in which one or more of the variable regions (V_H and or V_L) have been replaced with a dAb of the invention. In one embodiment, each of the variable regions (2 V_H regions and 2 V_L
25 regions) is replaced with a dAb or single variable domain, at least one of which is an anti- TNFR1 dAb according to the invention. The dAb(s) or single variable domain(s) that are included in an IgG-like format can have the same specificity or different specificities. In some embodiments, the IgG-like format is tetravalent and can have one (anti- TNFR1 only), two (e.g., anti- TNFR1 and anti-SA), three or four specificities.
30 For example, the IgG-like format can be monospecific and comprises 4 dAbs that have

- 84 -

the same specificity; bispecific and comprises 3 dAbs that have the same specificity and another dAb that has a different specificity; bispecific and comprise two dAbs that have the same specificity and two dAbs that have a common but different specificity; trispecific and comprises first and second dAbs that have the same specificity, a third
5 dAb with a different specificity and a fourth dAb with a different specificity from the first, second and third dAbs; or tetraspecific and comprise four dAbs that each have a different specificity. Antigen-binding fragments of IgG-like formats (e.g, Fab, F(ab')₂, Fab', Fv, scFv) can be prepared. In one embodiment, the IgG-like formats or antigen-binding fragments may be monovalent for TNFR1. If complement activation and/or
10 antibody dependent cellular cytotoxicity (ADCC) function is desired, the ligand can be an IgG1-like format. If desired, the IgG-like format can comprise a mutated constant region (variant IgG heavy chain constant region) to minimize binding to Fc receptors and/or ability to fix complement. (see *e.g.*, Winter *et al.*, GB 2,209,757 B; Morrison *et al.*, WO 89/07142; Morgan *et al.*, WO 94/29351, December 22, 1994).

15 The ligands of the invention (e.g., polypeptides, dAbs and antagonists) can be formatted as a fusion protein that contains a first immunoglobulin single variable domain that is fused directly to a second immunoglobulin single variable domain. If desired such a format can further comprise a half-life extending moiety. For example, the ligand can comprise a first immunoglobulin single variable domain that is fused
20 directly to a second immunoglobulin single variable domain that is fused directly to an immunoglobulin single variable domain that binds serum albumin.

Generally the orientation of the polypeptide domains that have a binding site with binding specificity for a target, and whether the ligand comprises a linker, is a matter of design choice. However, some orientations, with or without linkers, may provide better
25 binding characteristics than other orientations. All orientations (*e.g.*, dAb1-linker-dAb2; dAb2-linker-dAb1) are encompassed by the invention are ligands that contain an orientation that provides desired binding characteristics can be easily identified by screening.

Polypeptides and dAbs according to the invention, including dAb monomers, dimers
30 and trimers, can be linked to an antibody Fc region, comprising one or both of C_H2 and

- 85 -

C_H3 domains, and optionally a hinge region. For example, vectors encoding ligands linked as a single nucleotide sequence to an Fc region may be used to prepare such polypeptides.

The invention moreover provides dimers, trimers and polymers of the
5 aforementioned dAb monomers.

EXEMPLIFICATION

10 Naïve selection of anti-TNFR1 dAb

Two different mechanisms to inhibit signaling of the TNF receptor 1 (p55) have been described (WO2006038027). The first consists of inhibition of signaling by binding a domain antibody to TNFR1 at an epitope where it competes directly with the binding of TNF α for its receptor. This competition can be determined in *e.g.* an *in vitro*
15 receptor binding assay in which receptor is coated to a solid support and competition of the domain antibody with biotinylated TNF α for binding to the receptor is determined through measurement of residual biotinylated-TNF α binding using *e.g.* streptavidin-HRP. A competitive TNFR1 inhibitor will block TNF α binding to its receptor, leaving
20 no TNF α signal. Conversely, a non-competitive TNFR1 inhibitor will have little influence on the binding of TNF α to the receptor, resulting in a continued read-out for biotinylated TNF α even in the presence of μ M concentrations of inhibitory dAb. In a functional cell assay, *e.g.* the human MRC5 fibroblast cell line which upon stimulation with low levels of TNF α (10-200 pg/ml, for 18h) releases IL-8, however, both
25 competitive and non-competitive inhibitors reduce the IL-8 secretion in a dose dependent fashion. The latter demonstrates functional activity for both types of inhibitors in a cell-based system. Therefore the specific aim was to isolate domain antibodies which bind TNFR1 and inhibit its functional activity in cell assays, however these domain antibodies should not (substantially) compete with TNF α for binding to TNFR 1.

- 86 -

To isolate non-competitive, TNFR1-binding dAbs, a selection strategy was designed to enrich for this sub-class of dAbs. The approach consisted of using the Domantis' 4G and 6G naïve phage libraries, phage libraries displaying antibody single variable domains expressed from the GAS1 leader sequence (see WO2005093074) for 4G and additionally with heat/cool preselection for 6G (see WO04101790). These phage libraries were incubated in round 1 with 200 nM of biotinylated human TNFR1 (R&D systems, cat no. 636-R1/CF, biotinylated using EZ-Link NHS-LC-LC-biotin (Pierce cat no. 21343), according to the manufacturer's instructions), followed by pull-down on streptavidin-coated magnetic beads. In rounds 2 and 3, the phage were pre-incubated with TNFR1 (200 nM – round 2, 75 nM – round 3), and then with biotinylated TNF α (Peptotech cat no. 300-01A) (200 nM – round 2, 75 nM – round 3 nM) and pull-down on streptavidin-coated magnetic beads followed. In all rounds, beads were washed to remove weakly binding phage and bound phage were eluted by trypsin digestion prior to amplification. The rationale is that those dAbs which are able to bind TNFR1 in the presence of TNF α would be specifically enriched whereas those competing with TNF α would not be pulled down, as this epitope is required for the TNF α binding to the magnetic beads. Using this experimental design, 3 rounds of phage selection were done and both rounds 2 and 3 were cloned into the pDOM5 *E. coli* expression vector (see PCT/EP2008/067789; WO2009/002882), followed by dAbs expression and screening for TNFR1 binding on BIAcore™. The pDOM5 vector is a pUC119-based vector. Expression of proteins is driven by the LacZ promoter. A GAS1 leader sequence (see WO 2005/093074) ensures secretion of isolated, soluble dAbs into the periplasm and culture supernatant of *E. coli*. dAbs are cloned SalI/NotI in this vector, which appends a myc tag at the C-terminus of the dAb. Binding dAbs were expressed at 50 ml scale and affinity purified for functional characterisation. This consisted of determination of inhibition of TNF α -mediated signaling in a MRC5 cell assay (as described below) as well as inhibition of TNF α binding to TNFR1 in a receptor binding assay (as described below). Screening of 6000 supernatants yielded many TNFR1 binders. However, the vast majority either bound an irrelevant epitope, consequently having no activity in either the cell assay or the receptor binding assay, or were competitive as demonstrated

- 87 -

in the receptor binding assay. Notwithstanding this majority, sequence analysis of those dAbs which 1) bound TNFR1 on BIAcore (Figure 1), 2) inhibited TNF α in the MRC5 cell assay (Figure 2) whilst, 3) demonstrating no TNF α competition in the Receptor Binding Assay (Figure 3), identified five unique dAbs (data for DOM1h-543 is not shown in the figures). These five dAbs were: DOM1h-509, DOM1h-510, DOM1h-543, DOM1h-549 and DOM1h-574.

10 Test maturation of selected dAbs by error-prone mutagenesis

In order to determine the maturability of DOM1h-509, DOM1h-510, DOM1h-543, DOM1h-549 and DOM1h-574, error-prone PCR libraries of dAb mutants were generated using the Genemorph II kit (Stratagene (San Diego, USA) cat. no. 200550) according to the manufacturer's instructions. Sequence analysis revealed these libraries 15 to have an average mutation rate of about 2% on the amino-acid level. These libraries were cloned in the phage vector pDOM4 and expressed on phage. pDOM4 is a filamentous phage (fd) display vector, which is based on fd vector with a myc tag and wherein a protein sequence can be cloned in between restriction sites to provide a protein-gene III fusion. The genes encoding dAbs were cloned as *Sall/NotI* fragments.

20 Selections for improved binders were done over three sequential rounds of incubation with decreasing amounts of biotinylated human TNFR1 (R&D Systems) (50 nM (round 1), 5 nM (round 2) and 0.5 nM (round 3)). After three rounds of selections, the dAb genes were cloned into the *E. coli* expression vector pDOM5, expressed and the supernatants screened by BIAcore for improvements in binding kinetics. Variants 25 derived from all five parental lineages were screened; dAbs from the DOM1h-574 lineage showed significant improvements in the dissociation rate when screened on the BIAcore. Those dAbs with the most pronounced improvements in dissociation rate were purified and characterised in the MRC5 cell assay (Table 1 and Figure 4), the best dAbs being: DOM1h-574-7, DOM1h-574-8, DOM1h-574-10, DOM1h-574-11, DOM1h-574-12 and DOM1h-574-13. From the examination of these dAbs, we exercised our 30

- 88 -

judgement and identified positions and mutations which might be responsible for the affinity improvements, specifically: V30G, G44D, L45P, G55D, H56R and K94I (Kabat numbering). In search of an additive effect, we generated novel dAb variants which combine these specific mutations into a single dAb. The novel variants engineered using DOM1h-574 template were: DOM1h-574-14 (G55D, H56R and K94I), DOM1h-574-15 (G55D and K94I), DOM1h-574-16 (L45P, G55D, H56R and K94I), DOM1h-574-17 (L45P, G55D and K94I), DOM1h-574-18 (V30G, G44D, G55D, H56R and K94I) and DOM1h-574-19 (V30G, G44D, G55D and K94I) (Figure 5). Characterisation of these variants for potency in the MRC5 cell assay and affinity for TNFR1 on BIAcore identified further improvements (Table 1). The most potent dAb was DOM1h-574-16.

Table 1: Summary of BIAcore affinities and potencies in the MRC5 cell assay for DOM1h-574 parent and the dAbs identified during test maturation and constructed through recombination of beneficial mutations. DOM1h-574-16 combines the highest affinity on BIAcore with the highest potency in the MRC5 cell assay. Where values were not determined, this is indicated (ND).

	<i>BIAcore</i> K_D (nM)	<i>MRC-5</i> EC_{50} (nM)
DOM1h-574-8	5.7	10
DOM1h-574-11	200	800
DOM1h-574-12	23	130
DOM1h-574-13	44	300
DOM1h-574-14	ND	ND
DOM1h-574-15	20	300
DOM1h-574-16	1.0	8
DOM1h-574-17	8.4	20

- 89 -

DOM1h-574-18	4.1	17
DOM1h-574-19	ND	140

EC₅₀ measurements were determined by Graphpad Prism. The EC₅₀ measurement for DOM1h-574 is estimated to be approximately 200 times the EC₅₀ measurement of DOM1h-574-16.

5 Species cross-reactivity of DOM1h-574-16

A significant advantage for an anti-TNFR1 dAb would be cross-reactivity between different species. Given the limited conservation of the sequence of the extracellular domain of TNFR1 between mouse, dog, *Cynomologus* monkey and human (figure 6), it would be exceptional for any antibody or single variable domain to recognize TNFR1 of these different species at similar affinities. Therefore, we tested the ability of DOM1h-574-16 to bind on BIAcore to mouse TNFR1 (R&D systems cat no. 425-R1-050/CF), dog TNFR1 (R&D Systems cat no. 4017-TR-025/CF) and human TNFR1 (R&D Systems). For mouse experiments the TNFR1 was biotinylated using EZ-Link NHS-LC-LC-biotin (Pierce cat no. 21343), according to the manufacturer's instructions, followed by binding of the biotinylated TNFR1 to a Streptavidin-coated BIAcore chip (mouse experiments). For human and dog TNFR1, amine-coupled TNFR1 was used. Subsequently, DOM1h-574-16 was injected over human, mouse and dog TNFR1 and binding was monitored on the BIAcore. Examples for binding to the different species are shown in Figures 7 and 8, with a summary of the results in Table 2. Clearly, DOM1h-574-16 demonstrates high-affinity binding to the different TNFR1 species in contrast to our previously described (WO2008149148) competitive anti-TNFR1 dAb DOM1h-131-206, which showed virtually no binding to mouse TNFR1 and only very weak binding to dog TNFR1 .

Table 2: Binding affinity of DOM1h-131-206 and DOM1h-574-16 for mouse, dog and human TNFR1 as determined by BIAcore. *= affinity too poor to be determined by BIAcore (> μ M)

- 90 -

	<i>Mouse TNFR1 (K_D)</i>	<i>Dog TNFR1 (K_D)</i>	<i>Human TNFR1 (K_D)</i>
DOM1h-131-206	ND*	> 500 nM	0.47 nM
DOM1h-574-16	20 nM	20 nM	1 nM

Data estimated using the Bioevaluation 3.1 package

Next, the potency of DOM1h-574-16 to inhibit TNF α -mediated cytotoxicity of mouse cells (L929) and inhibition of TNF α -mediated, IL-8 release of *Cynomologus* monkey cells (CYNOM-K1) was evaluated. Both the standard mouse L929 and CYNOM-K1 cell assays were performed as described previously (WO2006038027) and below. Briefly, mouse L929 cells were incubated overnight with 100 pg/ml of mouse TNF α in the presence of actinomycin D and a dose range of DOM1h-574-16. After 18h, cell viability was checked and plotted against the DOM1h-574-16 concentration. In the *Cynomologus* monkey CYNOM-K1 cell assay, cells were stimulated with TNF α (200 pg/ml) for 18h in the presence of a dose range of DOM1h-574-16. After the incubation, media was removed and the level of IL-8 was determined. The percentage of neutralization was plotted against the concentration of DOM1h-574-16. For both cell types, DOM1h-574-16 was able to efficiently inhibit the TNF α -mediated effects. Its potency was ~250 nM in the mouse standard L929 cell-based assay and ~10 nM in the *Cynomologus* monkey CYNOM-K1 assay (figures 9 and 10). These results demonstrate functional, species cross-reactivity of DOM1h-574-16 in cell-based assays.

Affinity maturation of DOM1h-574

Based on this test maturation and the results of the combination mutants, it was decided to use DOM1h-574-14 as the template for further affinity maturation. Whilst this particular dAb was not the most potent, it does not have any framework mutations compared to germline DP47 frameworks and was therefore chosen. For affinity maturation, the CDRs of DOM1h-574-14 were randomised by amplifying the CDRs using the following oligonucleotides: AS1029 and AS339 (CDR1), AS1030 and AS339 (CDR2) and AS1031 and AS339 (CDR3). The second PCR fragment for each library

- 91 -

was made using the following oligonucleotide combinations: AS1031' and AS9 (CDR1), AS1032 and AS9 (CDR2), AS1033 and AS9 (CDR3). Using SOE PCR (Horton *et al.* Gene, 77, p61 (1989)) the two CDR1 PCR products were combined to create the CDR1 library, the CDR2 products for the CDR2 library and the CDR3 products for the CDR3 library. For all reactions the SOE product was then amplified with the nested primers AS639 and AS65 and ligated SalI/NotI in the pIE2aA² vector, described in WO2006018650. The randomisation oligonucleotides (AS1029, AS1030 and AS1031) consisted of fixed positions (indicated by a capital letter and in which case 100% of oligonucleotides have the indicated nucleotide at that position) and mixed nucleotide composition, indicated by lower case in which case 85% of oligonucleotides will have the dominant nucleotide at this position and 15% will have an equal split between the remaining three nucleotides. Three different libraries were prepared using DNA-display construct pIE2aA². An aliquot of the library was used to transform *E. Coli* and sequenced. Relative to the parent clones, the affinity maturation libraries contained many mutations across the CDRs. Selections were performed using *in vitro* compartmentalisation in emulsions and DNA display through the scArc DNA binding protein (see WO2006018650). Thirteen rounds of selection were carried out in total, whilst keeping the libraries separate. Four rounds of equilibrium selections with 20, 20, 10 and 10 nM biotinylated human TNFR1 (R&D Systems), were followed by seven rounds of off-rate selection in the presence of 130 nM un-biotinylated hTNFR1 and 5nM biotinylated hTNFR1 for up to 150 min. The unlabelled hTNFR1 was a competitor. Selections were also made using pooled libraries (14 rounds of selection in total for pooled libraries). Library fitness during the selection process was assayed by real-time PCR. The principle of the method used is the following: *In vitro* titration of polyclonal population fitness by qPCR provides a semiquantitative measure of the average affinity of a polyclonal dAb population by measuring the amount of encoding DNA in complex with dAb-scArc protein that is captured by surface-bound antigen after *in vitro* expression reaction in solution conditions (no genotype-phenotype linkage). The higher is the fraction of input DNA which is recovered, the more potent is the polyclonal dAb population. Suitable reference points are the binding levels of parent

- 92 -

clone to a non-specific surface coated with irrelevant antigen and specific binding to the surface coated with target antigen. DNA templates recovered during the different stages of selection were diluted to 1.7 nM concentration in 0.1 mg/ml RNA solution. *In vitro* expression reactions were carried out in 10 µl volume of EcoPro T7 E.coli extract

5 supplemented with 0.3 µl of 100 mM oxidized glutathione, 0.05 µl of 340 nM anti-HA mAb 3F10 from Roche and 0.5 µl of 1.7 nM DNA template. The wells of Strep ThermoFast plates were coated with biotinylated hTNFR1 target antigen (0.1 µl of 30 µM stock/well) or BSA negative control (0.1 µl of 2 mg/ml stock/well) for 1 hour at room temperature, followed by three washes with buffer C (10 mM Tris, 100 mM KCl,

10 0.05% Tween 20, 5 mM MgCl₂ and 0.1 mM EDTA). *In vitro* expression reactions were incubated at 25°C for three hours, then diluted to 100 µl using buffer C, applied in two 50 µl aliquots to the wells of Strep ThermoFast plate (ABgene, UK) previously coated with biotinylated hTNFR1 or BSA, incubated for further one hour at room temperature and washed three times with buffer C to remove any unbound DNA. Bound DNA

15 molecules were amplified using oligonucleotides AS79 and AS80 and iQ SYBR Green Supermix (Bio-Rad Laboratories, cat no. 170-8880), which was used according to manufacture's instructions, and amplification cycles were: 2 min 94°C, followed by 40 cycles of 15 sec 94°C, 30 sec 60°C and 30 sec 72°C . The amount of DNA was quantified on a BioRad MiniOpticon Real-Time PCR Machine (Bio-Rad Laboratories,

20 Hercules CA) and analysed using Opticon Monitor version 3.1.32 (2005) software provided by Bio-Rad Laboratories. Standard curve from a sample of known DNA concentration covered the range from 500 to 5x10⁸ molecules per reaction.

Up to tenth round of selection, the fitness of the library increased as each round recovered more DNA than the previous rounds, indicating that the average number of

25 binding dAbs was increasing. From this point onwards, no increases were seen in the level of recovered DNA, as determined by real-time PCR, suggesting that additional rounds of selection were not yielding significant further improvements in dAb affinities.

- 93 -

The selected population of rounds 9 and 14 were cloned into a pDOM13 vector (see WO2008/149148), sequenced, expressed and BIAcore-assayed for dissociation rate constants in unpurified form.

- 5 It was found that the library diversity was greatly reduced, with a number of clones displaying improved (2-3 fold) dissociation rate constants as determined by BIAcore dAb supernatant screening. DNA sequencing of these improved dAbs identified DOM1h-574-25 to DOM1h-574-40.
- 10 The beneficial mutations identified based on these dAbs are listed below for each CDR separately (numbering according to Kabat):
- CDR1: V30 is beneficially mutated to I, L or F.
- CDR2: S52 is beneficially mutated to A or T,
- 15 N52a is beneficially mutated to D or E,
- G54 is beneficially mutated to A or R,
- T57 is beneficially mutated to R, K or A,
- A60 is beneficially mutated to D, S, T or K,
- D61 is beneficially mutated to E, H or G,
- S62 is beneficially mutated to A or T,
- 20 CDR3: E100 is beneficially mutated to Q, V, A, D or S,
- D101 is beneficially mutated to E, V, H or K.

- At first, the CDR1+2 of clones DOM1h-574-30, -31, -38 and -39 was recombined in a mini-library with the CDR3s of clones DOM1h-574-25, -27, -28, -29 and -32. These
- 25 dAbs were chosen as they represented the dAbs with the largest improvements in BIAcore affinity and therefore combinations of these dAbs would have the best chance at identifying novel sequences with enhanced affinity. The resulting recombined dAbs were DOM1h-574-65 to DOM1h-574-79 and DOM1h-574-84 to DOM1h-574-88, of which DOM1h-574-72 (SEQ ID NO: 2) was the most potent. This dAb was
- 30 subsequently used to evaluate the usefulness of individual amino acid mutations by

- 94 -

using -72 as a template and introducing amino acid changes to produce clones DOM1h-574-89 to DOM1h-574-93, DOM1h-574-109 to DOM1h-574-149, and DOM1h-574-151 to DOM1h-574-180. Most of these clones were expressed, purified and assayed for binding on BIAcore, potency in the MRC5 cell assay and protease stability as

5 determined by resistance to trypsin digestion. The protease stability was determined by incubation of dAb at 1 mg/ml in PBS with decreasing amounts of trypsin (Promega, V511A trypsin). Incubation was performed at 5 different concentrations of trypsin (34, 17, 8.5, 4.25 and 2.13 µg/ml) as well as a control lacking trypsin. After incubation at 37 °C for three hours, the proteolytic reaction was stopped by adding loading dye and the

10 amounts of residual, uncleaved dAb was determined on a LabChip 90 system (Caliper Life Sciences). The most improved clones have about 30-fold potency improvement over DOM1h-574-16, the starting dAb used for affinity maturation. The most potent in the MRC5 cell assay are: DOM1h-574-109, DOM1h-574-132, DOM1h-574-135, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180 (figure

15 11).

Surprisingly, it was found that the structural determinants for affinity/potency on one hand and the protease stability on the other hand are different. Whilst most of the listed mutations improved affinity to sub-nM range as determined by BIAcore, they also led to decreased trypsin resistance (see WO2008149143 and WO2008149148 for more

20 description on suitable assays for determining protease stability of dAbs). On the other hand, mutation D101V (Kabat numbering) was very frequently associated with the best protease stability, albeit at the expense of about a two-fold reduction of dAb affinity, compared with any other tested sequence. The most protease stable dAbs are: DOM1h-574-93, DOM1h-574-123, DOM1h-574-125, DOM1h-574-126, DOM1h-574-129,

25 DOM1h-574-133, DOM1h-574-137 and DOM1h-574-160 (figure 12).

Characterisation of most promising DOM0100 dAbs

Based on the data for BIAcore binding and MRC5 cell assay potency, a subset of 12 DOM0100 dAbs were chosen for further characterisation of binding kinetics to TNFR1,

30 potency in cell assays and biophysical properties. For all these experiments the dAbs

- 95 -

were expressed in *E. coli* and purified using Protein A streamline followed by dialysis in PBS. The 12 dAbs used for this characterisation were: DOM1h-574-72, DOM1h-574-109, DOM1h-574-126, DOM1h-574-133, DOM1h-574-135, DOM1h-574-138, DOM1h-574-139, DOM1h-574-155, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180. For certain experiments DOM1h-574-16 is included as a reference (figure 13).

Binding properties DOM0100 dAbs (anti-TNFR1 dAbs)

BIAcore was done to determine the association and dissociation rates of the different dAbs and in that way establish their binding affinity for both human and mouse TNFR1. Experiments were done using biotinylated TNFR1 (R&D Systems), of the respective species, coupled to streptavidin-coated BIAcore chips followed by injection of a concentration range of the dAbs. The results are summarised in Table 3. All dAbs show high affinity binding to human TNFR1 ($K_D < 350$ pM) as well as good affinity for mouse TNFR1 ($K_D < 7$ nM). This difference in dAb affinity of about 20-fold between human and mouse TNFR1 is quite surprising given the limited sequence homology between mouse and human TNFR1 and might indicate the targeting of a highly conserved motif in the receptor.

Table 3: BIAcore analysis of association and dissociation of DOM0100 dAbs for human and mouse TNFR1. The most potent anti-human TNFR1 dAbs tend to also be the most potent anti-mouse TNFR1 dAbs, e.g. DOM1h-574-138 and DOM1h-574-156.

DOM0100 dAb	Human			Mouse		
	K_{on} ($\times 10^5 M^{-1} s^{-1}$)	K_{off} ($\times 10^{-5} s^{-1}$)	K_D (pM)	K_{on} ($\times 10^5 M^{-1} s^{-1}$)	K_{off} ($\times 10^{-4} s^{-1}$)	K_D (nM)
DOM1h-574-72	2.5	8.4	350	1.0	6.8	6.9
DOM1h-574-109	2.4	5.5	230	1.2	3.3	2.8
DOM1h-574-126	3.8	7.9	210	1.6	6.8	4.4
DOM1h-574-133	2.6	8.8	340	1.4	7.5	5.2

- 96 -

DOM1h-574-135	2.5	5.2	210	1.1	4.5	3.8
DOM1h-574-138	2.5	3.8	150	1.3	3.0	2.4
DOM1h-574-139	1.4	3.7	270	0.7	3.0	4.4
DOM1h-574-155	2.4	4.3	180	1.1	3.3	3.7
DOM1h-574-156	3.0	4.3	150	1.4	3.0	2.1
DOM1h-574-162	2.9	4.4	150	1.4	3.4	2.5
DOM1h-574-180	2.7	4.1	150	1.2	3.2	2.7

Biophysical properties of DOM0100 dAbs

The DOM0100 dAbs were further characterized for their biophysical properties, which included their protease stability, thermal stability and in-solution state. The protease stability was determined by incubation of dAb at 1 mg/ml in PBS with decreasing amounts of trypsin (Promega, V511A trypsin). Incubation was performed at 5 different concentrations of trypsin (34, 17, 8.5, 4.25 and 2.13 μ g/ml) as well as a control lacking trypsin. After incubation at 37 °C for three hours, the proteolytic reaction was stopped by adding loading dye and the amounts of residual, uncleaved dAb was determined on a LabChip 90 system (Caliper Life Sciences). Amounts were quantified as a percentage of the amount present in the control reaction and are summarized in Table 4. Thermal stability of the DOM0100 dAbs was determined using a differential scanning calorimetry (DSC) instrument (MicroCal, MA). dAbs, at 1 mg/ml in PBS, were incubated in the instrument and the melting temperature determined. The results are summarized in table 4. Finally, the in-solution state of the dAbs was determined using size-exclusion chromatography and multi-angle laser light scattering (SEC-MALLS). The dAbs were injected on the SEC-MALLS at 1 mg/ml in PBS and the mass of the main peak determined. The DOM0100 dAbs could be divided in two groups, either monomeric or dimeric, based on their in-solution state. For a summary see Table 4.

Table 4: Summary of biophysical properties of DOM0100 dAbs. The combination of properties in a dAb to be aimed for is high trypsin stability, high thermal stability and

- 97 -

monomeric in-solution state to avoid receptor cross-linking and subsequent agonism or lack of activity. The table lists the residual activity after 3h incubation at 37°C with 34 µg/ml trypsin as a percentage of the activity at t0. The melting temperature (Tm) was determined by DSC and the in-solution state by SEC-MALLS. The table indicates that the most trypsin-stable dAb (DOM1h-574-133) is dimeric and therefore unfavorable. The dAbs with the best combination of properties are: DOM1h-574-109, DOM1h-574-156 and DOM1h-574-162. Where indicated values were not determined (ND).

DOM0100 dAb	trypsin stability	Tm	in-solution state
	(% residual activity)	°C	
DOM1h-574-72	15	56	Monomer (70%)
DOM1h-574-109	23	55.2	Monomer (70%)
DOM1h-574-125	ND	53.5 / 57.2	poor data
DOM1h-574-126	50	55.4/59.6	poor data
DOM1h-574-133	60	57.6 / 59.6	Dimer (90%)
DOM1h-574-135	5	51.5	Monomer (90%)
DOM1h-574-138	17	54 / 56.9	monomer/dimer equilibrium
DOM1h-574-139	2	52.1 / 55.1	poor data
DOM1h-574-155	7	53	Monomer (75%)
DOM1h-574-156	12	55	Monomer (90%)
DOM1h-574-162	10	54.2	Monomer (90%)
DOM1h-574-180	5	53.2	Monomer (75%)

10 Functional characterization of DOM0100 dAbs

The DOM0100 dAbs were characterized for functional activity and cross-species reactivity using the human MRC-5 cell assay, the mouse L929 cell line and the *Cynomolgous* monkey CYNOM-K1 cell line described below. For functional

- 98 -

inhibition of human TNFR1 signaling, the human fibroblast cell line MRC-5 was incubated with a dose-range of dAb and then stimulated for 18h with 200 pg/ml of TNF α (Peprotech) (except that 20pg/ml mouse TNF α (R&D Systems) was used for the L929 assay). After this stimulation, the media was removed and the levels of IL-8 in the media, produced by the cells in response to TNF α , was determined using the ABI8200 (Applied Biosystems). The ability of the dAbs to block the secretion of IL-8 is a functional read-out of how well they inhibit TNFR1-mediated signaling. The results of testing the 12 DOM0100 dAbs in the MRC5 cell assay are shown in Table 5. Functional mouse cross-reactivity was determined using the mouse L929 cell line, in which the level of protection provided by the 12 DOM0100 dAbs against TNF α -induced cytotoxicity was evaluated. In this assay, cells are again incubated with a dose-range of dAb followed by stimulation with TNF α in the presence of actinomycine. After overnight incubation, the viability of the cells is measured and plotted against dAb concentration. The DOM0100 dAbs protected against TNF α cytotoxicity and resulted in ND50 values in the 20-40 nM range. The potency differences of the DOM0100 dAbs observed between the human MRC5 cells and the mouse L929 cells is of a similar order of magnitude as the differences in affinity determined by BIAcore.

Finally, the *Cynomologous* monkey cross-reactivity of the dAbs was tested using the CYNOM-K1 cell line. Briefly, the dAb was incubated with CYNOM-K1 cells (ECACC 90071809) (5×10^3 cells/well) for one hour at 37°C in a flat bottom cell culture plate. Recombinant human TNF alpha (Peprotech) was added (final concentration of 200pg/ml) and the plates were incubated for 18-20 hours. The level of secreted IL-8 was then measured in the culture supernatant using the DuoSet ELISA development system (R&D Systems, cat# DY208), according to the manufacturer's instructions (document number 750364.16 version 11/08). The ND50 was determined by plotting dAb concentration against the percentage of inhibition of IL-8 secretion. The results for the DOM0100 dAbs is shown in Table 5.

Table 5: Summary of functional activity of DOM0100 dAbs in cell-based assays for different species. All values presented are ND50 values (in nM) determined in the

- 99 -

respective cell assay, whilst ND stands for, not determined. Although the difference between the DOM0100 dAbs in the MRC5 assay is limited, it follows the same trend as observed in the mouse and cyno cell assays. Across species, DOM1h-574-156, DOM1h-574-109 and DOM1h-574-138 are the most potent dAbs. For the MRC5
 5 assay, we took curves that were judged to be sigmoidal. Average values from these curves are shown in the table.

DOM0100 dAb	Human	Mouse	<i>Cynomologus</i>
	<i>MRC5</i>	<i>L929</i>	<i>CYNOM-K1</i>
	nM	nM	nM
DOM1h-574-72	2.7	46	2.3
DOM1h-574-109	1.8	63	1.6
DOM1h-574-125		35	1.2
DOM1h-574-126	1.9	35	1.2
DOM1h-574-133	2.1	110	1.7
DOM1h-574-135	1.8	47	1.5
DOM1h-574-138	1.4	23	1.2
DOM1h-574-139	1.1	28	1.8
DOM1h-574-155	2.1	67	1.6
DOM1h-574-156	0.9	22	ND
DOM1h-574-162	1.2	27	ND
DOM1h-574-180	1.9	34	ND

Epitope mapping for DOM0100 dAbs

10 As the binding epitope on TNFR1 of the DOM0100 dAbs can be correlated to the mechanism of action, multiple efforts were under taken to establish which residues in TNFR1 are recognized by the DOM0100 dAbs. Two experimental approaches were chosen to establish the epitope: 1) BIAcore epitope competition and 2) peptide scanning using partially overlapping peptides.

- 100 -

1) *BIAcore epitope competition:*

A qualitative approach to determining if competition between two different antibodies or antibody fragments exists for a single epitope on TNFR1 can be done by BIAcore (Malmborg, *J. Immunol. Methods* 183, p7 (1995)). For this purpose, biotinylated-
5 TNFR1 is coated on a BIAcore SA-chip followed by the sequential injections of different dAbs or antibodies to establish binding levels for each antibody in the absence of any competing antibody (fragment). Subsequently, the injections are repeated using the same concentration of antibody (fragment), but now immediately after injection of the antibody with which competition is to be determined. Bound antibody (fragment) is
10 quantified in Resonance Units (RUs) and compared in the presence and absence of a second antibody. If no competition exists between the two antibodies (fragments), the number of RUs bound will be identical in the presence and absence of the other antibody. Conversely, if competition does exist there will be little or no RUs bound during the injection of the second antibody (fragment). For DOM1h-574-16 it was
15 shown that the number of resonance units bound in the presence or absence of a TNF α -competitive dAb (DOM1h-131-511 (see WO2008149144)) and mAb (mAb225 (R&D systems; cat no. MAB225) was unchanged, indicating an epitope novel to the mentioned dAb and mAb (figures 14 and 15). TNFR1 is a multi-domain receptor, consisting of four cysteine-rich domains. Domains two and three are responsible for
20 TNF α binding (Banner *et al.*, *Cell*, 73, p431 (1993)), while the first domain, also known as the preligand assembly domain (PLAD), facilitates the pre-assembly of the receptor prior to TNF α binding (Chan *et al.* *Science*, vol 288, p2351 (2000)). Competition with a known PLAD-binding mAb Clone 4.12, (Supplied by Invitrogen, cat. no. Zymed 33-0100) on the BIAcore was very limited, showing at best a decrease of 20% in the
25 number of RUs of Clone 4.12 bound in the presence of the DOM0100 dAb (DOM1h-574-16) compared to its absence (figure 16). This indicates that the vast majority of the epitope recognized by DOM1h-574-16 is not recognized by Clone 4.12. The only dAb to show full competition with DOM1h-574-16 was another DOM0100 dAb isolated during the selections: DOM1h-510 (figure 17). As the DOM0100 dAb shows cross-
30 reactive binding to mouse TNFR1, the same experiments could be performed on mouse

- 101 -

TNFR1 coated to BIAcore chips to establish if competition exists with anti-murine TNFR1, non-competitive dAb DOM1m-21-23 (see WO2006038027). Strikingly, no competition was seen between DOM1m-21-23 and the DOM0100 dAb DOM1h-574-16 (figure 18). The unique property of the DOM1h-574 dAbs to be cross-reactive with mouse also highlights that a novel epitope must be recognized as none of the above mentioned dAbs or antibodies (DOM1h-131-511, mAB225, Clone 4.12 and DOM1m-21-23) show any significant mouse/human cross-reactivity.

2) peptide scanning of TNFR1.

To establish if any linear epitope on the TNFR1 is recognized by our DOM1h-574 dAb lineage, scanning 15-mer peptides, each offset by three residues, were synthesized to cover the complete extracellular domain of TNFR1. These peptides each contained a biotin group, which was used for coupling to different sensor tips of a ForteBio Octet instrument (Menlo Park, CA, USA). The ForteBio Octet instrument uses Bio-Layer Interferometry (BLI), a label-free, biosensor technology that enables the real-time measurement of molecular interactions. The Octet instrument shines white light down the biosensor and collects the light reflected back. Any change in the number of molecules bound to the biosensor tip causes a shift in this interference pattern of the reflected light and is determined in real-time. In our experiment, each tip was coated with a different peptide and were incubated with DOM1h-574-16 dAb and binding of dAb to each tip was monitored. The vast majority of tips showed no reliable binding. Three peptides, together with a negative control peptide that had not shown any binding on the BioForte Octet, were coupled to a streptavidin-coated, BIAcore chip and binding of DOM1h-574-16, DOM1h-131-511 and DOM1m-21-23 to these peptides were determined (figures 19, 20 and 21). Only the DOM0100 dAb (DOM1h-574-16) showed any binding to the three specific peptides, while none of the other dAbs showed any binding. No binding for any dAbs was observed on the negative peptide control. The three TNFR1 peptides could be divided into two groups: 1) peptide 1 (NSICCTKCHKGTYLY) located in domain 1 and 2) peptides 2 (CRKNQYRHYWSENLF) and 3 (NQYRHYWSENLFQCF), which overlap and are in

- 102 -

domain 3 of TNFR1. Especially peptide 1 is noteworthy as, with the exception of the very last residue, this sequence corresponds to the only stretch of 15 sequential amino-acid residues in TNFR1 which are fully conserved between mouse and human TNFR1 (this conserved stretch has the sequence: NSICCTKCHKGYL). Binding to this epitope would explain the mouse cross-reactivity observed for the DOM1h-574 lineage.

Formatting of DOM0100 dAbs for extended *in vivo* half-life

For the DOM0100 dAbs to be useful in treating a chronic inflammatory disorder, such as *e.g.* RA and psoriasis, it would be desirable that the dAb will be delivered systemically and be active for prolonged periods of time. Many different approaches are available to accomplish this, which include *e.g.* addition of a PEG moiety to the dAb, expression of the dAb as a genetic fusion with a serum albumin-binding dAb (AlbudAbTM) or genetic fusion to the Fc portion of an IgG. For the DOM0100 (anti-TNFR1) dAb DOM1h-574-16 both the PEG and AlbudAb fusion were tested.

1) Half-life extension by conjugation with 40K (40 KDa) linear PEG.

For this purpose a variant of DOM1h-574-16 was made which had a free cysteine at the C-terminus of the dAb (C-terminal serine was substituted by cysteine). The variant was expressed in *E. coli* and purified using Protein-A streamline. Using maleimide chemistry (see WO04081026), 40K linear PEG (DOWpharma) was conjugated to the C-terminus of this DOM1h-574-16 variant and the reaction cleaned by running on a FPLC column. The molecule was named DMS0162. The effect of the PEG conjugation on extending the half-life of DMS0162 was evaluated in a rat PK study. Three female Sprague-Dawley rats were administered i.v. with a target dose of 2.5 mg/kg of protein. Blood samples were taken from the rats at 0.17, 1, 4, 8, 24, 48, 72, 96, 120 and 168 hours post administration and assayed to determine amounts of DMS0162 in blood. DMS0162 samples were tested in a TNFR1-capture and goat anti-hfAb detection ELISA. Raw data from the assays were converted into concentrations of drug in each serum sample. The mean µg/mL values at each timepoint were then analysed in the

- 103 -

WinNonLin analysis package, eg version 5.1 (available from Pharsight Corp., Mountain View, CA94040, USA), using non-compartmental analysis (NCA). These data gave an average terminal half-life of DMS0162 in rat of 20.4h.

5 2) Half-life extension through genetic fusion with an AlbudAb™

a) Functional characterisation of anti-TNFR1 dAb fusions with AlbudAbs

Previously we have described the use of genetic fusions with an albumin-binding dAb (AlbudAb) to extend the PK half-life of dAbs in vivo (see, eg, WO04003019, 10 WO2006038027, WO2008149148). Desirable aspects of these fusions are:

- 1) fusion of the AlbudAb should not substantially affect the binding affinity of the TNFR1-binding dAb,
- 2) the affinity of the AlbudAb for albumin, from different species, should be such that an increase in PK half-life can be expected.

15 To evaluate the pairing of DOM1h-574-16 with different AlbudAbs the pairings listed in Table 6 were made (constructs were, N- to C-terminally, anti-TNFR1 dAb (ie, DOM0100 dAb-linker-AlbudAb-myc). With the exception of DMS0184, all contained a myc-tag at the C-terminus which could possibly be used for detection purposes.

20 **Table 6:** BIAcore off-rate parameters of anti-TNFR1 dAb/AlbudAb fusions and potency of anti-TNFR1 dAb in the MRC5 cell assay. All dAb/AlbudAb fusions listed contained a -myc tag at the C-terminus of the AlbudAb, with the exception of DMS0184. In some cases no binding (NB) to the serum albumin was observed by BIAcore, whereas for other it was not determined (ND). For the MRC5 assay, some 25 data were not determined sufficiently often to justify quoting a value (ND*).

DMS	DOM0100 dAb	Linker	AlbudAb	Koff	Koff	ND50
	N-terminal dAb		C-terminal dAb	MSA	HSA	(MRC5
				s ⁻¹	s ⁻¹	)

- 104 -

						nM
DMS0182	DOM1h-574- 16	AST	DOM7h-11	0.75	0.17	6
DMS0184	DOM1h-574- 16	ASTSGPS	DOM7h-11	0.72	0.16	19
DMS0186	DOM1h-574- 16	AST	DOM7h-11-12	0.08	0.12	20
DMS0188	DOM1h-574- 16	ASTSGPS	DOM7h-11-12	0.08	0.12	17
DMS0189	DOM1h-574- 16	AST	DOM7h-11-3	0.13	0.017	ND*
DMS0190	DOM1h-574- 16	ASTSGPS	DOM7h-11-3	0.16	0.019	ND*
DMS0191	DOM1h-574- 16	AST	DOM7m-16	0.11	NB	ND*
DMS0192	DOM1h-574- 16	ASTSGPS	DOM7m-16	0.09	NB	ND*
DMS0163	DOM1h-574- 16	ASTSGPS	DOM7h-11-15	0.0062	0.0024	12
DMS0168	DOM1h-574- 72	ASTSGPS	DOM7m-16	ND	ND	16
DMS0169	DOM1h-574- 72	ASTSGPS	DOM7h-11-12	ND	ND	2.7

The sequences of all AlbudAbs is given below. The nucleotide and amino acid sequences of DOM7h-11 and DOM7m-16 are disclosed herein.

After expression and purification, all constructs were tested on the BIAcore for binding
5 to both mouse and human serum albumin. The off-rates were determined and used to discriminate between the AlbudAbs for their suitability in prolonging the half-life of the fusion molecule. Whereas the linker had little influence on the affinity of the AlbudAb

- 105 -

for albumin, a significant difference existed between the dAbs and their albumin affinity. The best AlbudAb for mouse binding was DOM7h-11-15 followed by DOM7m-16 and DOM7h-11-12 (figure 22). However, DOM7m-16 showed no binding on human albumin, while DOM7h-11-15 and DOM7h-11-3 were the best pairings for human albumin binding (figure 23). Although assay variability was seen, there generally was only a limited drop in affinity in the human MRC-5 cell assay ND50 values obtained for the monomer DOM1h-574-16 and the same dAb when fused to any AlbudAbs of the DOM7h-11 lineage. An impact of the AlbudAb DOM7m-16 was however seen when paired with DOM1h-574-72 and when compared to DOM7h-11-12. The DOM7m-16 pairing resulted in a significant drop in potency for the anti-TNFR1 part of the fusion in the MRC-5 cell assay, which was not seen when the same anti-TNFR1 dAb was paired with DOM7h-11-12. These results highlight the advantages of pairings with AlbudAbs from the DOM7h-11 lineage (eg, anti-serum albumin dAbs having an amino acid sequence that is at least 80, 90 or 95 % identical to the amino acid sequence of DOM7h-11).

b) mouse and rat PK for different DOM0100-AlbudAb fusions

An alternative to PEG would be expressing the DOM0100 dAb as a genetic fusion with a domain antibody recognising serum albumin (AlbudAb). To evaluate this approach, a genetic construct was made consisting of DOM1h-574-16, an Alanine Serine Threonine (AST) linker and DOM7h-11 followed by a myc tag (DMS0182). This construct was ligated into the *E. coli* expression vector pDOM5, transformed to the *E. coli* strain HB2151 and expressed. The DMS0182 was purified from the supernatant using ProteinL coupled to a solid support followed by ProteinA-streamline to remove any free monomer. DMS0182 was administered to three female Sprague-Dawley rats i.v. at a dose of 5 mg/kg. Blood samples were taken 0.17, 1, 4, 8, 24, 48, 72, 96, 120 and 168 hours post administration. Serum samples were prepared and these were then tested in 3 separate ELISAs: 1) goat anti-myc capture with rabbit anti-human kappa chain detection, 2) goat anti-myc capture with TNFR1-Fc detection and readout through anti-human-Fc/HRP and 3) TNFR1 capture with goat anti-fAb detection and readout

- 106 -

through anti-goat HRP. Raw data from the assays were converted into concentrations of drug in each serum sample. The mean $\mu\text{g/mL}$ values at each timepoint were then analysed in WinNonLin using non-compartmental analysis (NCA). DMS0182 was tested in the three mentioned assays, with a mean terminal half-life of 5.2 – 6.4 hours.

- 5 Using the same DMS0182, an additional PK study was done, this time in mice dosed intraperitoneal at 10 mg/kg. Three mice were bled at each of the following time points: 0.17, 1, 4, 12, 24, 48 and 96h. Analysis of serum using the assay option 2 mentioned previously identified a serum half-life of DMS0182 in mice of about 5.9h (figure 24). Clearly the addition of the AlbudAb DOM7h-11 has extended the half-life of the dAb
- 10 over that seen in the past when free dAb was injected in mice and rat ($T_{1/2}$ of about 20 minutes, see, eg, WO04003019 WO04003019). However, further improvements in half-life would be beneficial. Examination of the binding affinity of DOM7h-11, when fused to DOM1h-574-16, for rat and mouse albumin identified affinities in excess of 1 μM , as determined by BIAcore. Therefore, changes were made to both the AlbudAb as well as
- 15 the linker used for these in-line fusions. Two new genetic constructs were made consisting of a different DOM0100 dAb (DOM1h-574-72), a different linker (ASTSGPS), two different AlbudAbs (DOM7m-16 and DOM7h-11-12) and both followed by a –myc tag, creating DMS0168 and DMS0169, respectively (constructs were, N- to C-terminally, anti-TNFR1 dAb (ie, DOM0100 dAb)-linker-AlbudAb-myc).
- 20 These constructs were cloned in pDOM5, expressed in *E. coli* and purified using Protein-L and Protein-A. Both were analysed on BIAcore for their binding to MSA and significant improvements were observed resulting in mouse albumin-binding affinities of about 200 nM for both constructs. To determine the effects of improved albumin binding on half-life extension, DMS0168 and DMS0169 were dosed i.v. at 2.5 mg/kg in
- 25 mice, followed by bleeding three mice at each of the the following time points: 0.17, 1, 4, 8, 24, 48, 96 and 168h. Serum half-life for both these molecules were determined by quantification of the fusion protein in serum in an ELISA based methods; for DMS0168, goat anti-myc was used for capture followed by detection with TNFR1-Fc and readout through anti-human-Fc/HRP. DMS0169 was captured using TNFR1-Fc
- 30 followed by detection with goat anti-Fab and readout through anti-goat HRP. In

- 107 -

addition to this method, BIAcore quantification of DMS0169 through binding to a chip coated with a high-density of human TNFR1 was used and the data were plotted to calculate the terminal half-life in mice. DMS0168 had a terminal half-life of 15.4 h (ELISA) and DMS0169 had either a terminal half-life of 17.8 h (ELISA) or 22.0 h (BIAcore) (figure 24). Both of these half-lives are a significant extension compared to the half-lives when the DOM0100 dAb was fused to DOM7h-11, and highlight the impact of increased affinity for albumin on the terminal half-life of the AlbudAb fusion.

Functional characterisation and biophysical properties of DOM0100-AlbudAb fusions

To determine the optimal format of an anti-TNFR1 dAb fused with an anti-albumin dAb, a single anti-TNFR1 dAb was taken (DOM1h-574-72) and paired with four different AlbudAbs (DOM7h-11-3, DOM7h-11-12, DOM7h-14-10 and DOM7h-14-18) using three different linkers (AST, ASTSGPS and AS(GGGGS)₃). None of these constructs contained a -myc tag. All 12 constructs were expressed in *E. coli* and purified using a two-step process of Protein L followed by Protein A purification and quantification of expression levels. In addition, the in-solution state of the molecules was determined using SEC-MALLS. The results are summarised in Table 7. The analysis of the results lead to a few striking observations: 1) Pairings of DOM1h-574-72 with the DOM7h-11 lineage dAbs resulted in significantly higher levels of expression when compared to the DOM7h-14 lineage pairings, 2) a monomeric in-solution state was observed for the DOM7h-11 pairings, whilst pairing with DOM7h-14 resulted in monomer/dimer equilibrium. A monomeric in-solution state is preferable as these molecules would be less likely to induce receptor cross-linking and consequently lead to receptor activation (agonism) or to neutralisation of inhibitor activity. Furthermore, monomeric in-solution state is desirable from a development point of view as these molecules tend to aggregate less and be cleaner when analysed by size exclusion chromatography (SEC). The observation that pairing with DOM7h-11 AlbudAbs lead to both higher expression levels and a higher percentage of monomeric in-solution state compared to DOM7h-14 AlbudAbs pairings, favour the DOM7h-11 pairings.

Table 7: Overview of combination of fusion molecules produced to evaluate optimal combination of linker and AlbudAb for expression and in-solution state. Three different linkers were used, indicated by their aminoacid composition, AST, ASTSGPS and a Glycine-Serine linker consisting of AS and three repeats of four Glycines and one Serine (AS(G₄S)₃). The in-solution state was determined using SEC-MALLS and denoted as either monomer or monomer/dimer equilibrium. For some AlbudAb fusions the expression was so low that insufficient material was available for determination of the in-solution state and these are indicated by (ND).

DMS	DOM0100 dAb	Linker	AlbudAb	Expression (mg/l)	SEC-MALLS
DMS0111	DOM1h- 574-72	AST	DOM7h- 11-3	12	Monomer (95%)
DMS0112	DOM1h- 574-72	AST	DOM7h- 11-12	11	Monomer (95%)
DMS0113	DOM1h- 574-72	AST	DOM7h- 14-10	0	ND
DMS0114	DOM1h- 574-72	AST	DOM7h- 14-18	1	ND
DMS0115	DOM1h- 574-72	ASTSGPS	DOM7h- 11-3	26	Monomer (98%)
DMS0116	DOM1h- 574-72	ASTSGPS	DOM7h- 11-12	15	Monomer
DMS0117	DOM1h- 574-72	ASTSGPS	DOM7h- 14-10	9	Monomer/dimer equilibrium
DMS0118	DOM1h- 574-72	ASTSGPS	DOM7h- 14-18	3	Monomer/dimer equilibrium
DMS0121	DOM1h- 574-72	AS(G ₄ S) ₃	DOM7h- 11-3	14	Monomer (98%)
DMS0122	DOM1h- 574-72	AS(G ₄ S) ₃	DOM7h- 11-12	12	Monomer (98%)

- 109 -

DMS0123	DOM1h- 574-72	AS(G ₄ S) ₃	DOM7h- 14-10	5	Monomer/dimer equilibrium
DMS0124	DOM1h- 574-72	AS(G ₄ S) ₃	DOM7h- 14-18	7	Monomer/dimer equilibrium

Furthermore, the affinity and potency of the purified fusion molecules were determined using a BIAcore T100 and the MRC5 cell assay, respectively. The BIAcore T100 is a highly sensitive BIAcore version ideally suited for determination of high affinity binders (Papalia et al., *Anal Biochem.* 359, p112 (2006)). Biotinylated, human TNFR1 was coated on the chip and each of the twelve AlbuDAb fusions were passed over this surface at four different concentrations (2, 10, 50 and 250 nM). The aim was to establish if the pairings had any significant effect on the binding affinity of the anti-TNFR1 dAb (DOM1h-574-72) to its target. As can be seen from Table 8 below, there was no significant difference between the pairings and their effect on affinity by BIAcore. All combinations resulted in a similar affinity, with the exception of the DOM7h-14-18 pairings (DMS0118 and DMS0124) which showed a 3-fold higher affinity than the other pairings. What is surprising though is the at least 2-3 fold improvement in affinity (KD) observed for DOM1h-574-72 in all AlbuDAb fusion molecules when compared to the un-fused DOM1h-574-72 dAb. This improvement is observed regardless of the AlbuDAb used for pairing and largest for the pairings with DOM7h-14-18. A second experiment used to establish if the different pairings affected the functional activity of the anti-TNFR1 dAb was the MRC5 cell assay (Table 8). A more marked difference between the pairings is observed in the MRC5 assay, in which the best potencies are observed in pairings with DOM7h-11-3 and DOM7h-11-12 while pairings with DOM7h-14-10 (DMS0117) lead to significant decreases in potency.

Table 8: BIAcore T100 and MRC5 analysis of the pairings of DOM1h-574-72 with four different AlbuDAbs using three different linkers. For the composition of the DMS

- 110 -

clones please see Table 7. The affinity constants were not determined (ND) for all constructs due to insufficient material. Overall no hits in affinity were observed on BIAcore after AlbudAb pairing. The most consistent data were obtained for DOM7h-11-3 and DOM7h-11-12 pairings in the MRC5 assay.

DMS	BIAcore Kon (M⁻¹ s⁻¹)	BIAcore koff (s⁻¹)	BIAcore KD (nM)	MRC5 (ND50 in nM)
DMS0111	3.7E+5	6.2E-5	0.17	1.6
DMS0112	4.0E+5	5.5E-5	0.14	1.3
DMS0114	ND	ND	ND	3.7
DMS0115	3.6E+5	5.8E-5	0.16	1.7
DMS0116	3.7E+5	5.4E-5	0.14	1.7
DMS0117	ND	ND	ND	25.9
DMS0118	6.4E+5	4.9E-5	0.076	1.4
DMS0121	3.0E+5	6.0E-5	0.2	1.8
DMS0122	ND	ND	ND	1.5
DMS0123	ND	ND	ND	5.0
DMS0124	4.5E+5	3.5E-5	0.077	1.9
DOM1h-574-72	2.0E+5	1.1E-4	0.53	2.7

5

Using the results of the biophysical and functional characterisation of both the monomer DOM1h-574 anti-TNFR1 dAbs and the pairings with the AlbudAbs, a subset of five fusion molecules were constructed, expressed, purified and characterised. These five each contained one of the following anti-TNFR1 dAbs: DOM1h-574-109, DOM1h-574-138, DOM1h-574-156, DOM1h-574-162 and DOM1h-574-180 each paired with DOM7h-11-3 using the AST linker. Constructs were, N- to C-terminally, anti-TNFR1 dAb (ie, DOM0100 dAb-linker-AlbudAb, none of these constructs contained a tag). The expressed molecules were characterised on SEC-MALLS for in-solution state, on DSC for thermal stability, on BIAcore for affinity to human and mouse TNFR1 and in the MRC5 cell assay for functional activity.

15

- 111 -

Biophysical characterisation of these five in-line fusion molecules demonstrated all to have melting temperatures $>55^{\circ}\text{C}$ and to be in-solution monomers (Table 9). A high melting temperature is indicative of an increased stability of the molecule which is beneficial during both downstream processing and storage of the molecule.

- 5 Furthermore, it might be beneficial to the stability of the molecule when functioning as a pharmaceutical drug *in vivo* in patients by making it less susceptible to degradation and thereby extending its terminal half-life.

Table 9: Overview of preferred combinations of anti-TNFR1 dAbs with DOM7h-11-3 AlbudAb for half-life extension. After purification, these fusion molecules were tested for thermal stability (DSC) and in-solution state (SEC-MALLS). All are monomeric while DMS0133 and DMS0134 have the highest melting temperatures.

DMS	Composition	DSC ($^{\circ}\text{C}$)	SEC-MALLS
Denoted N- to C-terminally			
DMS0132	DOM1h-574-109/AST/DOM7h-11-3	58.2/58.9	98% monomer
DMS0133	DOM1h-574-138/AST/DOM7h-11-3	59.0/59.4	98% monomer
DMS0134	DOM1h-574-156/AST/DOM7h-11-3	58.9/59.3	98% monomer
DMS0135	DOM1h-574-162/AST/DOM7h-11-3	58.0/58.7	98% monomer
DMS0136	DOM1h-574-180/AST/DOM7h-11-3	57.8/58.0	98% monomer

- Characterisation of the anti-TNFR1 affinity by BIAcore and the functional activity in the human MRC5 and standard mouse L929 cell assays (Table 10) indicated the differences between the dAbs to be limited. However, when all data are taken together from melting temperature, in-solution state, expression, BIAcore, human MRC5 cell assay and standard mouse L929 cell assay, DMS0133 and DMS0134 emerge as the preferred combinations. The melting temperature is the highest for these two, while they belong to the most potent combinations in the functional human and mouse cell assays. The functional activity in the cell assays is a key driver for determining the preferred molecule.

Table 10: Functional characterisation and expression of five best anti-TNFR1/AlbudAb fusion molecules. Expression levels were determined after purification. Affinities were determined by BIAcore and the functional activity was determined in both a human MRC5 and standard mouse L929 cell assay. Expression was best for DMS0132, DMS0135 and DMS0134, while the most potent combinations in the cell assays were DMS0133, DMS0134 and DMS0135.

DMS	Expression (mg/l)	BIAcore Kon (M ⁻¹ s ⁻¹)	BIAcore Koff (s ⁻¹)	BIAcore KD (nM)	MRC5 ND50 (nM)	L929 ND50 (nM)
DMS0132	12	1.9E+05	4.6E-05	0.25	1.04	6.8
DMS0133	6	3.6E-05	3.6E-05	0.20	0.99	4.2
DMS0134	9	1.9E+05	4.9E-05	0.26	0.96	6.52
DMS0135	11	1.8E+05	5.7E-05	0.32	1.17	5.9
DMS0136	3	1.9E+05	5.5E-05	0.30	1.97	5.4

Demonstration of *in vivo* efficacy of DOM0100 in a murine model for rheumatoid arthritis

To demonstrate that the activity of the described anti-TNFR1 dAb is useful and could be disease modifying, a murine model of rheumatoid arthritis was treated with DMS0169, a fusion, N- to C-terminally, of DOM1h-574-72 – ASTSGPS – DOM7h-11-12-myc tag. This murine model is a transgenic mouse model in which human TNF α is overexpressed (Tg197) and the gene encoding the mouse TNFR1 has been replaced with the human TNFR1 (hp55) gene. Over time these mice develop spontaneous arthritis which is scored by measuring joint sizes during treatment (clinical score) and by performing histological analysis of the joints after 15 weeks (Keffer *et al.*, *EMBO.J.*, 10, p4025 (1991)). In addition, the overall health of the mice can be inferred from their body weight, which is measured weekly. From week 6 onwards, 12 mice were treated twice a week with either 10 mg/kg of DMS0169 or with weekly saline injections (control group). From week 6 till week 15, each mouse was scored weekly for both

- 113 -

clinical score and body weight (figures 25 and 26). After 15 weeks the mice were sacrificed and histological analysis was done of joint inflammation (figure 27). The effects of DMS0169 on both clinical score and histology at 15 weeks were highly significant ($p < 0.001$) while body weight for the DMS0169 treated mice was favorable compared to saline treated control animals, indicating the potential for therapeutic benefit of DMS0169 in rheumatoid arthritis.

STANDARD CELL ASSAYS

10

Standard MRC-5 IL-8 release assay

The activities of certain dAbs that bind human TNFR1 were assessed in the following MRC-5 cell assay. The assay is based on the induction of IL-8 secretion by TNF α in MRC-5 cells and is adapted from the method described in Alceson, L. *et al. Journal of Biological Chemistry* 271:30517-30523 (1996), describing the induction of IL-8 by IL-1 in HUVEC. The activity of the dAbs was assayed by assessing IL-8 induction by human TNF α using MRC-5 cells instead of the HUVEC cell line. Briefly, MRC-5 cells (ATCC number: CCL-171) were plated in microtitre plates (5×10^3 cells/well) and the plates were incubated overnight with a dose-range of dAb and a fixed amount of human TNF α (200 pg/ml). Following incubation, the culture supernatant was aspirated and IL-8 release was determined using an IL-8 ABI 8200 cellular detection assay (FMAT). The IL-8 FMAT assay used detection and capture reagents from R&D Systems. Beads, goat anti-mouse IgG (H&L) coated polystyrene particles 0.5% w/v 6-8 μ m (Spherotech Inc, Cat#MP-60-5), were coated with the capture antibody mouse monoclonal anti-human IL-8 antibody (R&D systems, Cat# MAB208). For detection, biotinylated goat anti-human IL-8 antibody (R&D systems, Cat# BAF208) and Streptavidin Alexafluor 647 (Molecular Probes, Cat#S32357) were used. Recombinant human IL-8 (R&D systems, Cat# 208-IL) was used as the standard. Anti-TNFR1 dAb activity resulted in a decrease in IL-8 secretion into the supernatant compared with control wells that were incubated with TNF α only.

Standard Cynomologus monkey CYNOM-K1 assay

5 The anti-TNFR1 dAbs were tested for potency in the CYNOM-K1 cell assay. Briefly, the dAb was incubated with CYNOM-K1 cells (ECACC 90071809) (5×10^3 cells/well) for one hour at 37°C in a flat bottom cell culture plate. Recombinant human TNF alpha (Peprotech) was added (final concentration of 200pg/ml) and the plates were incubated for 18-20 hours. The level of secreted IL-8 was then measured in the culture supernatant
10 using the DuoSet ELISA development system (R&D Systems, cat# DY208), according to the manufacturer's instructions, (document number 750364.16 version 11/08). The ND50 was determined by plotting dAb concentration against the percentage of inhibition of IL-8 secretion.

15 *Standard L929 Cytotoxicity Assay*

Anti-TNFR1 dAbs were also tested for the ability to neutralise the cytotoxic activity of TNF α on mouse L929 fibroblasts (ATCC CCL-1) (Evans, T. (2000) Molecular Biotechnology 15, 243-248). Briefly, L929 cells plated in microtitre plates (1×10^4 cells/well) were incubated overnight with anti-TNFR1 dAb, 100pg/ml TNF α and
20 1 μ g/ml actinomycin D (Sigma, Poole, UK). Cell viability was measured by reading absorbance at 490nm following an incubation with [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (Promega, Madison, USA). Anti-TNFR1 dAb activity lead to a decrease in TNF α cytotoxicity and therefore an increase in absorbance compared with the TNF α only control.

25

Standard Receptor binding assay

The potency of the dAbs was determined against human TNFR1 in a receptor binding assay. This assay measures the binding of TNF-alpha to TNFR1 and the ability of soluble dAb to block this interaction. The TNFR1-FC fusion is captured on a bead pre-
30 coated with goat anti-human IgG (H&L). The receptor coated beads are incubated with TNF- alpha (10ng/ml), dAb, biotin conjugated anti-TNF- alpha and streptavidin alexa

- 115 -

fluor 647 in a black sided clear bottomed 384 well plate. After 6 hours the plate is read on the ABI 8200 Cellular Detection system and bead associated fluorescence determined. If the dAb blocks TNF- alpha binding to TNFR1 the fluorescent intensity will be reduced.

5

Data was analysed using the ABI 8200 analysis software. Concentration effect curves and potency (EC₅₀) values were determined using GraphPad Prism and a sigmoidal dose response curve with variable slope.

10

Construction and purification of fusions with DOM7h-11-12 for in vivo efficacy studies

15 In order to perform *in vivo* efficacy studies with different anti-TNFR1 and control dAbs, genetic fusions were cloned of the different dAbs with the AlbudAb (anti-serum albumin dAb) DOM7h-11-12 using an Ala-Ser-Thr linker between the dAbs. Four constructs were made for this purpose: DMS5537 (DOM1h-574-156-AST-DOM7h-11-12), DMS5538 (VhD2-AST-DOM7h-11-12), DMS5539 (DOM1m-15-12-AST-
20 DOM7h-11-12dh) and DMS5540 (DOM1m-21-23-AST-DOM7h-11-12).

Construction of each of these four constructs was as follows:

DMS5537: The Vh dAb DOM1h-574-156 was PCR amplified using primers AS9 and ZHT304 from DMS0126. The Vk dAb DOM7h-11-12 was PCR amplified from
25 DMS0169 (no tag) in the pDOM5 vector, using primers PAS40 and AS65 to add AST linker. The reaction products were joined by SOE-PCR and reamplified using primers JAL102 and ZHT327. The reamplification reaction product is cut with Nde I/Not I and cloned into Nde I/Not I-cut pET30a (Merck). For expression the construct is transformed to the *E. coli* strain BL21(DE3) (Novagen, Cat no. 69450).

- 116 -

DMS5538: The Vh dAb VhD2, a so called 'Dummy dAb' with no specific antigen recognition, was PCR amplified using primers AS9 and ZHT304. The Vk dAb DOM7h-11-12 was PCR amplified from DMS0169 no tag using primers PAS40 and AS65. Both products are gel purified and reassembled using SOE-PCR. The SOE product is reamplified using primers JAL102 and ZHT327. The reamplification reaction product is cut with Nde I and Not I enzymes, gel purified and ligated into pET30 cut with Nde I and Not I enzymes. For expression the construct is transformed to the *E. coli* strain BL21(DE3).

10

DMS5539: the anti-mouse TNFR1 Vk dAb DOM1m-15-12 was PCR amplified from pDOM5/Vk(DOM1m-15-12) using primers AS9 and ZHT334. As both the anti-TNFR1 and anti-Albumin dAb, DOM7h-11-12, are Vks, a standard DNA dehomologisation approach of DOM7h-11-12 was performed, i.e. silent mutations, which do not affect the amino-acid sequence, were introduced at the DNA level. These mutations reduce the chance of homologous recombination and increase plasmid stability during DNA amplification and protein expression. In addition, the DOM7h-11-12 dAb also contains a mutation of Ser at position 12 to Pro to reduce binding to Protein-L of the in-line fusion and facilitate purification. The dehomologised version of the Vk DOM7h-11-12 S12P (DOM7h-11-12dh S12P) is PCR amplified from pDOM5/Vk(DOM7h-11-12dh) using primers ZHT333 and AS65. Both products are gel purified and reassembled by SOE-PCR. The SOE product is reamplified using primers ZHT332 + ZHT327. The reaction product is cut with Nde I and Not I enzymes, gel purified and ligated into pET30 cut with Nde I and Not I enzymes. For expression the construct is transformed to the *E. coli* strain BL21(DE3).

25

DMS5540: The anti-mouse TNFR1 Vh dAb DOM1m-21-23 (see WO2006038027) is PCR amplified from DMS0127 using primers AS9 and ZHT335. The Vk dAb DOM7h-11-12 is PCR amplified from DMS0169 using primers PAS40 and AS65. Both products are gel purified and reassembled by SOE-PCR. The SOE product is reamplified using

30

- 117 -

primers JAL102 and ZHT327. The reaction product is cut with Nde I and Not I enzymes, gel purified and ligated into pET30 cut with Nde I and Not I enzymes. For expression the construct is transformed to the *E. coli* strain BL21(DE3).

- 5 All four constructs were then expressed in a fermentor using the following conditions: all at 27 degrees post induction, 0.01mM IPTG except for DMS5540 which was induced with 0.025mM IPTG. All fermentations were to high cell density in minimal medium at the 5L scale.
- 10 Purification was done from the supernatant by batch binding to Protein-L followed by elution, neutralization and a second step of batch binding to Protein-A. Eluted protein was buffer-exchanged to PBS and concentrated before functional characterization. DMS5539 was purified by Protein L and then further purified by SEC with simultaneous buffer exchange into PBS. All molecules were then endotoxin depleted.

15

- 118 -

Table 11: Amino Acid Sequences

DOM1h-574 and DOM1h-574' differ by a single amino acid (R in the former is H in the latter at amino acid 98 according to Kabat numbering).

>DOM1h-509

EVQLLES GGGGLVQPGGSLRLSCAASGFTFSQYRMHWVRQAPGKSLEWVSSIDTRGSST
YYADPVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKAVTMFSPFFDYWGQGT
LVTVSS

>DOM1h-510

EVQLLES GGGGLVQPGGSLRLSCAASGFTFADYGMRWVRQAPGKGLEWVSSI TRTGRVT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKWRNRHGEYLADF DYWGQ
GTLVTVSS

>DOM1h-543

EVQLLES GGGGLVQPGGSLRLSCAASGFTFMRYRMHWVRQAPGKGLEWVSSID SNGSST
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKDRTERS P VF DYWGQGT
LVTVSS

>DOM1h-549

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVDYEMHWVRQAPGKGLEWVSSI SESGTTT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKRRFSAST F DYWGQGT
LVTVSS

>DOM1h-574 (SEQ ID NO: 11)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQI SNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTG R WEP F DYWGQGT
LVTVSS

>DOM1h-574'

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQI SNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTG H WEP F DYWGQGT
LVTVSS

>DOM1h-574-1

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQI SNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTG R WEP Y DYWGQGT
LVTVSS

- 119 -

>DOM1h-574-2

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGRWEPFDYWGQGTLVT
VSS

5

>DOM1h-574-4

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGRWEPFEYWGQGTLVT
VSS

10

>DOM1h-574-7

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

15

>DOM1h-574-8

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

20

>DOM1h-574-9

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYMQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

25

>DOM1h-574-10

EVQLLES GGGGLVQP GGS LRLSCAASGFTFGKYS MGWVRQAPGKDLEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

30

>DOM1h-574-11

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGRWEPFDHWGQGTLVT
VSS

35

>DOM1h-574-12

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGRWEPFDYWGQGTLVT
VSS

40

>DOM1h-574-13

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGRWEPFDYWGQGTLVT
VSS

45

- 120 -

>DOM1h-574-14 (SEQ ID NO: 10)

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

5

>DOM1h-574-15

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTGDHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

10

>DOM1h-574-16

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

15

>DOM1h-574-17

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGPEWVSQISNTGDHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

20

>DOM1h-574-18

EVQLLESGGGLVQPGGSLRLSCAASGFTFGKYSMGWVRQAPGKDLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

25

>DOM1h-574-19

EVQLLESGGGLVQPGGSLRLSCAASGFTFGKYSMGWVRQAPGKDLEWVSQISNTGDHT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

30

>DOM1h-574-25

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

35

>DOM1h-574-26

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFEYWGQGTLVT
VSS

40

>DOM1h-574-27

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWKPFYWGQGTLVT
VSS

45

- 121 -

>DOM1h-574-28

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

5

>DOM1h-574-29

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPFYWGQGTLVT
VSS

10

>DOM1h-574-30

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAAYYCAIYTGRWEPFDYWGQGTLVT
VSS

15

>DOM1h-574-31

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFNYWGQGTLVT
VSS

20

>DOM1h-574-32

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

25

>DOM1h-574-33

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNSLYLQMNSLRAEDTAVYYCAIYTGRWVPFDNWGQGTLVT
VSS

30

>DOM1h-574-35

EVQLLES GGGGLVQP GGS LRLSCAASGFTFITYSMGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFQYWGQGTLVT
VSS

35

>DOM1h-574-36

EVQLLES GGGGLVQP GGS LRLSCAASGFTFGKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

40

>DOM1h-574-37

EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

45

- 122 -

>DOM1h-574-38

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

5

>DOM1h-574-39

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

10

>DOM1h-574-40

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFKYWGQGTLVT
VSS

15

>DOM1h-574-53

EVQLLES GGGLVQP GGSLRLSCAASGFTFSKYS MGWVRQAPGKGLEWVSQISNTGERR
YYADSVKGRFTISRDN PKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFEYWGQGTLVT
VSS

20

>DOM1h-574-54

EVQLLES GGGLVQP GGSLRLSCAASGFTFVNYS MGWVRQAPGKGLEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPYEYWGQGTLVT
VTS

25

>DOM1h-574-65

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

30

>DOM1h-574-66

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWKPFYWGQGTLVT
VSS

35

>DOM1h-574-67

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

40

>DOM1h-574-68

EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPFYWGQGTLVT
VSS

45

- 123 -

>DOM1h-574-69

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

5

>DOM1h-574-70

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAVYTGRWEPFVYWGQGT LVT
VSS

10

>DOM1h-574-71

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWKPF EYWGQGT LVT
VSS

15

>DOM1h-574-72 (SEQ ID NO: 2)

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS

20

>DOM1h-574-73

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPF EYWGQGT LVT
VSS

25

>DOM1h-574-74

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

30

>DOM1h-574-75

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS

35

>DOM1h-574-76

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWKPF EYWGQGT LVT
VSS

40

>DOM1h-574-77

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS

45

- 124 -

>DOM1h-574-78

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPF EYWGQGT LVT
VSS

5

>DOM1h-574-79

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPF EYWGQGT LVT
VSS

10

>DOM1h-574-84

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPF VYWGQGT LVT
VSS

15

>DOM1h-574-85

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWKPF EYWGQGT LVT
VSS

20

>DOM1h-574-86

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPF EYWGQGT LVT
VSS

25

>DOM1h-574-87

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPF EYWGQGT LVT
VSS

30

>DOM1h-574-88

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPF EYWGQGT LVT
VSS

35

>DOM1h-574-90

EVQLLES GGGLVQPGGSLRLSCAASGFTFLKF SMGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPF EYWGQGT LVT
VSS

40

>DOM1h-574-91

EVQLLES GGGLVQPGGSLRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISNTADRT
YYAHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPF EYWGQGT LVT
VSS

45

- 125 -

>DOM1h-574-92

EVQLLES GGGLVQPGGSLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

5

>DOM1h-574-93 (SEQ ID NO: 12)

EVQLLES GGGLVQPGGSLRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

10

>DOM1h-574-94

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAAYYCAIYTGRWPDFDYWGQGTLVT
VSS

15

>DOM1h-574-95

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQIANTGDRR
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAAYYCAIYTGRWPDFEYWGQGTLVT
VSS

20

>DOM1h-574-96

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
YYAHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWPDFDYWGQGTLVT
VSS

25

>DOM1h-574-97

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
YYAHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWPDFEYWGQGTLVT
VSS

30

>DOM1h-574-98

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWPDFDYWGQGTLVT
VSS

35

>DOM1h-574-99

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISDTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWPDFEYWGQGTLVT
VSS

40

>DOM1h-574-100

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISAWGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

45

- 126 -

>DOM1h-574-101

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISDGGQRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

5

>DOM1h-574-102

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISDSGYRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

10

>DOM1h-574-103

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISDGGTRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

15

>DOM1h-574-104

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISDKGTRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

20

>DOM1h-574-105

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISETGRRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

25

>DOM1h-574-106

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQINNTGSTT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGTLVT
VSS

30

>DOM1h-574-107

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

35

>DOM1h-574-108

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

40

>DOM1h-574-109 (SEQ ID NO: 3)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

45

- 127 -

>DOM1h-574-110

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

5

>DOM1h-574-111

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPF EYWGQGT LVT
VSS

10

>DOM1h-574-112

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYTHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

15

>DOM1h-574-113

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRR
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

20

>DOM1h-574-114

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQILNTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

25

>DOM1h-574-115

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

30

>DOM1h-574-116

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRR
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

35

>DOM1h-574-117

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRR
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

40

>DOM1h-574-118

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAVYTGRWVSFEYWGQGT LVT
VSS

45

- 128 -

>DOM1h-574-119

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCALYTGRWVSFEYWGQGT LVT
VSS

5

>DOM1h-574-120

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAVYTGRWVPFEYWGQGT LVT
VSS

10

>DOM1h-574-121

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCALYTGRWVPFEYWGQGT LVT
VSS

15

>DOM1h-574-122

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIANTADRR
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

20

>DOM1h-574-123 (SEQ ID NO: 13)

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS

25

>DOM1h-574-124

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTGDRR
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS

30

>DOM1h-574-125 (SEQ ID NO: 14)

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIANTADRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS

35

>DOM1h-574-126 (SEQ ID NO: 15)

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIANTGDRR
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS

40

>DOM1h-574-127

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRR
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS

45

- 129 -

>DOM1h-574-128

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ IANTADRR
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

5

>DOM1h-574-129 (SEQ ID NO: 16)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ IANTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

10

>DOM1h-574-130

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ IANTGDRR
YYADAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

15

>DOM1h-574-131

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ ISDTADRT
YYDHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

20

>DOM1h-574-132 (SEQ ID NO: 7)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ ISDTADRT
YYDHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPFYWGQGTLVT
VSS

25

>DOM1h-574-133 (SEQ ID NO: 17)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ ISDTADRT
YYDHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

30

>DOM1h-574-134

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ ISDTADRT
YYSHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

35

>DOM1h-574-135 (SEQ ID NO: 8)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ ISDTADRT
YYTHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

40

>DOM1h-574-137 (SEQ ID NO: 18)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQ ISDTADRT
YYTDAV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

45

- 130 -

>DOM1h-574-138 (SEQ ID NO: 4)
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

5

>DOM1h-574-139 (SEQ ID NO: 20)
EVQLLES GGGGLVQP GGS LRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

10

>DOM1h-574-140
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQIADTGDRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

15

>DOM1h-574-141
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

20

>DOM1h-574-142
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTGDRR
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

25

>DOM1h-574-143
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTGDRR
YYDDAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

30

>DOM1h-574-144
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQIADTADRR
YYDDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

35

>DOM1h-574-145
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQIADTGDRR
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

40

>DOM1h-574-146
EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQIADTGDRR
YYDDAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGTLVT
VSS

45

- 131 -

>DOM1h-574-147

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWGPFVYWGQGTLVT
VSS

5

>DOM1h-574-148

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFAYWGQGTLVT
VSS

10

>DOM1h-574-149

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWGPFQYWGQGTLVT
VSS

15

>DOM1h-574-150

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFQYWGQGTLVT
VSS

20

>DOM1h-574-151

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

25

>DOM1h-574-152

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFQYWGQGTLVT
VSS

30

>DOM1h-574-153

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFQYWGQGTLVT
VSS

35

>DOM1h-574-154

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTGDRR
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGTLVT
VSS

40

>DOM1h-574-155 (SEQ ID NO: 21)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFLKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

45

- 132 -

>DOM1h-574-156 (SEQ ID NO: 1)
EVQLLES GGGLVQP GGSLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

5

>DOM1h-574-157
EVQLLES GGGLVQP GGSLRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISDTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPF EYWGQGTLVT
VSS

10

>DOM1h-574-158
EVQLLES GGGLVQP GGSLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWRPF EYWGQGTLVT
VSS

15

>DOM1h-574-159
EVQLLES GGGLVQP GGSLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPF VYWGQGTLVT
VSS

20

>DOM1h-574-160 (SEQ ID NO: 19)
EVQLLES GGGLVQP GGSLRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISDTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPF VYWGQGTLVT
VSS

25

>DOM1h-574-161
EVQLLES GGGLVQP GGSLRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISDTADRT
YYSHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

30

>DOM1h-574-162 (SEQ ID NO: 5)
EVQLLES GGGLVQP GGSLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
YYSHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

35

>DOM1h-574-163
EVQLLES GGGLVQP GGSLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
YYTHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

40

>DOM1h-574-164
EVQLLES GGGLVQP GGSLRLSCAASGFTFLKY SMGWVRQAPGKGLEWVSQISDTADRT
YYTHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGTLVT
VSS

45

- 133 -

>DOM1h-574-165

EVQLLESGGGLVQPGGSLRLSCAASGFTFFKYSMGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

5

>DOM1h-574-166

EVQLLESGGGLVQPGGSLRLSCAASGFTFLKYSMGWVRQAPGKGLEWVSQISDTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

10

>DOM1h-574-167

EVQLLESGGGLVQPGGSLRLSCAASGFTFLKYSMGWVRQAPGKGLEWVSQISDTGDRR
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

15

>DOM1h-574-168

EVQLLESGGGLVQPGGSLRLSCAASGFTFFKYSMGWVRQAPGKGLEWVSQISDTGDRR
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

20

>DOM1h-574-169

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIADTADRT
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS

25

>DOM1h-574-170

EVQLLESGGGLVQPGGSLRLSCAASGFTFFKYSMGWVRQAPGKGLEWVSQISDTADRT
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS

30

>DOM1h-574-171

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIADTADRT
YYDHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS

35

>DOM1h-574-172

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIADTADRT
YYDHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS

40

>DOM1h-574-173

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQIADTADRR
YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS

45

- 134 -

- >DOM1h-574-174
EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRR
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS
- 5 >DOM1h-574-175
EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIADTADRR
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS
- 10 >DOM1h-574-176
EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRR
YYDHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS
- 15 >DOM1h-574-177
EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIADTADRR
YYDHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS
- 20 >DOM1h-574-178
EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQIADTADRR
YYDHSV KGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT LVT
VSS
- 25 >DOM1h-574-179
EVQLLES GGGLVQP GGSLRLSCAASGFTFFKYS MGWVRQAPGKGLEWVSQISDTADRR
YYDDAVKGRFTITRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFVYWGQGT LVT
VSS
- 30 >DOM1h-574-180 (SEQ ID NO: 6)
EVQLLES GGGLVQP GGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISDTADRT
YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
VSS
- 35 DOM1m-15-12 (SEQ ID NO: 36)
DIQMTQSPSSLSASVGDRVTITCRASQYIHTSVQWYQQKPGKAPKLLIYGSSRLHSGV
PSRFGSGSGTDFTLTIS SLQPEDFATYYCQQNHYS PFTYGGGTKVEIKR
- 40 DOM1m-21-23 (SEQ ID NO: 37)
EVQLLES GGGLVQP GGSLRLSCAASGFTFNRYSMGWLRQAPGKGLEWVSRIDS YGRGT
YYEDPVKGRFSISRDN SKNTLYLQMNSLRAEDTAVYYCAKISQFGSNAFDYWGQGTQV
TVSS
- 45 >DMS0111 (SEQ ID NO: 45)

- 135 -

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLILWNS
 RLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

5

>DMS0112 (SEQ ID NO: 46)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLILFGS
 RLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

10

>DMS0113 (SEQ ID NO: 47)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASQWIGS QL SWYQQKPGKAPKLLIMWRS
 SLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQGLRHPKTFGQGTKVEIKR

15

>DMS0114 (SEQ ID NO: 48)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASQWIGS QL SWYQQKPGKAPKLLIMWRS
 SLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQGLMKPMTFGQGTKVEIKR

20

>DMS0115 (SEQ ID NO: 49)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLI
 LWN SRLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 KR

25

>DMS0116 (SEQ ID NO: 50)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLI
 LFGS RLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 KR

30

>DMS0117 (SEQ ID NO: 51)

EVQLLES GGGGLVQPGGSLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASQWIGS QL SWYQQKPGKAPKLLI
 MWR SSLQSGVPSRFRSGSGSGTDFTLTIS SLQPEDFATYYCAQGLRHPKTFGQGTKVEI
 KR

35

>DMS0118 (SEQ ID NO: 52)

40

45

- 136 -

EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASQWIGSQLSWYQQKPGKAPKLLI
 MWRSSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQGLMKPMTFGQGTKVEI
 5 KR

>DMS0121 (SEQ ID NO: 53)
 EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT
 10 VSSASGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASRPIGTTLSWYQQ
 KPGKAPKLLILWNSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPT
 TFGQGTKVEIKR

>DMS0122 (SEQ ID NO: 54)
 15 EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT
 VSSASGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASRPIGTMLS
 WYQQKPGKAPKLLILFGSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPT
 TFGQGTKVEIKR

20 >DMS0123 (SEQ ID NO: 55)
 EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT
 VSSASGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQWIGSQLSWYQQ
 25 KPGKAPKLLIMWRSSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQGLRHPK
 TFGQGTKVEIKR

>DMS0124 (SEQ ID NO: 56)
 EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISNTADRT
 30 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT
 VSSASGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQWIGSQLSWYQQ
 KPGKAPKLLIMWRSSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQGLMKPM
 TFGQGTKVEIKR

35 >DMS0132 (SEQ ID NO: 57)
 EVQLLESGGGLVQPGGSLRLSCAASGFTFVKYSMGWVRQAPGKGLEWVSQISDTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRPIGTTLSWYQQKPGKAPKLLILWNS
 RLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR
 40

>DMS0133 (SEQ ID NO: 58)
 EVQLLESGGGLVQPGGSLRLSCAASGFTFFKYSMGWVRQAPGKGLEWVSQISDTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWAPFEYWGQGT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRPIGTTLSWYQQKPGKAPKLLILWNS
 45 RLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

- 137 -

>DMS0134 (SEQ ID NO: 59)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 5 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLILWNS
 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

>DMS0135 (SEQ ID NO: 60)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFFKY SMGWVRQAPGKGLEWVSQISDTADRT
 10 YYSHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLILWNS
 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

>DMS0136 (SEQ ID NO: 61)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISDTADRT
 15 YYAHAVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLILWNS
 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

20 >DMS0162 (SEQ ID NO: 62)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 VSC-40K linear PEG

25 >DMS0163 (SEQ ID NO: 63)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLI
 LAFSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 30 KRAAAEQKLISEEDLN

>DMS0163-no tag (SEQ ID NO: 64)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 35 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLI
 LAFSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 KR

>DMS0168 (SEQ ID NO: 65)

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFVKY SMGWVRQAPGKGLEWVSQISNTADRT
 40 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASQSI I KHLKWYQQKPGKAPKLLI
 YGASRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCQQGARWPQTFGQGTKVEI
 KRAAAEQKLISEEDLN

45

- 138 -

>DMS0168-no tag (SEQ ID NO: 66)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASQSI IKHLK WYQQKPGKAPKLLI
 5 YGASRLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQGARWPQTFGQG TKVEI
 KR

>DMS0169 (SEQ ID NO: 67)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 10 YYAHSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLI
 LF GSRLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQG TKVEI
 KRAAAEQKLISEEDLN

15 >DMS0169-no tag (SEQ ID NO: 68)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLI
 20 LF GSRLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQG TKVEI
 KR

>DMS0176 (SEQ ID NO: 69)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
 YYADSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 25 VSSDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLIWF GSRLQ
 SGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQG TKVEIKR

>DMS0177 (SEQ ID NO: 70)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
 30 YYADSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 VSSDIQMTQSPSSLSASVGDRVTITCRASQWIGS QLSWYQQKPGKAPKLLIMWRSSLQ
 SGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCAQGAALPRTFGQG TKVEIKR

>DMS0182 (SEQ ID NO: 71)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
 35 YYADSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLIWF GS
 RLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQG TKVEIKRAA
 40 AEQKLISEEDLN

>DMS0182-no tag (SEQ ID NO: 72)

EVQLLES GGGLVQPGGSLRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
 YYADSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLIWF GS
 45 RLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCAQAGTHPTTFGQG TKVEIKR

- 139 -

>DMS0184 (SEQ ID NO: 73)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
5 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLI
WFGSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQG TKVEI
KR

>DMS0186 (SEQ ID NO: 74)

10 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLILFGS
RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQG TKVEIKRAA
AEQKLISEEDLN

15

>DMS0186-no tag (SEQ ID NO: 75)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLILFGS
20 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQG TKVEIKR

>DMS0188 (SEQ ID NO: 76)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
25 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLI
LFGSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQG TKVEI
KRAAAEQKLISEEDLN

>DMS0188-no tag (SEQ ID NO: 77)

30 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTML SWYQQKPGKAPKLLI
LFGSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQG TKVEI
KR

35

>DMS0189 (SEQ ID NO: 78)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTTL SWYQQKPGKAPKLLILWNS
40 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQG TKVEIKRAA
AEQKLISEEDLN

>DMS0189-no tag (SEQ ID NO: 79)

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKY SMGWVRQAPGKGPEWVSQISNTGDRT
45 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT

- 140 -

VSSASTDIQMTQSPSSLSASVGDRVTITCRASRPIGTTLWSYQQKPGKAPKLLILWNS
RLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

>DMS0190 (SEQ ID NO: 80)

5 EVQLLES GGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRPIGTTLWSYQQKPGKAPKLLI
LWNSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPTTFGQGTKVEI
KRAAAEQKLISEEDLN

10

>DMS0190-no tag (SEQ ID NO: 81)

EVQLLES GGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRPIGTTLWSYQQKPGKAPKLLI
15 LWNSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPTTFGQGTKVEI
KR

>DMS0191 (SEQ ID NO: 82)

EVQLLES GGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
20 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTDIQMTQSPSSLSASVGDRVTITCRASQSI IKHLKWKYQQKPGKAPKLLIYGAS
RLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGTRWPQTTFGQGTKVEIKRAA
AEQKLISEEDLN

25 >DMS0191-no tag (SEQ ID NO: 83)

EVQLLES GGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTDIQMTQSPSSLSASVGDRVTITCRASQSI IKHLKWKYQQKPGKAPKLLIYGAS
RLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGTRWPQTTFGQGTKVEIKR

30

>DMS0192 (SEQ ID NO: 84)

EVQLLES GGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASQSI IKHLKWKYQQKPGKAPKLLI
35 YGASRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGARWPQTTFGQGTKVEI
KRAAAEQKLISEEDLN

>DMS0192-no tag (SEQ ID NO: 85)

EVQLLES GGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGPEWVSQISNTGDRT
40 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWEPFDYWGQGT LVT
VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASQSI IKHLKWKYQQKPGKAPKLLI
YGASRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGARWPQTTFGQGTKVEI
KR

45 >DMS5519 (SEQ ID NO: 86)

- 141 -

EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLI
 LAFSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 5 KR

>DMS5520 (SEQ ID NO: 87)
 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGHWEPFDYWGQGT LVT
 10 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLI
 LWNSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 KR

>DMS5521 (SEQ ID NO: 88)
 15 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLILAFS
 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

20 >DMS5522 (SEQ ID NO: 89)
 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLILAFS
 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKRAA
 25 AEQKLISEEDLN

>DMS5522-no tag (SEQ ID NO: 90)
 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 30 VSSASTDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLILAFS
 RLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

>DMS5525 (SEQ ID NO: 91)
 EVQLLES GGGGLVQP GGS LRLSCAASGFTFVKYS MGWVRQAPGKGLEWVSQISNTGGHT
 35 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKYTGHWEPFDYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLI
 LAFSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 KR

40 >DMS5527 (SEQ ID NO: 92)
 EVQLLES GGGGLVQP GGS LRLSCAASGFTFFKYS MGWVRQAPGKGLEWVSQISDTADRT
 YYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPFEYWGQGT LVT
 VSSASTSGPSDIQMTQSPSSLSASVGDRVTITCRASRP IGTMLSWYQQKPGKAPKLLI
 LFGSRLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCAQAGTHPTTFGQGTKVEI
 45 KR

- 142 -

>DOM7h-11 (SEQ ID NO: 28)

DIQMTQSPSSLSASVGDRVITICRASRPIGTTLSWYQQKPGKAPKLLIWFGSRLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

5

>DOM7h-11-3 (SEQ ID NO: 29)

DIQMTQSPSSLSASVGDRVITICRASRPIGTTLSWYQQKPGKAPKLLILWNSRLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

10 >DOM7h-11-12 (SEQ ID NO: 30)

DIQMTQSPSSLSASVGDRVITICRASRPIGTMLS WYQQKPGKAPKLLILFGSRLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

>DOM7h-11-15 (SEQ ID NO: 31)

15 DIQMTQSPSSLSASVGDRVITICRASRPIGTMLS WYQQKPGKAPKLLILAFSRLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQAGTHPTTFGQGTKVEIKR

>DOM7h-14 (SEQ ID NO: 32)

20 DIQMTQSPSSLSASVGDRVITICRASQWIGSQLSWYQQKPGKAPKLLIMWRSSLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGAALPRTFGQGTKVEIKR

>DOM7h-14-10 (SEQ ID NO: 33)

25 DIQMTQSPSSLSASVGDRVITICRASQWIGSQLSWYQQKPGKAPKLLIMWRSSLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGLRHPKTFGQGTKVEIKR

>DOM7h-14-18 (SEQ ID NO: 34)

DIQMTQSPSSLSASVGDRVITICRASQWIGSQLSWYQQKPGKAPKLLIMWRSSLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGLMKPMTFGQGTKVEIKR

30 >DOM7m-16 (SEQ ID NO: 35)

DIQMTQSPSSLSASVGDRVITICRASQSIIKHLK WYQQKPGKAPKLLIYGASRLQSGV
PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGARWPQTFGQGTKVEIKR

DMS0127:

35 EVQLLES GGGLVQPGGSLRLSCAASGFTFNRYSMGWLRQAPGKGLEWVSRIDS
YGRGTYIEDPVKGRFSISRDN SKNTLYLQMNSLRAEDTAVYYCAKISQFGSNA
FDYWGQGTQVTVSSASTSGPSDIQMTQSPSSLSASVGDRVITICRASRPIGTMLS
WYQQKPGKAPKLLILFGSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCA
QAGTHPTTFGQGTKVEIKR

40

DMS5537 (SEQ ID NO: 39)

EVQLLES GGGLVQPGGSLRLSCAASGFTFFKYSMGWVRQAPGKGLEWVSQISD
TADRTYYAHSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAIYTGRWVPF
EYWGQGT LVT VSSASTDIQMTQSPSSLSASVGDRVITICRASRPIGTMLS WYQQ

- 143 -

KPGKAPKLLILFGSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGT
HPTTFGQGTKVEIKR

DMS5539 (SEQ ID NO: 41)

5 DIQMTQSPSSLSASVGDRVTITCRASQYIHTSVQWYQQKPGKAPKLLIYGSSRL
HSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQNHYSPTFYGQGKVEIKRA
STDIQMTQSPSSLPASVGDRVTITCRASRPITMLSWYQQKPGKAPKLLILFSR
LQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAGTHPTTFGQGKVEIKR

10 DMS5538 (SEQ ID NO: 40)

EVQLLES GGGLVQPGGSLRLSCAASGVNVSHDSMTWVRQAPGKGLEWVSAIR
GPNGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCASGARHAD
TERPPSQQTMPFWGQGT LVTVSSASTDIQMTQSPSSLSASVGDRVTITCRASRP
ITMLSWYQQKPGKAPKLLILFGSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFA
15 TYYCAQAGTHPTTFGQGKVEIKR

DMS5540 (SEQ ID NO: 42)

EVQLLES GGGLVQPGGSLRLSCAASGFTFNRYSMGWLRQAPGKGLEWVSRIDS
YGRGTYIEDPVKGRFSISRDN SKNTLYLQMNSLRAEDTAVYYCAKISQFGSNA
20 FDYWGQGTQVTVSSASTDIQMTQSPSSLSASVGDRVTITCRASRPITMLSWYQ
QKPGKAPKLLILFGSRLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCAQAG
THPTTFGQGKVEIKR

Table 12: Nucleotide Sequences

	>DOM1h-509
	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
	TCTCCTGTGCAGCCTCCGGATTACCTTTAGTCAGTATAGGATGCATTGGGTCCGCCA
5	GGCTCCAGGGAAGAGTCTAGAGTGGGTCTCAAGTATTGATACTAGGGGTTCGTCTACA
	TACTACGCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
	CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
	GAAAGCTGTGACGATGTTTTCTCCTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTC
10	ACCGTCTCGAGC
	>DOM1h-510
	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
	TCTCCTGTGCAGCCTCCGGATTACCTTTGCTGATTATGGGATGCGTTGGGTCCGCCA
	GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGCGGACTGGTCGTGTTACA
15	TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
	CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
	GAAATGGCGGAATCGGCATGGTGAGTATCTTGCTGATTTTGACTACTGGGGTCAGGGA
	ACCCTGGTCACCGTCTCGAGC
20	>DOM1h-543
	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
	TCTCCTGTGCAGCCTCCGGATTACCTTTATGAGGTATAGGATGCATTGGGTCCGCCA
	GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATTCTAATGGTTCTAGTACA
	TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
25	CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
	GAAAGATCGTACGGAGCGTTCGCCGGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTC
	ACCGTCTCGAGC
	>DOM1h-549
30	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCCCTGCGTC
	TCTCCTGTGCAGCCTCCGGATTACCTTTGTTGATTATGAGATGCATTGGGTCCGCCA
	GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAGTGAGAGTGGTACGACGACA
	TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
	CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
35	GAAACGTCGTTTTTTCTGCTTCTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
	GTCTCGAGC
	>DOM1h-574
	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
40	TCTCCTGTGCAGCCTCCGGATTACCTTTGTTAAGTATTCGATGGGGTGGGTCCGCCA
	GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCTGAATACGGGTGGTCATACA
	TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
	CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 145 -

GAAATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574'

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GAAATATACGGGTCATTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-1

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GAAATATACGGGTCGTTGGGAGCCTTATGACTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-2

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GAAATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-4

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
35 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GAAATATACGGGTCGTTGGGAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-7

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 146 -

GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-8

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGC

>DOM1h-574-9

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATATCCCGCGACAATTCCAAGAACA
CGCTGTATATGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-10

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGATCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-11

GAGGTGCAGCTGTTGGAGTCAGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
35 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GAAATATACGGGTCGTTGGGAGCCTTTTGACCACTGGGGTCAGGGGACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-12

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCATA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 147 -

GAAATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-13

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GAAATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-14

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-15

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCATAACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-16

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
35 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGC

40 >DOM1h-574-17

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCATAACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 148 -

GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGC

>DOM1h-574-18

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGGTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGATCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-19

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGGTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGATCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCATAACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
20 GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-25

25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
30 GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-26

35 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
40 GATATATACGGGTCGTTGGGAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-27

45 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCGGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC

- 149 -

GATATATACGGGTCGTTGGAAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-28

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
10 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-29

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-30

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGCATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGC

>DOM1h-574-31

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTAACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-32

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 150 -

GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-33

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACT
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGTGCCTTTTGACAACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-35

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTATTACGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTCAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-36

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGGTAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCGGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-37

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
35 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAAGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-38

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 151 -

GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-39

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-40

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTAAAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-53

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTAGTAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGAGCGTAGA
TACTACGCAGACTCAGTGAAGGGCCGGTTACCATCTCCCGCGACAATCCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGAGCCTTTTGAATACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-54

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAACTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
35 TACTACGCGGACTCCGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTATGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCACGAGC

40

>DOM1h-574-65

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTACCATCTCCCGCGATAATTCCAAGAACA
45 CACTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 152 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-66

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGAAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-67

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-68

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-69

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
35 TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-70

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 153 -

GGTATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-71

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGAAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-72 (SEQ ID NO: 23)

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-73

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-74

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-75

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 154 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-76

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCCCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGAAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-77

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-78

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-79

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACGGGTGATCGTAGA
35 TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-84

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCAATACGGGTGATCGTAGA
TACTACGACAGCGCGGTGAAGGGGCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 155 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-85

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGAAGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-86

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCCCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAAGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-87

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-88

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTAGA
35 TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-90

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTTTTTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 156 -

GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-91

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-92

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-93

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGC

>DOM1h-574-94

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
35 TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGCATATTACTGTGC
GATATATACGGGTCGGTGGCCCGACTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-95

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGCATATTACTGTGC

- 157 -

GATATATACGGGTCGGTGGCCCGACTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-96

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGGTGGCCCGACTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-97

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
20 GATATATACGGGTCGGTGGCCCGACTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-98

25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
30 GATATATACGGGTCGGTGGCCCGACTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-99

35 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGATACGGGTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
40 GATATATACGGGTCGGTGGCCCGACTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-100

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAGGTCCAGAGTGGGTCTCACAGATTTTGGCCTGGGGTGACAGGACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 158 -

GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC
>DOM1h-574-101
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
5 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTCGGACGGCGGTTCAGAGGACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
10 GTCTCGAGC

>DOM1h-574-102
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
15 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTCGGACTCCGGTTACCGCACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-103
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTCGGACGGGGGTACGCGGACA
25 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30 >DOM1h-574-104
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTCGGACAAGGGTACGCGCACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
35 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-105
40 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTCGGAGACCGGTTCGAGGACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 159 -

GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-106

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTAACAATACGGGTTCGACCACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-107

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCCAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
20 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-108

25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCCAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
30 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-109 (SEQ ID NO: 24)

35 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
40 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-110

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 160 -

GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-111

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-112

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACACACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-113

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGCAGA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-114

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
35 TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-115

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 161 -

GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-116

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTAGA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-117

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTAGA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
20 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-118

25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GGTATATACTGGGCGTTGGGTGTCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGC

>DOM1h-574-119

35 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GCTATATACTGGGCGTTGGGTGTCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-120

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTTACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 162 -

GGTATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-121

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GCTATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-122

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACTGCTGATCGTAGA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-123

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGC

>DOM1h-574-124

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCGGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGCGATCGTAGA
35 TACTACGCACACGCGGTGAAGGGGCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-125

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACTGCTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 163 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-126

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCACACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-127

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTGGAATACTGCTGATCGTAGA
TACTACGCACACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-128

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGCTGATCGTAGA
TACTACGCACACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-129

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGTGAATACGGGTGATCGTAGA
35 TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-130

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGAATACGGGTGATCGTAGA
TACTACGCAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 164 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-131

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-132

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-133

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-134

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
35 TACTACTCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-135

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACACACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC

- 165 -

GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-137

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACACAGACGCGGTGAAGGGGCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-138 (SEQ ID NO: 25)

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-139

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-140

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACGGGTGATCGTAGA
35 TACTACGATGACTCTGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-141

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 166 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-142

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACGGGTGATCGTAGA
TACTACGATCACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGAACCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-143

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACGGGTGATCGTAGA
TACTACGATGACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-144

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTAGA
TACTACGATGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-145

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACGGGTGATCGTAGA
35 TACTACGATCACTCTGTGAAGGGCCGGTTCATCTCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-146

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACGGGTGATCGTAGA
TACTACGATGACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 167 -

GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-147

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGGGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-148

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGTGCCTTTTGCCTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-149

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGGACCTTTTCAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-150

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTCAGTACTGGGGTCAGGGAACCTCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-151

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 168 -

GATATATACGGGTCGTTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-152

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGGCGCCTTTTCAGTACTGGGGTCAGGGAACCTCTGGTCACC
GTCTCGAGC

>DOM1h-574-153

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGTGCCTTTTCAGTACTGGGGTCAGGGCACCCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-154

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACCGGTGATCGTAGA
TACTACGATCACTCTGTGAAGGGCCGGTTCACTATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGC

>DOM1h-574-155

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-156 (SEQ ID NO: 22)

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC

- 169 -

GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-157

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-158

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGAGGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-159

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-160

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
35 TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-161

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACTCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC

- 170 -

GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-162 (SEQ ID NO: 26)

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACTCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
10 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-163

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACACACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-164

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACACACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-165

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-166

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 171 -

GATATATACGGGTCGTTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-167

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTGAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACCGGTGATCGTAGA
TACTACGATCACTCTGTGAAGGGCCGGTTCCTATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-168

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACCGGTGATCGTAGA
TACTACGATCACTCTGTGAAGGGCCGGTTCCTATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-169

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGCGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-170

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCCGATACTGCTGATCGTACA
35 TACTACGCACACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40

>DOM1h-574-171

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTACA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC

- 172 -

GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-172

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTACA
TACTACGATCACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
10 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-173

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTAGA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-174

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTAGA
TACTACGCACACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGC

>DOM1h-574-175

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTAGA
35 TACTACGCACACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 >DOM1h-574-176

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTAGA
TACTACGATCACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
45 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC

- 173 -

GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-177

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTAGA
TACTACGATCACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
10 GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGGACCCTGGTCACC
GTCTCGAGC

>DOM1h-574-178

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGCGGATACTGCTGATCGTAGA
TACTACGATCACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGC

>DOM1h-574-179

GAGGTGCAGCTGCTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
25 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTAGA
TACTACGATGACGCGGTGAAGGGCCGGTTCACCATCACCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

30

>DOM1h-574-180 (SEQ ID NO: 27)

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
35 TACTACGCACACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC

40 DOM1m-15-12

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCAGTATATTCATACGAGTGTACAGTGGTACCAGCAGAA
ACCAGGGAAAGCCCCTAAACTCCTGATCTATGGGTTCGTCCAGGTTGCATAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC

- 174 -

TGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAATCATTATAGTCCTTTTAC
GTACGGCCAAGGGACCAAGGTGGAAATCAAACGG

DOM1m-21-23

5 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTAATAGGTATAGTATGGGGTGGCTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTGATTCTTATGGTTCGTGGTACA
TACTACGAAGACCCCGTGAAGGGCCGGTTCAGCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCCGTATATTACTGTGC
10 GAAAATTTCTCAGTTTGGGTCAAATGCGTTTGACTACTGGGGTCAGGGAACCCAGGTC
ACCGTCTCGAGC

>DMS0111

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
15 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
20 GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGGAATTCC
CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
25 TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0112

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
30 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
35 CTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTGTGTTGGTTCC
CGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

40

>DMS0113

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
45 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA

- 175 -

CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTT
5 ATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCC
TCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGG
TTTGAGGCATCCTAAGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

10 >DMS0114
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
15 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTT
ATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCC
20 TCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGG
TCTTATGAAGCCTATGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0115
25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
30 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCGTCCGAT
TGGGACGACGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
CTTTGGAATTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
35 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

>DMS0116
40 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
45 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC

- 176 -

GTCTCGAGCGCTAGCACCAAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTCCGAT
TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
5 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

>DMS0117

10 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
15 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGAT
TGGGTCTCAGTTATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
ATGTGGCGTTCCTCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
20 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCTCAGGGTTTGAGGCATCCTAAGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

>DMS0118

25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
30 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGAT
TGGGTCTCAGTTATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
ATGTGGCGTTCCTCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
35 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCTCAGGGTCTTATGAAGCCTATGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

>DMS0121

40 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
45 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC

- 177 -

GTCTCGAGCGCTAGCGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGAT
CCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGT
CACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTAAAGTTGGTACCAGCAG
AAACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCCCGTTTGCAAAGTGGGG
5 TCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAG
TCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACG
ACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0122

10 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
15 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGAT
CCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGT
CACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTAAAGTTGGTACCAGCAG
AAACCAGGGAAAGCCCCCTAAGCTCCTGATCTTGTTTGGTTCCCGGTTGCAAAGTGGGG
20 TCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAG
TCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACG
ACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0123

25 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
30 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGAT
CCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGT
CACCATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTTATCTTGGTACCAGCAG
AAACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCTCGTTGCAAAGTGGGG
35 TCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAG
TCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTTTGAGGCATCCTAAG
ACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0124

40 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
45 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC

- 178 -

GTCTCGAGCGCTAGCGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGAT
CCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGT
CACCATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTTATCTTGGTACCAGCAG
AAACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCCTCGTTGCAAAGTGGGG
5 TCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAG
TCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTCTTATGAAGCCTATG
ACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0132

10 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
15 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCC
CGTTTGCAAAGTGGGGTCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
20 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0133

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
25 TCTCCTGTGCAGCCTCCGGATTACCTTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGGTGGGCGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
30 GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCC
CGTTTGCAAAGTGGGGTCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
35 TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0134

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
40 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
45 CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT

- 179 -

AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCC
CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

5

>DMS0135

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
10 TACTACTCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
15 AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCC
CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

20

>DMS0136

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
TACTACGCACACGCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
25 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCC
30 CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

35

>DMS0162

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
40 GGCTCCAGGGAAGGTCCAGAGTGGGTCTCACAGATTTTCGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGTGT

45

- 180 -

>DMS0163

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
5 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGAAGTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGAT
10 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
CTTGCTTTTTTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGCGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGGGCGGCCGCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

15

>DMS0163-no tag

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
20 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGAAGTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGAT
25 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
CTTGCTTTTTTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGCGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

30

>DMS0168

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCAGAGCAT
40 TATTAAGCATTTAAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
TATGGTGCATCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGGGCGGCCGCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

45

- 181 -

>DMS0168-no tag

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
5 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGCAT
10 TATTAAGCATTTAAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
TATGGTGCATCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

15

>DMS0169

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
20 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTCCGAT
25 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGGGCGGCCGCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

30

>DMS0169-no tag

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
35 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTCCGAT
40 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCCTAAGCTCCTGATC
TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

45

- 182 -

>DMS0176

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
5 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAG
ACCGTGTCAACCATCACTTGCCGGGGCAAGTCGTCCGATTGGGACGACGTTAAGTTGGTA
10 CCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTGGTTTGGTTCCCGGTTGCAA
AGTGGGGTCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCA
TCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCA
TCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

15 >DMS0177

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
20 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAG
ACCGTGTCAACCATCACTTGCCGGGGCAAGTCAGTGGATTGGGTCTCAGTTATCTTGGTA
CCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCATGTGGCGTTCCTCGTTGCAA
25 AGTGGGGTCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCA
TCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTGC GGCGTT
GCCTAGGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0182

30 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
35 GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTGGTTTGGTTCC
CGGTTGCAAAGTGGGGTCCCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
40 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCC
GCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

>DMS0182-no tag

- 183 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 GATATATACGGGTTCGTTGGGAGCCTTTTGA TACTACTGGGGTCAGGGAACCCTGGTCACA
 GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
 CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
 AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTGGTTTGGTTCC
 10 CGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
 TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0184

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 20 GATATATACGGGTTCGTTGGGAGCCTTTTGA TACTACTGGGGTCAGGGAACCCTGGTCACA
 GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
 CCCTGTCTGCATCTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGAT
 TGGGACGACGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
 TGGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
 25 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
 CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
 AAACGG

>DMS0186

30 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 35 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 GATATATACGGGTTCGTTGGGAGCCTTTTGA TACTACTGGGGTCAGGGAACCCTGGTCACA
 GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
 CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTT
 AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTTGTTTGGTTCC
 40 CGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
 TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCC
 GCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

45 >DMS0186-no tag

- 184 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
 GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
 CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTT
 AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTTGTTTGGTTCC
 10 CGGTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
 TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0188

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 20 GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
 GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
 CCCTGTCTGCATCTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGAT
 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
 TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
 25 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
 CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
 AAACGGGCGGCCGCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

>DMS0188-no tag

30 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
 GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 35 GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
 GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
 CCCTGTCTGCATCTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGAT
 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
 TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
 40 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
 CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
 AAACGG

>DMS0189

- 185 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGGAATTCC
10 CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCC
GCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

15 >DMS0189-no tag
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
20 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGGAATTCC
25 CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0190
30 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
35 GATATATACGGGTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTCAACATCACTTGCCGGGCAAGTCGTCCGAT
TGGGACGACGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
CTTTGGAATTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
40 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGGGCGGCCGCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

>DMS0190-no tag

- 186 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTACTACTGGGGTCAGGGAACCCTGGTCACA
GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGAT
TGGGACGACGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
10 CTTTGGAATTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

15 >DMS0191
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
20 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTT
AAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCC
25 CGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGG
GACTCGGTGGCCTCAGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCC
GCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

30 >DMS0191-no tag
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTCTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
35 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTCGTTGGGAGCCTTTTACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTT
AAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCC
40 CGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGG
GACTCGGTGGCCTCAGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS0192

- 187 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGTGACCGTGTACCATCACTTGCCGGGCAAGTCAGAGCAT
TATTAAGCATTTAAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
10 TATGGTGCATCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGGGCGGCCGCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

15 >DMS0192-no tag
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGATGGGTCCGCCA
GGCTCCAGGGAAAGGTCCAGAGTGGGTCTCACAGATTTTGAATACGGGTGATCGTACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
20 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GATATATACGGGTTCGTTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGTGACCGTGTACCATCACTTGCCGGGCAAGTCAGAGCAT
TATTAAGCATTTAAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
25 TATGGTGCATCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTCAACAGGGGGCTCGGTGGCCTCAGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

30 >DMS5519
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAAGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
35 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGAT
TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
40 CTTGCTTTTTTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGCGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

45 >DMS5520

- 188 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACGGGTGGTCATACA
TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
GAAATATACGGGTCATTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
CCCTGTCTGCATCTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGAT
TGGGACGACGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
10 CTTTGGAATTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
AAACGG

15 >DMS5521
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
20 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTGCTTTTTCC
25 CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGCGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS5522
30 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
35 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACCGTGTACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTT
AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTGCTTTTTCC
CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
40 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGCGCGCAGGC
TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCC
GCAGAACAAAACTCATCTCAGAAGAGGATCTGAAT

>DMS5522-no tag

- 189 -

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 5 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
 GTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
 CTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTT
 AAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTGCTTTTTCC
 10 CGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCA
 CTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGCGCGCAGGC
 TGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DMS5525

15 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTGTAAAGTATTCGATGGGGTGGGTCCGCCA
 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTGAATACTGCTGATCGTACA
 TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 CGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGC
 20 GAAATATACGGGTCATTGGGAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
 GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
 CCCTGTCTGCATCTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGAT
 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
 CTTGCTTTTTTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
 25 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
 CTGCGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
 AAACGG

>DMS5527

30 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTC
 TCTCCTGTGCAGCCTCCGGATTACCTTTTTTCAAGTATTCGATGGGGTGGGTCCGCCA
 GGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTTCGGATACTGCTGATCGTACA
 TACTACGCACACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACA
 CGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGC
 35 GATATATACTGGGCGTTGGGTGCCTTTTGAGTACTGGGGTCAGGGAACCCTGGTCACC
 GTCTCGAGCGCTAGCACCGAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCT
 CCCTGTCTGCATCTGTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGAT
 TGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
 TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTG
 40 GGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTA
 CTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATC
 AAACGG

>DOM7h-11

- 190 -

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTTAAGTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCTGGTTTGGTTCCCGGTTGCAAAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
5 TGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACGAC
GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DOM7h-11-3

10 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGACGTTAAGTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTTGGAATTCCTCGTTTGCAAAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
TGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACGAC
15 GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DOM7h-11-12

20 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTTAAGTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCTTGTTTGGTTCCCGGTTGCAAAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
TGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACGAC
GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DOM7h-11-15

25 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGTTAAGTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCCTTGCTTTTTCCCGTTTGCAAAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
TGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACGAC
30 GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DOM7h-14

35 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTTATCTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCCTCGTTGCAAAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
TGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTGCGGCGTTGCCTAGGAC
GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

40 >DOM7h-14-10

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTTATCTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCCTCGTTGCAAAGTGGGGTC
CCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC

- 191 -

TGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTTTGAGGCATCCTAAGAC
GTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

5 >DOM7h-14-18

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCAGTGGATTGGGTCTCAGTTATCTTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCATGTGGCGTTCCTCGTTGCAAAGTGGGGTC
CCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
10 TGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTCTTATGAAGCCTATGAC
GTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

>DOM7m-16

15 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCA
CCATCACTTGCCGGGCAAGTCAGAGCATTATTAAGCATTTAAAGTGGTACCAGCAGAA
ACCAGGGAAAGCCCCCTAAGCTCCTGATCTATGGTGCATCCCGGTTGCAAAGTGGGGTC
CCATCACGTTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTC
TGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGGGGGCTCGGTGGCCTCAGAC
20 GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

VhD2:

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGGTCC
CTGCGTCTCTCCTGTGCAGCCTCCGGAGTTAACGTTAGCCATGACTCTATGA
25 CCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCAGCCATTC
GGGGGCCTAACGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCA
CCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCT
GCGTGCCGAGGACACCGCGGTATATTATTGCGCGAGTGGGGCTAGGCATGC
GGATACGGAGCGGCCTCCGTGCGCAGCAGACCATGCCGTTTTTGGGGTCAGGG
30 AACCCTGGTCACCGTCTCGAGC

DOM1m-21-23:

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGGTCC
CTGCGTCTCTCCTGTGCAGCCTCCGGATTACCTTTAATAGGTATAGTATGG
35 GGTGGCTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTG
ATTCTTATGGTCGTGGTACATACTACGAAGACCCCGTGAAGGGCCGGTTCA
GCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCC
TGCGTGCCGAGGACACCGCCGTATATTACTGTGCGAAAATTTCTCAGTTTGG
GTCAAATGCGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAG
40 C

DOM1m-15-12:

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACC
GTGTCACCATCACTTGCCGGGCAAGTCAGTATATTCATACGAGTGTACAGTG
45 GTACCAGCAGAAACCAGGGAAAGCCCCCTAAACTCCTGATCTATGGGTCGTC

- 192 -

CAGGTTGCATAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGAC
AGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTAC
TACTGTCAACAGAATCATTATAGTCCTTTTACGTACGGCCAAGGGACCAAG
GTGGAAATCAAACGG

5

DOM7h-11-12dh S12P:

GATATCCAGATGACGCAGTCTCCGAGCTCTCTGCCAGCGAGCGTTGGCGAC
CGTGTGACCATCACTTGCCGCGCTTCTCGTCCGATCGGTACCATGCTGTCTT
GGTACCAGCAGAAACCAGGCCAAAGCCCCGAAACTCCTGATCCTGTTTCGGTT
10 CTCGCCTGCAGTCTGGTGTACCGAGCCGTTTCAGCGGTTCTGGTAGCGGCAC
CGACTTTACCCTCACGATCTCTAGCCTGCAGCCAGAGGATTTTCGCGACCTAT
TACTGTGCTCAGGCGGGGTACCCACCCGACTACCTTCGGCCAGGGTACGAAG
GTGGAAATCAAACGG

15 DMS0127:

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGGTCC
CTGCGTCTCTCCTGTGCAGCCTCCGGATTACCTTTAATAGGTATAGTATGG
GGTGGCTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTG
ATTCTTATGGTCGTGGTACATACTACGAAGACCCCGTGAAGGGCCGGTTCA
20 GCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCC
TGCGTGCCGAGGACACCGCCGTATATTACTGTGCGAAAATTTCTCAGTTTGG
GTCAAATGCGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAG
CGCTAGCACCAAGTGGTCCATCGGACATCCAGATGACCCAGTCTCCATCCTCC
CTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTC
25 CGATTGGGACGATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTA
AGCTCCTGATCTTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTT
CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCA
ACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACG
ACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

30

DMS5537 (SEQ ID NO: 43)

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGGTCC
CTGCGTCTCTCCTGTGCAGCCTCCGGATTACCTTTTTCAAGTATTCGATGGG
35 GTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTT
GGATACTGCTGATCGTACATACTACGCACACTCCGTGAAGGGCCGGTTTCA
CATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCT
GCGTGCTGAGGACACCGCGGTATATTACTGTGCGATATATACTGGGCGTTG
GGTGCCTTTTGAGTACTGGGGTCAGGGAACCCCTGGTCACCGTCTCGAGCGCT
40 AGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAG
GAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACGATGT
TAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTTGT
TTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATC
TGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCT

- 193 -

ACGTACTACTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCAAGGG
ACCAAGGTGGAAATCAAACGG

DMS5539 (SEQ ID NO: 38)

5 GACATCCAGATGACCCAGAGCCCATCTAGCCTGTCTGCTTCTGTAGGTGACC
GCGTTACTATTACCTGTCGTGCAAGCCAGTACATCCACACCTCTGTTCAGTG
GTATCAGCAGAAACCGGGTAAAGCGCCAAAACCTGCTGATTTACGGTTCTTC
CCGTCTGCACAGCGGCGTTCCATCTCGCTTCTCTGGCAGCGGTTCTGGTACG
GATTTACGCTGACCATTAGCTCTCTCCAGCCGGAAGACTTTGCCACGTACT
10 ACTGCCAGCAGAACCACTACTCTCCGTTTACCTACGGTCAGGGGCACCAAAG
TGGAGATTAAACGTGCTAGCACCGATATCCAGATGACGCAGTCTCCGAGCT
CTCTGCCAGCGAGCGTTGGCGACCGTGTGACCATCACTTGCCGCGCTTCTCG
TCCGATCGGTACCATGCTGTCTTGGTACCAGCAGAAACCAGGCAAAGCCCC
GAAACTCCTGATCCTGTTCGGTTCTCGCCTGCAGTCTGGTGTACCGAGCCGT
15 TTCAGCGGTTCTGGTAGCGGCACCGACTTTACCCTCACGATCTCTAGCCTGC
AGCCAGAGGATTTTCGCGACCTATTACTGTGCTCAGGCGGGTACCCACCCGA
CTACCTTCGGCCAGGGTACGAAGGTGGAAATCAAACGG

DMS5538 (SEQ ID NO: 44)

20 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCC
CTGCGTCTCTCCTGTGCAGCCTCCGGAGTTAACGTTAGCCATGACTCTATGA
CCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCAGCCATTC
GGGGGCCTAACGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCA
CCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCT
25 GCGTGCCGAGGACACCGCGGTATATTATTGCGCGAGTGGGGCTAGGCATGC
GGATACGGAGCGGCCTCCGTGCGAGCAGACCATGCCGTTTTTGGGGTCAGGG
AACCCTGGTCACCGTCTCGAGCGCTAGCACCGACATCCAGATGACCCAGTC
TCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCAACCATCACTTGCCGG
GCAAGTCGTCCGATTGGGACGATGTAAAGTTGGTACCAGCAGAAACCAGGG
30 AAAGCCCCTAAGCTCCTGATCTTGTTTGGTTCCCGGTTGCAAAGTGGGGTCC
CATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAG
CAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGCTGGGACG
CATCCTACGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG

35 DMS5540 (SEQ ID NO: 9)

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCC
CTGCGTCTCTCCTGTGCAGCCTCCGGATTACCTTTAATAGGTATAGTATGG
GGTGGCTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTG
ATTCTTATGGTCGTGGTACATACTACGAAGACCCCGTGAAGGGCCGGTTCA
40 GCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCC
TGCGTGCCGAGGACACCGCCGTATATTACTGTGCGAAAATTTCTCAGTTTGG
GTCAAATGCGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAG
CGCTAGCACCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCT
GTAGGAGACCGTGTCAACCATCACTTGCCGGGCAAGTCGTCCGATTGGGACG

- 194 -

ATGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATC
 TTGTTTGGTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTG
 GATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTT
 TGCTACGTACTACTGTGCGCAGGCTGGGACGCATCCTACGACGTTTCGGCCA
 5 AGGGACCAAGGTGGAAATCAAACGG

10 Oligonucleotide sequences

AS9: CAGGAAACAGCTATGACCATG
 AS65: TTGTAAAACGACGGCCAGTG
 AS339: TTCAGGCTGCGCAACTGTTG
 15 AS639: CGCCAAGCTTGCATGCAAATTC
 AS1029:
 CCTGTGCAGCCTCCGGATTACCTTTgtTaagtaTtcGatgggGTGGGTCCGCCAGG
 AS1030:
 TCCAGGGAAGGGTCTAGAGTGGGTCTCAcagatttcgaatacgggtgatcgtacataC
 20 ta CgcagactccgtgaagggcCGGTTACCATCTCCC
 AS1031:
 GAGGACACCGCGGTATATTACTGTGCGatAtaTacgggtcgttgGgagccttttgact
 aCT GGGGTCAGGGAACCCTGGTC
 AS1031': AAAGGTGAATCCGGAGGCTGCACAGG
 25 AS1032: TGAGACCCACTCTAGACCCTTCCCTGGA
 AS1033: CGCACAGTAATATACCGCGGTGTCCTC
 PAS40: TCAAGCGCTAGCACCGACATCCAGATGACCCAGTCTC

 JAL102:
 30 GGAATTCCATATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTC
 CTCGCTGCCCAGCCGGCGATGGCCGAGGTGCAGCTGTTGGAGTCTGGGGG

 ZHT304: CATCTGGATGTCGGTGCTAGCGCTTGAGACGGTGACCAG

 35 ZHT327:
 GGTTAACCGCGGCCGCGAATTCGGATCCCTCGAGTCATTACCGTTTGATTTC
 CACCTT

 ZHT332:
 40 GGAATTCCATATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTC
 CTCGCTGCCCAGCCGGCGATGGCCGACATCCAGATGACCCAGAGCCCA

 ZHT333: AAACGTGCTAGCACCGATATCCAGATGACGCAGTCTCC

 45 ZHT334: GGATATCGGTGCTAGCACGTTTAATCTCCACTTT

- 195 -

ZHT335: CATCTGGATGTCGGTGCTAGCGCTCGAGACGGT

5

- 196 -

CLAIMS

1. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable
5 domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).
- 10 2. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is a mutant of DOM1h-574-14 (SEQ ID NO: 10) comprising one or more of the following mutations (numbering according to Kabat)
15 position 30 is L or F,
position 52 is A or T,
position 52a is D or E,
position 54 is A or R,
position 57 is R, K or A,
20 position 60 is D, S, T or K,
position 61 is E, H or G,
position 62 is A or T,
position 100 is R, G, N, K, Q, V, A, D, S or V, and
position 101 is A, Q, N, E, V, H or K.
- 25 3. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin heavy chain single variable domain comprising valine at position 101 (numbering according to Kabat).

- 197 -

4. The single variable domain according to claim 3, wherein the variable domain is as defined in claim 1.
5. The single variable domain of any preceding claim comprising one or more of 30G, 44D, 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat.
5
6. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising one or more of 30G, 44D, 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat, wherein the amino acid sequence of the single variable domain is otherwise identical to the amino acid sequence of DOM1h-574 (SEQ ID NO: 11; figure 5).
10
7. The immunoglobulin single variable domain of claim 5 or 6 comprising 45P, 55D, 56R, 94I and 98R, wherein numbering is according to Kabat.
8. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-132 (SEQ ID NO: 7), DOM1h-574-135 (SEQ ID NO: 8), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 9) or DOM1h-574-180 (SEQ ID NO: 6).
15
9. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 94% identical to the amino acid sequence of DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-93 (SEQ ID NO: 12), DOM1h-574-123 (SEQ ID NO: 13), DOM1h-574-125 (SEQ ID NO: 14), DOM1h-574-126 (SEQ ID NO: 15) or DOM1h-574-129 (SEQ ID NO: 16), DOM1h-574-133 (SEQ ID NO: 17), DOM1h-574-137 (SEQ ID NO: 18) or DOM1h-574-160 (SEQ ID NO: 19).
20
25

- 198 -

10. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-125 (SEQ ID NO: 14), DOM1h-574-126 (SEQ ID NO: 15), DOM1h-574-133 (SEQ ID NO: 17), DOM1h-574-135 (SEQ ID NO: 8), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-139 (SEQ ID NO: 20), DOM1h-574-155 (SEQ ID NO: 21), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).
11. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain for binding human, murine or *Cynomologus monkey* TNFR1, wherein the single variable domain is encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence of DOM1h-574-156 (SEQ ID NO: 22), DOM1h-574-72 (SEQ ID NO: 23), DOM1h-574-109 (SEQ ID NO: 109), DOM1h-574-138 (SEQ ID NO: 25), DOM1h-574-162 (SEQ ID NO: 26) or DOM1h-574-180 (SEQ ID NO: 27).
12. The single variable domain of any preceding claim, wherein the single variable domain comprises a binding site that specifically binds human TNFR1 with a dissociation constant (KD) of 500 pM or less as determined by surface plasmon resonance.
13. The single variable domain of any preceding claim, wherein the single variable domain comprises a binding site that specifically binds human TNFR1 with an off-rate constant (Koff) of $2 \times 10^{-4} \text{ s}^{-1}$ or less as determined by surface plasmon resonance.
14. The single variable domain of any preceding claim, wherein the single variable domain specifically binds human, *Cynomologus monkey* and optionally canine TNFR1.

- 199 -

15. The single variable domain of claim 14, wherein the single variable domain binds murine TNFR1.
16. The single variable domain of any preceding claim, wherein the single variable domain inhibits the binding of human, *Cynomologus monkey* and optionally canine TNFR1 to DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).
17. The single variable domain of any one of any preceding claim, wherein the single variable domain inhibits the binding of human, murine, *Cynomologus monkey* and optionally canine TNFR1 to DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).
18. The single variable domain of any preceding claim, wherein the single variable domain neutralizes TNFR1 with an ND50 of about 5 nM or less *in a standard MRC5* assay as determined by inhibition of TNF alpha-induced IL-8 secretion.
19. The single variable domain of any preceding claim, wherein the single variable domain neutralizes TNFR1 with an ND50 of about 150 nM or less in a standard L929 assay as determined by inhibition of TNF alpha-induced cytotoxicity.
20. The single variable domain of any preceding claim, wherein the single variable domain neutralises TNFR1 with an ND50 of about 5 nM or less in a standard *Cynomologus* KI assay as determined by inhibition of TNF alpha-induced IL-8 secretion.
21. The single variable domain of any preceding claim, wherein the single variable domain is a non-competitive inhibitor of TNFR1.

- 200 -

22. The single variable domain of claim 21, wherein the single variable domain specifically binds domain 1 of human TNFR1.
23. The single variable domain of claim 21 or 22, wherein the single variable domain is specific for PLAD domain of human TNFR1.
- 5 24. An immunoglobulin single variable domain of any preceding claim, wherein the single variable domain comprises a terminal, optionally C-terminal, cysteine residue.
25. An immunoglobulin single variable domain of any preceding claim, wherein the single variable domain is linked to a polyalkylene glycol moiety, optionally a
10 polyethylene glycol moiety.
26. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain comprising an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3),
15 DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6) or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% identical to the CDR1 sequence of said selected amino acid sequence.
- 20 27. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprising an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or
25 DOM1h-574-180 (SEQ ID NO: 6) or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a CDR2 sequence that

- 201 -

is at least 50% identical to the CDR2 sequence of said selected amino acid sequence.

28. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprising an amino acid sequence that is identical to the amino acid sequence selected from the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6) or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of said selected amino acid sequence.
29. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain according to claim 26, comprising a CDR2 sequence that is at least 50% identical to the CDR2 sequence of said selected amino acid sequence.
30. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain according to claim 26, comprising a CDR3 sequence that is at least 50% identical to the CDR3 sequence of said selected amino acid sequence.
31. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain according to claim 27, comprising a CDR3 sequence that is at least 50% identical to the CDR3 sequence of said selected amino acid sequence.
32. An anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain according to claim 31, comprising a CDR1 sequence that is at least 50% identical to the CDR1 sequence of DOM1h-574-72 (SEQ ID NO: 2).
33. A protease resistant anti- TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain, wherein the single variable domain is resistant to protease when incubated with

- 202 -

(i) a concentration (c) of at least 10 micrograms/ml protease at 37°C for time (t) of at least one hour; or

(ii) a concentration (c') of at least 40 micrograms/ml protease at 30°C for time (t) of at least one hour.

5 wherein the variable domain comprises an amino acid sequence that is at least 94% identical to the amino acid sequence of DOM1h-574-126 (SEQ ID NO: 15) or DOM1h-574-133 (SEQ ID NO: 17), and optionally comprises a valine at position 101 (Kabat numbering).

10 34. The single variable domain of any preceding claim, wherein the single variable domain that has a T_m of at least 50°C.

35. A polypeptide comprising an immunoglobulin single variable domain as defined in any preceding claim and an antibody constant domain, optionally an antibody Fc region, optionally wherein the N-terminus of the Fc is linked (optionally directly linked) to the C-terminus of the variable domain.

15 36. A multispecific ligand comprising an immunoglobulin single variable domain as defined in any preceding claim and optionally at least one immunoglobulin single variable domain that specifically binds serum albumin (SA).

20 37. The multispecific ligand of claim 36, wherein the anti-SA single variable domain comprises an amino acid sequence that is at least 80% identical to the sequence of DOM7h-11 (SEQ ID NO: 28), DOM7h-11-3 (SEQ ID NO: 29), DOM7h-11-12 (SEQ ID NO: 30), DOM7h-11-15 (SEQ ID NO: 31), DOM7h-14 (SEQ ID NO: 32), DOM7h-14-10 (SEQ ID NO: 33), DOM7h-14-18 (SEQ ID NO: 34) or DOM7m-16 (SEQ ID NO: 35).

25 38. The multispecific ligand of claim 36 or 37, wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS.

- 203 -

39. A multispecific ligand comprising (i) an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 93% identical to the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), (ii) at least one anti-serum albumin (SA) immunoglobulin single variable domain that specifically binds SA, wherein the anti-SA single variable domain comprises an amino acid sequence that is at least 80% identical to the sequence of DOM7h-11-3 (SEQ ID NO: 29), and (iii) optionally wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS.
40. A multispecific ligand comprising (i) an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain which comprises an amino acid sequence that is at least 93% identical to the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), (ii) at least one anti-serum albumin (SA) immunoglobulin single variable domain that specifically binds SA, wherein the anti-SA single variable domain comprises an amino acid sequence that is at least 80% identical to the sequence of DOM7h-14-10 (SEQ ID NO: 33), and (iii) optionally wherein a linker is provided between the anti-TNFR1 single variable domain and the anti-SA single variable domain, the linker comprising the amino acid sequence AST, optionally ASTSGPS.
41. A TNFR1 antagonist comprising a single variable domain, polypeptide or multispecific ligand of any preceding claim.
42. A TNF α receptor type 1 (TNFR1; p55) antagonist comprising a variable domain according to claim 33, for oral delivery, delivery to the GI tract of a patient, pulmonary delivery, delivery to the lung of a patient or systemic delivery.
43. A TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomolgus monkey* TNFR1, the antagonist having a CDR1 sequence that is at least 50% identical to the CDR1 sequence of DOM1h-574-72 (SEQ ID NO: 2),

- 204 -

DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).

5 44. A TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).

10 45. A TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6).

46. A TNF α receptor type 1 (TNFR1; p55) antagonist according to claim 43 having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of said selected sequence.

20 47. A TNF α receptor type 1 (TNFR1; p55) antagonist according to claim 43 having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of said selected sequence.

48. A TNF α receptor type 1 (TNFR1; p55) antagonist according to claim 46 having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of said selected sequence.

- 205 -

49. A TNF α receptor type 1 (TNFR1; p55) antagonist according to claim 44 having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of said selected sequence.
50. A TNF α receptor type 1 (TNFR1; p55) antagonist for binding human, murine or *Cynomologus monkey* TNFR1, the antagonist comprising an immunoglobulin single variable domain comprising the sequence of CDR1, CDR2, and/or CDR3 of a single variable domain selected from DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-162 (SEQ ID NO: 5) and DOM1h-574-180 (SEQ ID NO: 6).
51. The TNFR1 antagonist of any one of claims 41 to 50 for treating and/or prophylaxis of an inflammatory condition.
52. Use of the TNFR1 antagonist of any one of claims 41 to 50 in the manufacture of a medicament for treating and/or prophylaxis of an inflammatory condition.
53. The antagonist of claim 51 or the use of claim 52, wherein the condition is selected from the group consisting of arthritis, multiple sclerosis, inflammatory bowel disease and chronic obstructive pulmonary disease.
54. The antagonist or the use of claim 53, wherein said arthritis is rheumatoid arthritis or juvenile rheumatoid arthritis.
55. The antagonist or the use of claim 53, wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis.
56. The antagonist or the use of claim 53, wherein said chronic obstructive pulmonary disease is selected from the group consisting of chronic bronchitis, chronic obstructive bronchitis and emphysema.

- 206 -

57. The antagonist or the use of claim 53, wherein said pneumonia is bacterial pneumonia.
58. The antagonist or the use of claim 57, wherein said bacterial pneumonia is Staphylococcal pneumonia.
- 5 59. The TNFR1 antagonist of any one of claims 41 to 50 for treating and/or prophylaxis of a respiratory disease.
60. Use of the TNFR1 antagonist of any one of claims 41 to 50 in the manufacture of a medicament for treating and/or prophylaxis of a respiratory disease.
- 10 61. The antagonist of claim 59 or the use of claim 60, wherein said respiratory disease is selected from the group consisting of lung inflammation, chronic obstructive pulmonary disease, asthma, pneumonia, hypersensitivity pneumonitis, pulmonary infiltrate with eosinophilia, environmental lung disease, pneumonia, bronchiectasis, cystic fibrosis, interstitial lung disease, primary pulmonary hypertension, pulmonary thromboembolism, disorders of the pleura, disorders of the mediastinum, disorders of the diaphragm, hypoventilation, hyperventilation, sleep apnea, acute respiratory distress syndrome, mesothelioma, sarcoma, graft rejection, graft versus host disease, lung cancer, allergic rhinitis, allergy, asbestosis, aspergilloma, aspergillosis, bronchiectasis, chronic bronchitis, emphysema, eosinophilic pneumonia, idiopathic pulmonary fibrosis, invasive pneumococcal disease, influenza, nontuberculous mycobacteria, pleural effusion, pneumoconiosis, pneumocytosis, pneumonia, pulmonary actinomycosis, pulmonary alveolar proteinosis, pulmonary anthrax, pulmonary edema, pulmonary embolus, pulmonary inflammation, pulmonary histiocytosis X, pulmonary hypertension, pulmonary nocardiosis, pulmonary tuberculosis, pulmonary veno-occlusive disease, rheumatoid lung disease, sarcoidosis, and Wegener's granulomatosis.
- 15
- 20
- 25

- 207 -

62. The anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand of any one of claims 1 to 50 for targeting one or more epitopic sequence of TNFR1 selected from the group consisting of NSICCTKCHKGTYLY, NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF.
63. The anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand of claim 62 for targeting one or more epitopic sequence of TNFR1 selected from the group consisting of NSICCTKCHKGTYLY, NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF, to treat and/or prevent a condition or disease specified in any one of claims 51 to 62.
64. A method of treating and/or preventing a condition or disease specified in any one of claims 51 to 62 in a patient, the method comprising administering to the patient the anti-TNFR1 antagonist, single variable domain, polypeptide or multispecific ligand of any one of claims 1 to 50 for targeting one or more epitopic sequence of TNFR1 selected from the group consisting of NSICCTKCHKGTYLY, NSICCTKCHKGTYL, CRKNQYRHYWSENLF and NQYRHYWSENLFQCF in the patient.
65. An isolated or recombinant nucleic acid, wherein the nucleic acid comprises a nucleotide sequence that is at least 80% identical to the nucleotide sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1h-574-72 (SEQ ID NO: 2), DOM1h-574-109 (SEQ ID NO: 3), DOM1h-574-138 (SEQ ID NO: 4), DOM1h-574-162 (SEQ ID NO: 5) or DOM1h-574-180 (SEQ ID NO: 6) and wherein the nucleic acid encodes a polypeptide comprising an immunoglobulin single variable domain that specifically binds to TNFR1.
66. A multispecific ligand comprising an anti-TNF α receptor type 1 (TNFR1; p55) immunoglobulin single variable domain and at least one immunoglobulin single

- 208 -

variable domain that specifically binds serum albumin (SA), wherein

(a) the anti-TNFR1 single variable domain comprises an amino acid that is at least 80% identical to the amino acid sequence of DOM1h-574-156 (SEQ ID NO: 1), DOM1m-15-12 (SEQ ID NO: 36) or DOM1m-21-23 (SEQ ID NO: 37);

5 and

(b) the anti-SA single variable domain comprises an amino acid that is at least 80% identical to the amino acid sequence of DOM7h-11-12 (SEQ ID NO: 30) or DOM7h-11-12dh (SEQ ID NO: 38); and

10 (c) the ligand comprises a linker between said variable domains, the linker comprising the amino acid sequence AS or AST.

67. A multispecific ligand comprising or consisting of DMS5537 (SEQ ID NO: 39), DMS5538 (SEQ ID NO: 40), DMS5539 (SEQ ID NO: 41) or DMS5540 (SEQ ID NO: 42).

15 68. A nucleic acid encoding a multispecific ligand of claim 66 or 67.

69. A nucleic acid comprising a nucleotide sequence that is at least 80% identical to the nucleotide sequence of DMS5537 (SEQ ID NO: 43), DMS5538 (SEQ ID NO: 44), DMS5539 (SEQ ID NO: 38) or DMS5540 (SEQ ID NO: 9).

20 70. A vector comprising the nucleic acid of claim 68 or 69.

71. A host, optionally a non-human embryonic cell, comprising the vector of claim 70.

25

1/35




Figure 1

2/35




Figure 2

3/35




Figure 3

4/35




Figure 4

[illegible]

[illegible]

[illegible][illegible]

Figure 5C

8/35

	10	20	30	40
human ECD TNFR1		MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKR		
Cyno ECD TNFR1		P.R.....		
Dog ECD TNFR1	...P...G.....A..LE...IS.TA....PRN.V..			
Mouse ECD TNFR1	----- ----- ----- ----- ----- -----	S.....		
	50	60	70	80
human ECD TNFR1		DSVCPQGKYIHPQNNNSICCTKCHKGTLYNDPCPGPGQD		
Cyno ECD TNFR1		V.....		
Dog ECD TNFR1	AIL.....DD.....L...			
Mouse ECD TNFR1	..L.....V.SK.....VS...S..R..V			
	90	100	110	120
human ECD TNFR1		CRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVD		
Cyno ECD TNFR1				
Dog ECD TNFR1	N.T.....Q.....N....P...Y			
Mouse ECD TNFR1	K.T....Q.Y..Q....KT.....S....P.QA.			
	130	140	150	160
human ECD TNFR1		RDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQE		
Cyno ECD TNFR1		Y.....		
Dog ECD TNFR1		F....T....N.....QI....		
Mouse ECD TNFR1	K.....KE..FQR.L..TH...VD..P.F....TIP.K.			
	170	180	190	200
human ECD TNFR1		KQNTVCTCHAGFFLRENECVSCSNCKRSLECTKLCLP-QI		
Cyno ECD TNFR1		T.....-..T		
Dog ECD TNFR1		I.....H....V....NT..G.....-PV		
Mouse ECD TNFR1	T.....N.....S...P..H...NE..M.....PPL			

Figure 6

9/35




Figure 7

10/35




Figure 8

11/35




Figure 9

12/35




Figure 10

Figure 11A

Figure 11B

[illegible]

[illegible]

Figure 12A

[illegible]

[illegible]

Figure 12C

Figure 13A

Figure 13B

Figure 13C

22/35




Figure 14

23/35




Figure 15

24/35




Figure 16

25/35




Figure 17

26/35




Figure 18

27/35




Figure 19

28/35




Figure 20

29/35




Figure 21

30/35




Figure 22

31/35




Figure 23

32/35




Figure 24

33/35




Figure 25

34/35




Figure 26

35/35




Figure 27